WEST Search History

DATE: Thursday, January 30, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L4	fusaric adj acid and (protein same conformation$)	9	L4
L3	fusaric adj acid and (protein same aggregation)	3	L3
L2	L1 and (solubil$)	100	L2
L1	(picolin$ or (picolinic adj acid)) and (protein same aggregation)	164	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 9 of 9 returned.

1. Document ID: US 20020128250 A1

L4: Entry 1 of 9 File: PGPB Sep 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020128250
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020128250 A1

TITLE: Methods for improving secondary metabolite production in fungi

PUBLICATION-DATE: September 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Busby, Robert	Weymouth	MA	US	
Cali, Brian	Arlington	MA	US	
Hecht, Peter	Newton	MA	US	
Holtzman, Doug	Jamaica Plan	MA	US	
Madden, Kevin	Charlestown	MA	US	
Maxon, Mary	Somerville	MA	US	
Milne, Todd	Brookline	MA	US	
Norman, Thea	Belmont	MA	US	
Royer, John	Lexington	MA	US	
Salama, Sofie	Boston	MA	US	
Sherman, Amir	Boston	MA	US	
Silva, Jeff	Beverly	MA	US	
Summers, Eric	Brookline	MA	US	

US-CL-CURRENT: 514/192; 435/124, 435/254.2, 435/254.3, 435/43

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

2. Document ID: US 20020090376 A1

L4: Entry 2 of 9 File: PGPB Jul 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020090376
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020090376 A1

TITLE: METHODS OF PRODUCING AND USING VIRULENCE ATTENUATED POXR MUTANT BACTERIA

PUBLICATION-DATE: July 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
KANIGA, KONE	ST. LOUIS	MO	US	
SUNDARAM, PREETI	CHESTERFIELD	MO	US	

US-CL-CURRENT: 424/184.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 3. Document ID: US 20020037908 A1

L4: Entry 3 of 9 File: PGPB Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037908
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020037908 A1

TITLE: Methods and compositions for controlling protein assembly or aggregation

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Douglas, Michael G.	St. Louis	MO	US	
Amin, Avinash N.	St. Louis	MO	US	

US-CL-CURRENT: 514/350; 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 4. Document ID: US 6399074 B1

L4: Entry 4 of 9 File: USPT Jun 4, 2002

US-PAT-NO: 6399074
DOCUMENT-IDENTIFIER: US 6399074 B1

TITLE: Live attenuated salmonella vaccines to control avian pathogens

DATE-ISSUED: June 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roland; Kenneth L.	St. Louis	MO		

US-CL-CURRENT: 424/200.1; 424/184.1, 424/93.2, 435/252.1, 435/252.3, 435/252.8, 435/320.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 5. Document ID: US 6355479 B1

L4: Entry 5 of 9 File: USPT Mar 12, 2002

US-PAT-NO: 6355479
DOCUMENT-IDENTIFIER: US 6355479 B1

TITLE: MHC class II antigen-presenting systems and methods for activating CD4+ T cells

DATE-ISSUED: March 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Webb; Susan R.	La Jolla	CA		
Winqvist; Ola	Uppsala			SE
Karlsson; Lars	La Jolla	CA		
Jackson; Michael R.	Del Mar	CA		
Peterson; Per A.	Rancho Santa Fe	CA		

US-CL-CURRENT: 435/325; 435/320.1, 435/348, 435/373, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

6. Document ID: US 6027888 A

L4: Entry 6 of 9 File: USPT Feb 22, 2000

US-PAT-NO: 6027888
DOCUMENT-IDENTIFIER: US 6027888 A

TITLE: Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells

DATE-ISSUED: February 22, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Georgiou; George	Austin	TX		
Ostermeier; Marc	State College	PA		

US-CL-CURRENT: 435/6; 435/243, 435/320.1, 435/69.1, 435/91.1, 530/350, 536/23.2, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

7. Document ID: US 5198346 A

L4: Entry 7 of 9 File: USPT Mar 30, 1993

US-PAT-NO: 5198346
DOCUMENT-IDENTIFIER: US 5198346 A

TITLE: Generation and selection of novel DNA-binding proteins and polypeptides

DATE-ISSUED: March 30, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ladner; Robert C.	Ijamsville	MD		
Guterman; Sonia K.	Belmont	MA		
Kent; Rachel B.	Boxborough	MA		
Ley; Arthur C.	Newton	MA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/489

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 8. Document ID: US 5096815 A

L4: Entry 8 of 9 File: USPT Mar 17, 1992

US-PAT-NO: 5096815
DOCUMENT-IDENTIFIER: US 5096815 A

TITLE: Generation and selection of novel DNA-binding proteins and polypeptides

DATE-ISSUED: March 17, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ladner; Robert C.	Ijamsville	MD		
Guterman; Sonia K.	Belmont	MA		
Kent; Rachel B.	Wilmington	MA		
Ley; Arthur C.	Newton	MA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 9. Document ID: US 20020037908 A1

L4: Entry 9 of 9 File: DWPI Mar 28, 2002

DERWENT-ACC-NO: 2002-589123
DERWENT-WEEK: 200263
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Composition capable of solubilizing conformationally altered protein useful for treating e.g. Alzheimer's disease and cerebral amyloid angiopathy, comprises picolinic acid derivative and cation

INVENTOR: AMIN, A N; DOUGLAS, M G

PRIORITY-DATA: 2001US-0904987 (July 12, 2001), 1995US-0581351 (December 29, 1995), 1996US-026992P (September 20, 1996), 1996US-024221P (October 22, 1996), 1997US-0843157 (April 11, 1997), 1998US-0127620 (August 1, 1998), 2000US-0657554 (September 8, 2000), 2000US-0657989 (September 8, 2000), 2000US-0677500 (October 2, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020037908 A1	March 28, 2002		024	A61K031/455

INT-CL (IPC): A61 K 31/455; C07 K 14/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

Generate Collection | Print

Term	Documents
FUSARIC.DWPI,TDBD,EPAB,USPT,PGPB.	226
FUSARICS	0
ACID.DWPI,TDBD,EPAB,USPT,PGPB.	1448149
ACIDS.DWPI,TDBD,EPAB,USPT,PGPB.	510872
PROTEIN.DWPI,TDBD,EPAB,USPT,PGPB.	236295
PROTEINS.DWPI,TDBD,EPAB,USPT,PGPB.	153327
CONFORMATION$	0
CONFORMATION.DWPI,TDBD,EPAB,USPT,PGPB.	22573
CONFORMATIONA.DWPI,TDBD,EPAB,USPT,PGPB.	3
CONFORMATIONAI.DWPI,TDBD,EPAB,USPT,PGPB.	1
(FUSARIC ADJ ACID AND (PROTEIN SAME CONFORMATION$)).USPT,PGPB,EPAB,DWPI,TDBD.	9

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 100 of 100 returned.

1. Document ID: US 20030022284 A1

L2: Entry 1 of 100 File: PGPB Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022284
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022284 A1

TITLE: Uses of GDNF and GDNF receptor

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Klein, Robert D.	South San Francisco	CA	US	
Moore, Mark W.	San Francisco	CA	US	
Rosenthal, Arnon	Burlwgane	CA	US	
Ryan, Anne M.	Millbrae	CA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/7.1, 435/7.2, 530/387.1, 530/388.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

2. Document ID: US 20030018175 A1

L2: Entry 2 of 100 File: PGPB Jan 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030018175
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030018175 A1

TITLE: Protein C or activated protein C-like molecules

PUBLICATION-DATE: January 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Andersen, Kim Vilbour	Broenshoej		DK	
Pedersen, Anders Hjelholt	Lyngby		DK	
Freskgaard, Per Ola	Vellinge		SE	

US-CL-CURRENT: 530/395

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

3. Document ID: US 20030004109 A1

L2: Entry 3 of 100 File: PGPB Jan 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030004109
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030004109 A1

TITLE: Leptin/ob receptor having a WSX motif

PUBLICATION-DATE: January 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bennett, Brian	Pacifica	CA	US	
Matthews, William	Woodside	CA	US	

US-CL-CURRENT: 514/12; 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 20020193571 A1

L2: Entry 4 of 100 File: PGPB Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020193571
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020193571 A1

TITLE: WSX RECEPTOR AGONIST ANTIBODIES

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
CARTER, PAUL J.	SAN FRANCISCO	CA	US	
CHIANG, NANCY Y.	SAN FRANCISCO	CA	US	
KIM, KYUNG JIN	LOS ALTOS	CA	US	
MATTHEWS, WILLIAM	WOODSIDE	CA	US	
RODRIGUES, MARIA L.	SOUTH SAN FRANCISCO	CA	US	

US-CL-CURRENT: 530/387.3; 530/388.15, 530/388.22, 530/388.7, 530/389.2, 530/389.6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 20020192183 A1

L2: Entry 5 of 100 File: PGPB Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020192183
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020192183 A1

TITLE: Interferon gamma polypeptide variants

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jensen, Anne Dam	Copenhagen		DK	

US-CL-CURRENT: 424/85.5; 435/320.1, 435/325, 435/69.51, 530/351, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 20020176859 A1

L2: Entry 6 of 100 File: PGPB Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020176859
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020176859 A1

TITLE: Treatment of hearing impairments

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gao, Wei-Qiang	Foster City	CA	US	

US-CL-CURRENT: 424/146.1; 424/649, 514/12, 514/162, 514/305, 514/36, 514/37, 514/41

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 20020169290 A1

L2: Entry 7 of 100 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169290
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169290 A1

TITLE: New multimeric interferon beta polypeptides

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bornaes, Claus	Hellerup		DK	
Andersen, Kim Vilbour	Broenshoej		DK	
Rasmussen, Poul Baad	Soeborg		DK	
Pedersen, Anders Hjelholt	Lyngby		DK	

US-CL-CURRENT: 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 8. Document ID: US 20020169124 A1

L2: Entry 8 of 100 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169124
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169124 A1

TITLE: Treatment of balance impairments

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gao, Wei-Qiang	Foster City	CA	US	

US-CL-CURRENT: 514/12; 424/649, 514/37, 514/38, 514/39

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Drawi Desc | Image

---

9. Document ID: US 20020168363 A1

L2: Entry 9 of 100 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168363
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168363 A1

TITLE: Integrin/adhesion antagonists

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Feige, Ulrich	Newbury Park	CA	US	
Kohno, Tadahiko	Thousand Oaks	CA	US	
Lacey, David Lee	Newbury Park	CA	US	
Boone, Thomas Charles	Newbury Park	CA	US	

US-CL-CURRENT: 424/146.1; 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Drawi Desc | Image

---

10. Document ID: US 20020160109 A1

L2: Entry 10 of 100 File: PGPB Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160109
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160109 A1

TITLE: Microencapsulation of drugs by solvent exchange

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yeo, Yoon	Lafayette	IN	US	
Chen, Alvin Un-Teh	West Lafayette	IN	US	
Basaran, Osman A.	West Lafayette	IN	US	
Park, Kinam	West Lafayette	IN	US	

US-CL-CURRENT: 427/213.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWMC | Draw. Desc | Image

---

☐ 11. Document ID: US 20020146428 A1

L2: Entry 11 of 100 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146428
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146428 A1

TITLE: Treatment or prophylaxis of diseases caused by pilus-forming bacteria

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hultgren, Scott	Ballwin	MO	US	
Kuehn, Meta	Berkeley	CA	US	
Xu, Zheng	Blue Bell	PA	US	
Ogg, Derek	Stockholm	MO	SE	
Harris, Mark	Uppsala		SE	
Lepisto, Matti	Lund		SE	
Jones, Charles Hal	Saint Louis		US	
Kihlberg, Jan	Dalby		SE	

US-CL-CURRENT: 424/190.1; 424/242.1, 435/183, 435/252.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWMC | Draw. Desc | Image

---

☐ 12. Document ID: US 20020142964 A1

L2: Entry 12 of 100 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142964
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020142964 A1

TITLE: Single-chain polypeptides

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nissen, Torben Lauesgaard	Frederiksberg C		DK	
Jensen, Anne Dam	Copenhagen		DK	

US-CL-CURRENT: 514/12; 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

13. Document ID: US 20020142444 A1

L2: Entry 13 of 100 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142444
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020142444 A1

TITLE: AL-2 neurotrophic factor

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Caras, Ingrid W.	San Francisco	CA	US	

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

14. Document ID: US 20020090646 A1

L2: Entry 14 of 100 File: PGPB Jul 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020090646
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020090646 A1

TITLE: Calcitonin-related molecules

PUBLICATION-DATE: July 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Chuan-Fa	Longmont	CO	US	
Marshall, William S.	Boulder	CO	US	
Reynolds, Angela	Evergreen	CO	US	

US-CL-CURRENT: 435/7.1; 530/389.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

15. Document ID: US 20020082397 A1

L2: Entry 15 of 100 File: PGPB Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020082397
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020082397 A1

TITLE: NOVEL RECEPTOR-TYPE PHOSPHOTYROSINE PHOSPHATASE-KAPPA

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schlessinger, Joseph	New York	NY	US	
Sap, Jan M.	New York	NY	US	
Ullrich, Axel	Munchen 40		DE	
Vogel, Wolfgang	Germering		DE	
Fuchs, Miriam	Starnberg		DE	

US-CL-CURRENT: 530/388.26; 424/146.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

16. Document ID: US 20020054878 A1

L2: Entry 16 of 100 File: PGPB May 9, 2002

PGPUB-DOCUMENT-NUMBER: 20020054878
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020054878 A1

TITLE: Anti-IgE antibodies

PUBLICATION-DATE: May 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lowman, Henry B.	El Granada	CA	US	
Presta, Leonard G.	San Francisco	CA	US	
Jardieu, Paula M.	San Mateo	CA	US	
Lowe, John	Daly City	CA	US	

US-CL-CURRENT: 424/171.1; 424/130.1, 424/133.1, 435/7.1, 530/387.3, 536/23.53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

17. Document ID: US 20020051972 A1

L2: Entry 17 of 100 File: PGPB May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020051972
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020051972 A1

TITLE: NEURTURIN RECEPTOR

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
KLEIN, ROBERT D.	PALO ALTO	CA	US	
ROSENTHAL, ARNON	BURLINGAME	CA	US	

US-CL-CURRENT: 435/6; 435/7.1, 530/300, 530/350, 530/412, 530/417

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

18. Document ID: US 20020045199 A1

L2: Entry 18 of 100 File: PGPB Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020045199
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020045199 A1

TITLE: Treatment or prophylaxis of diseases caused by pilus-forming bacteria

PUBLICATION-DATE: April 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hultgren, Scott	Ballwin	MO	US	
Kuehn, Meta	Berkeley	CA	US	
Xu, Zheng	Blue Bell	PA	US	
Ogg, Derek	Stockholm	MO	SE	
Harris, Mark	Uppsala		SE	
Lepisto, Matti	Lund		SE	
Jones, Charles Hal	Saint Louis		US	
Kihlberg, Jan	Dalby		SE	

US-CL-CURRENT: 435/7.32; 514/23, 536/116, 546/242, 549/28

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

19. Document ID: US 20020042087 A1

L2: Entry 19 of 100 File: PGPB Apr 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020042087
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020042087 A1

TITLE: Use of heregulin as a growth factor

PUBLICATION-DATE: April 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sliwkowski, Mark X.	San Carlos	CA	US	
Kern, Jeffrey A.	Iowa City	IA	US	

US-CL-CURRENT: 435/7.23; 514/2, 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

20. Document ID: US 20020039995 A1

L2: Entry 20 of 100 File: PGPB Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039995
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039995 A1

TITLE: Treatment of hearing impairments

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gao, Wei-Qiang	Foster City	CA	US	

US-CL-CURRENT: 514/2; 424/130.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

21. Document ID: US 20020037908 A1

L2: Entry 21 of 100 File: PGPB Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037908
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020037908 A1

TITLE: Methods and compositions for controlling protein assembly or aggregation

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Douglas, Michael G.	St. Louis	MO	US	
Amin, Avinash N.	St. Louis	MO	US	

US-CL-CURRENT: 514/350; 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

22. Document ID: US 20020006959 A1

L2: Entry 22 of 100 File: PGPB Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006959
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020006959 A1

TITLE: Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Henderson, Samuel T.	Broomfield	CO	US	

US-CL-CURRENT: 514/552; 514/561

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 23. Document ID: US 20020004483 A1

L2: Entry 23 of 100 File: PGPB Jan 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020004483
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020004483 A1

TITLE: G-CSF conjugates

PUBLICATION-DATE: January 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nissen, Torben Lauesgaard	Frederiksberg		DK	
Andersen, Kim Vilbour	Copenhagen		DK	
Hansen, Christian Karsten	Vedbaek		DK	
Mikkelsen, Jan Moller	Gentofte		DK	
Schambye, Hans Thalsgard	Frederiksberg		DK	

US-CL-CURRENT: 514/12; 530/395

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 24. Document ID: US 20010023241 A1

L2: Entry 24 of 100 File: PGPB Sep 20, 2001

PGPUB-DOCUMENT-NUMBER: 20010023241
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010023241 A1

TITLE: Use of heregulin as a growth factor

PUBLICATION-DATE: September 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sliwkowski, Mark X.	San Carlos	CA	US	
Kern, Jeffrey A.	Iowa City	IA	US	

US-CL-CURRENT: 514/2; 424/93.7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 25. Document ID: US 6504007 B1

L2: Entry 25 of 100 File: USPT Jan 7, 2003

US-PAT-NO: 6504007
DOCUMENT-IDENTIFIER: US 6504007 B1

TITLE: GDNF receptor

DATE-ISSUED: January 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; Robert D.	South San Francisco	CA		
Moore; Mark W.	San Francisco	CA		
Rosenthal; Arnon	Burlingham	CA		
Ryan; Anne M.	Millbrae	CA		

US-CL-CURRENT: 530/350; 930/10

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 26. Document ID: US 6479258 B1

L2: Entry 26 of 100 File: USPT Nov 12, 2002

US-PAT-NO: 6479258
DOCUMENT-IDENTIFIER: US 6479258 B1

TITLE: Non-stochastic generation of genetic vaccines

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Short; Jay M.	Rancho Santa Fe	CA		

US-CL-CURRENT: 435/69.1; 530/350, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 27. Document ID: US 6455262 B1

L2: Entry 27 of 100 File: USPT Sep 24, 2002

US-PAT-NO: 6455262
DOCUMENT-IDENTIFIER: US 6455262 B1

TITLE: Receptor polypeptides and their production and uses

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cox; Edward T.	Foster City	CA		
Mather; Jennie P.	Millbrae	CA		
Sliwkowski; Mary B.	San Carlos	CA		
Woodruff; Teresa K.	Millbrae	CA		

US-CL-CURRENT: 435/7.1; 435/7.2, 436/501

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

28. Document ID: US 6451764 B1

L2: Entry 28 of 100 File: USPT Sep 17, 2002

US-PAT-NO: 6451764
DOCUMENT-IDENTIFIER: US 6451764 B1

TITLE: VEGF-related protein

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; James	San Bruno	CA		
Wood; William	San Mateo	CA		

US-CL-CURRENT: 514/12; 530/399, 530/402

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

29. Document ID: US 6429196 B1

L2: Entry 29 of 100 File: USPT Aug 6, 2002

US-PAT-NO: 6429196
DOCUMENT-IDENTIFIER: US 6429196 B1

TITLE: Treatment of balance impairments

DATE-ISSUED: August 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gao; Wei-Qiang	Foster City	CA		

US-CL-CURRENT: 514/12; 514/21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

30. Document ID: US 6429191 B1

L2: Entry 30 of 100 File: USPT Aug 6, 2002

US-PAT-NO: 6429191
DOCUMENT-IDENTIFIER: US 6429191 B1

TITLE: Treatment of hearing impairments

DATE-ISSUED: August 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gao; Wei-Qiang	Foster City	CA		

US-CL-CURRENT: 514/2; 514/12, 514/192, 514/198, 514/199

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

31. Document ID: US 6420127 B1

L2: Entry 31 of 100 File: USPT Jul 16, 2002

US-PAT-NO: 6420127
DOCUMENT-IDENTIFIER: US 6420127 B1

TITLE: Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections

DATE-ISSUED: July 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hultgren; Scott	Ballwin	MO		
Kuehn; Meta	Berkeley	CA		
Xu; Zheng	Blue Bell	PA		
Ogg; Derek	Uppsala			SE
Harris; Mark	Uppsala			SE
Lepisto; Matti	Lund			SE
Jones; Charles Hal	Saint Louis	MO		
Kihlberg; Jan	Dalby			SE

US-CL-CURRENT: 435/7.37; 424/241.1, 424/242.1, 424/257.1, 435/849

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

32. Document ID: US 6372453 B1

L2: Entry 32 of 100 File: USPT Apr 16, 2002

US-PAT-NO: 6372453
DOCUMENT-IDENTIFIER: US 6372453 B1

TITLE: Neurturin receptor

DATE-ISSUED: April 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; Robert D.	Palo Alto	CA		
Rosenthal; Arnon	Burlingame	CA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/69.7, 435/70.1, 435/71.1, 530/300, 530/350, 530/827, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

33. Document ID: US 6342348 B1

L2: Entry 33 of 100 File: USPT Jan 29, 2002

US-PAT-NO: 6342348
DOCUMENT-IDENTIFIER: US 6342348 B1

TITLE: Neurturin receptor

DATE-ISSUED: January 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; Robert D.	Palo Alto	CA		
Rosenthal; Arnon	Burlingame	CA		
Hynes; Mary A.	San Mateo	CA		

US-CL-CURRENT: 435/4; 435/7.1, 435/7.8, 435/7.92, 435/7.93, 530/350, 530/412

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 34. Document ID: US 6331285 B1

L2: Entry 34 of 100 File: USPT Dec 18, 2001

US-PAT-NO: 6331285
DOCUMENT-IDENTIFIER: US 6331285 B1

TITLE: Structurally determined cyclic metallo-constructs and applications

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sharma; Shubh D.	Plainsboro	NJ		

US-CL-CURRENT: 424/1.69; 424/1.11, 424/1.65, 530/300, 530/317, 530/326, 530/333, 530/334

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 35. Document ID: US 6290957 B1

L2: Entry 35 of 100 File: USPT Sep 18, 2001

US-PAT-NO: 6290957
DOCUMENT-IDENTIFIER: US 6290957 B1

TITLE: Anti-IgE antibodies and method of improving polypeptides

DATE-ISSUED: September 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lowman; Henry B.	El Granada	CA	94018	
Presta; Leonard G.	San Francisco	CA	94109	
Jardieu; Paula M.	San Mateo	CA	94401-4319	
Lowe; John	Daly City	CA	94080	

US-CL-CURRENT: 424/133.1; 424/153.1, 424/810

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 36. Document ID: US 6270987 B1

L2: Entry 36 of 100 File: USPT Aug 7, 2001

US-PAT-NO: 6270987
DOCUMENT-IDENTIFIER: US 6270987 B1

TITLE: O-fucosyltransferase

DATE-ISSUED: August 7, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wang; Yang	Milbrae	CA		
Spellman; Michael W.	Belmont	CA		

US-CL-CURRENT: 435/68.1; 435/15, 435/193, 435/200, 435/41, 435/53, 435/72, 435/97

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 37. Document ID: US 6248867 B1

L2: Entry 37 of 100 File: USPT Jun 19, 2001

US-PAT-NO: 6248867
DOCUMENT-IDENTIFIER: US 6248867 B1

TITLE: Trabecular meshwork induced glucocorticoid response (TIGR) fusion protein

DATE-ISSUED: June 19, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nguyen; Thai D.	Mill Valley	CA	94941	
Polansky; Jon R.	Mill Valley	CA	94941	
Huang; Weidong	San Francisco	CA	94131	

US-CL-CURRENT: 530/350; 435/69.7, 536/23.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 38. Document ID: US 6225282 B1

L2: Entry 38 of 100 File: USPT May 1, 2001

US-PAT-NO: 6225282
DOCUMENT-IDENTIFIER: US 6225282 B1

TITLE: Treatment of hearing impairments

DATE-ISSUED: May 1, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gao; Wei-Qiang	Foster City	CA		

US-CL-CURRENT: 514/2; 514/12, 514/192, 514/198, 514/199

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 39. Document ID: US 6172213 B1

L2: Entry 39 of 100 File: USPT Jan 9, 2001

US-PAT-NO: 6172213
DOCUMENT-IDENTIFIER: US 6172213 B1

TITLE: Anti-IgE antibodies and method of improving polypeptides

DATE-ISSUED: January 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lowman; Henry B.	El Granada	CA		
Presta; Leonard G.	San Francisco	CA		
Jardieu; Paula M.	San Mateo	CA		
Lowe; John	Daly City	CA		

US-CL-CURRENT: 536/23.53; 435/252.3, 435/320.1, 435/69.6, 530/387.3, 530/388.73

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 40. Document ID: US 6159462 A

L2: Entry 40 of 100 File: USPT Dec 12, 2000

US-PAT-NO: 6159462
DOCUMENT-IDENTIFIER: US 6159462 A

TITLE: Uses of Wnt polypeptides

DATE-ISSUED: December 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Matthews; William	Woodside	CA		
Austin; Timothy W.	Morgan Hill	CA		

US-CL-CURRENT: 424/85.1; 424/85.2, 435/383, 435/395, 435/404, 435/405, 435/406, 514/2, 514/814, 530/350, 530/351, 530/868

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 41. Document ID: US 6153588 A

L2: Entry 41 of 100 File: USPT Nov 28, 2000

US-PAT-NO: 6153588
DOCUMENT-IDENTIFIER: US 6153588 A

TITLE: Stable non-hygroscopic crystalline form of N-[N-[N-4-(piperidin-4-yl)butanoyl)-N-ethylglycyl] aspartyl]-L-.beta.-cyclohexyl alanine amide

DATE-ISSUED: November 28, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chrzan; Zofia J.	Sellersville	PA		
Mencel; James J.	Lansdale	PA		
Toledo-Velasquez; David	Lansdale	PA		
Windisch; Vincent	Green Lane	PA		
Woodward; Rick G.	Harleysville	PA		
Salazar, deceased; Diane C.	late of Wayne	PA		
Vemuri; Narasimha M.	Phoenixville	PA		
Gardetto; Anthony J.	Oley	PA		
Powers; Matthew R.	Barto	PA		
Kubiak; Gregory G.	Wilmington	DE		
Liu; Robert C.	Walnut Creek	CA		
Vanasse; Benoit J.	Collegeville	PA		
Sherbine; James P.	Voorhees	NJ		
Rodriguez; Walter	Douglasville	PA		
Sledeski; Adam W.	Collegeville	PA		

US-CL-CURRENT: 514/18; 514/19, 530/331

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 42. Document ID: US 6153396 A

L2: Entry 42 of 100 File: USPT Nov 28, 2000

US-PAT-NO: 6153396
DOCUMENT-IDENTIFIER: US 6153396 A

TITLE: Treatment or prophylaxis of diseases caused by pilus-forming bacteria

DATE-ISSUED: November 28, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hultgren; Scott	Ballwin	MO		
Kuehn; Meta	Berkeley	CA		
Xu; Zheng	Blue Bell	PA		
Ogg; Derek	Uppsala			SE
Harris; Mark	Uppsala			SE
Lepisto ; Matti	Lund			SE
Kihlberg; Jan	Dalby			SE
Jones; Charles Hal	St. Louis	MO		

US-CL-CURRENT: 435/7.32; 424/241.1, 424/242.1, 424/257.1, 435/7.37, 435/849

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 43. Document ID: US 6150161 A

L2: Entry 43 of 100 File: USPT Nov 21, 2000

US-PAT-NO: 6150161
DOCUMENT-IDENTIFIER: US 6150161 A

TITLE: Methods for the diagnosis of glaucoma

DATE-ISSUED: November 21, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nguyen; Thai D.	Mill Valley	CA		
Polansky; Jon R.	Mill Valley	CA		
Huang; Weidong	San Francisco	CA		

US-CL-CURRENT: 435/325; 435/252.3, 435/254.2, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 44. Document ID: US 6121235 A

L2: Entry 44 of 100 File: USPT Sep 19, 2000

US-PAT-NO: 6121235
DOCUMENT-IDENTIFIER: US 6121235 A

TITLE: Treatment of balance impairments

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gao; Wei-Qiang	Foster City	CA		

US-CL-CURRENT: 514/12; 436/63, 436/86, 436/87, 514/21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 45. Document ID: US 6114328 A

L2: Entry 45 of 100 File: USPT Sep 5, 2000

US-PAT-NO: 6114328
DOCUMENT-IDENTIFIER: US 6114328 A

TITLE: Isoxazoline and isoxazole fibrogen receptor antagonists

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wityak; John	West Grove	PA		
Xue; Chu-Biao	Hockessin	DE		
Sielecki-Dzurdz; Thais Motria	Newark	DE		
Olson; Richard Eric	Wilmington	DE		
Degrado; William Frank	Moylan	PA		
Cain; Gary Avonn	Wilmington	DE		
Batt; Douglas Guy	Wilmington	DE		
Pinto; Donald	Newark	DE		
Hussain; Munir Alwan	Wilmington	DE		
Mousa; Shaker Ahmed	Lincoln University	PA		

US-CL-CURRENT: 514/227.8; 514/236.8, 514/253.1, 514/269, 514/307, 514/326, 514/340, 514/365, 514/378, 514/379, 514/380, 544/111, 544/137, 544/140, 544/297, 544/298, 544/322, 544/333, 544/60, 546/141, 546/143, 546/209, 546/272.1, 548/146, 548/240, 548/243, 548/248

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 46. Document ID: US 6100076 A

L2: Entry 46 of 100 File: USPT Aug 8, 2000

US-PAT-NO: 6100076
DOCUMENT-IDENTIFIER: US 6100076 A

TITLE: O-fucosyltransferase

DATE-ISSUED: August 8, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wang; Yang	Milbrae	CA		
Spellman; Michael W.	Belmont	CA		

US-CL-CURRENT: 435/193

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 47. Document ID: US 6083748 A

L2: Entry 47 of 100 File: USPT Jul 4, 2000

US-PAT-NO: 6083748
DOCUMENT-IDENTIFIER: US 6083748 A

TITLE: Antibodies which specifically bind to a novel .kappa./.mu.-like protein tyrosineospatase, PTP.lambda., and hybridoma cell lines producing the same

DATE-ISSUED: July 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cheng; Jill	Burlingame	CA		
Lasky; Laurence A.	Sausalito	CA		

US-CL-CURRENT: 435/338; 435/331, 435/334, 530/388.1, 530/388.22, 530/388.26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 48. Document ID: US 6057324 A

L2: Entry 48 of 100 File: USPT May 2, 2000

US-PAT-NO: 6057324
DOCUMENT-IDENTIFIER: US 6057324 A

TITLE: Substituted amidinobenzene derivatives and medicinal compositions thereof

DATE-ISSUED: May 2, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Matsumoto; Yuzo	Toride			JP
Akamatsu; Seijiro	Tsukuba			JP
Ichihara; Masato	Tsukuba			JP
Kawasaki; Tomihisa	Tsukuba			JP
Kaku; Seiji	Tsukuba			JP
Yanagisawa; Isao	Tokyo			JP

US-CL-CURRENT: 514/253.01; 544/360

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 49. Document ID: US 6027711 A

L2: Entry 49 of 100 File: USPT Feb 22, 2000

US-PAT-NO: 6027711
DOCUMENT-IDENTIFIER: US 6027711 A

TITLE: Structurally determined metallo-constructs and applications

DATE-ISSUED: February 22, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sharma; Shubh D.	Albuquerque	NM		

US-CL-CURRENT: 424/1.69; 424/1.11, 424/1.65, 530/300, 530/326, 530/327, 530/328, 530/329, 530/330, 530/331, 534/14

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 50. Document ID: US 6025157 A

L2: Entry 50 of 100 File: USPT Feb 15, 2000

US-PAT-NO: 6025157
DOCUMENT-IDENTIFIER: US 6025157 A

TITLE: Neurturin receptor

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; Robert D.	Palo Alto	CA		
Rosenthal; Arnon	Burlingame	CA		
Hynes; Mary A.	San Mateo	CA		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 51. Document ID: US 6018021 A

L2: Entry 51 of 100 File: USPT Jan 25, 2000

US-PAT-NO: 6018021
DOCUMENT-IDENTIFIER: US 6018021 A

TITLE: Human transaldolase: an autoantigen with a function in metabolism

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Perl; Andras	Jamesville	NY		

US-CL-CURRENT: 530/350; 530/387.1, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 52. Document ID: US 6001823 A

L2: Entry 52 of 100 File: USPT Dec 14, 1999

US-PAT-NO: 6001823
DOCUMENT-IDENTIFIER: US 6001823 A

TITLE: Treatment or prophylaxis of diseases caused by pilus-forming bacteria

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hultgren; Scott	Ballwin	MO		
Kuehn; Meta	Berkeley	CA	94705	
Xu; Zheng	Blue Bell	PA	19422	
Ogg; Derek	Uppsala			SE
Harris; Mark	S-756 45 Uppsala			SE
Lepisto ; Matti	S-224 73 Lund			SE
Kihlberg; Jan	S-240 10 Dalby			SE
Jones; Charles Hal	St. Louis	MO	63110	

US-CL-CURRENT: 514/99; 514/382, 514/459, 514/460, 548/252, 548/253, 549/216, 549/416, 549/417, 549/419, 549/420

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 53. Document ID: US 5994511 A

L2: Entry 53 of 100 File: USPT Nov 30, 1999

US-PAT-NO: 5994511
DOCUMENT-IDENTIFIER: US 5994511 A

TITLE: Anti-IgE antibodies and methods of improving polypeptides

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lowman; Henry B.	El Granada	CA		
Presta; Leonard G.	San Francisco	CA		
Jardieu; Paula M.	San Mateo	CA		
Lowe; John	Daly City	CA		

US-CL-CURRENT: 530/387.3; 424/133.1, 424/135.1, 424/145.1, 424/810, 436/548, 530/388.25, 530/868

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 54. Document ID: US 5977101 A

L2: Entry 54 of 100 File: USPT Nov 2, 1999

US-PAT-NO: 5977101
DOCUMENT-IDENTIFIER: US 5977101 A

TITLE: Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ali; Fadia El-Fehail	Cherry Hill	NJ		
Bondinell; William	Wayne	PA		
Huffman; William Francis	Malvern	PA		
Lago; M. Amparo	Audubon	PA		
Keenan; Richard McCulloch	Malvern	PA		
Kwon; Chet	King of Prussia	PA		
Miller; William Henry	Schwenksville	PA		
Nguyen; Thomas	King of Prussia	PA		
Takata; Dennis T.	Flourtown	PA		

US-CL-CURRENT: 514/221; 514/218, 514/220, 540/542, 540/553, 540/559, 540/562, 540/568, 540/570, 540/575

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 55. Document ID: US 5976852 A

L2: Entry 55 of 100 File: USPT Nov 2, 1999

US-PAT-NO: 5976852
DOCUMENT-IDENTIFIER: US 5976852 A

TITLE: K.kappa./.mu.-like protein tyrosine phosphatase, PTP .lambda.

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cheng; Jill	Burlingame	CA		
Lasky; Laurence A.	Saulito	CA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/325, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 56. Document ID: US 5952306 A

L2: Entry 56 of 100 File: USPT Sep 14, 1999

US-PAT-NO: 5952306
DOCUMENT-IDENTIFIER: US 5952306 A

TITLE: Integrin receptor antagonists

DATE-ISSUED: September 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hartman; George D.	Lansdale	PA		
Duggan; Mark E.	Schwenksville	PA		
Perkins; James J.	Churchville	PA		
Hunt; Cecilia A.	Plymouth Meeting	PA		
Krause; Amy E.	Blue Bell	PA		
Hutchinson; John H.	Philadelphia	PA		
Askew; Benny C.	Lansdale	PA		
Brashear; Karen M.	Perkasie	PA		
Ihle; Nathan C.	Mercer Island	WA		

US-CL-CURRENT: 514/18; 514/19, 544/360, 544/393, 546/122, 546/194, 546/273.4, 546/277.4, 546/300, 546/309, 546/331

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 57. Document ID: US 5928887 A

L2: Entry 57 of 100 File: USPT Jul 27, 1999

US-PAT-NO: 5928887
DOCUMENT-IDENTIFIER: US 5928887 A

TITLE: .kappa./.mu.-Like protein tyrosine phosphatase, PTP .lambda.

DATE-ISSUED: July 27, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cheng; Jill	Burlingame	CA		
Lasky; Laurence A.	Saulito	CA		

US-CL-CURRENT: 435/21; 435/196, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 58. Document ID: US 5891916 A

L2: Entry 58 of 100 File: USPT Apr 6, 1999

US-PAT-NO: 5891916
DOCUMENT-IDENTIFIER: US 5891916 A

TITLE: Aromatic hydroxamix acid compounds, their production and use

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kato; Kaneyoshi	Kawanishi			JP
Sugiura; Yoshihiro	Nara			JP
Naruo; Ken-ichi	Sanda			JP
Takahashi; Hideki	Osaka			JP

US-CL-CURRENT: 514/575; 514/617, 514/618, 514/620, 514/626, 558/233, 558/312, 558/392, 560/115, 560/312, 560/32, 560/45 , 564/300

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 59. Document ID: US 5879909 A

L2: Entry 59 of 100 File: USPT Mar 9, 1999

US-PAT-NO: 5879909
DOCUMENT-IDENTIFIER: US 5879909 A

TITLE: Human transaldolase: an autoantigen with a function in metabolism

DATE-ISSUED: March 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Perl; Andras	Jamesville	NY		

US-CL-CURRENT: 435/69.1; 435/325, 530/350, 536/23.1, 536/24.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 60. Document ID: US 5863755 A

L2: Entry 60 of 100 File: USPT Jan 26, 1999

US-PAT-NO: 5863755
DOCUMENT-IDENTIFIER: US 5863755 A

TITLE: Nucleic acid encoding novel receptor-type phosphotyrosine phosphatase-.kappa.

DATE-ISSUED: January 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schlessinger; Joseph	New York	NY		
Sap; Jan M.	New York	NY		
Ullrich; Axel	Munchen			DE
Vogel; Wolfgang	Germering			DE
Fuchs; Miriam	Starnberg			DE

US-CL-CURRENT: 435/69.1; 435/196, 435/252.3, 435/254.11, 435/320.1, 435/325, 536/23.5, 536/24.31

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 61. Document ID: US 5861497 A

L2: Entry 61 of 100 File: USPT Jan 19, 1999

US-PAT-NO: 5861497
DOCUMENT-IDENTIFIER: US 5861497 A

TITLE: Trabecular meshwork induced glucocorticoid response (TIGR) nucleic acid molecules

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nguyen; Thai D.	Mill Valley	CA		
Polansky; Jon R.	Mill Valley	CA		
Huang; Weidong	San Francisco	CA		

US-CL-CURRENT: 536/23.5; 536/23.1, 536/24.33

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 62. Document ID: US 5856162 A

L2: Entry 62 of 100 File: USPT Jan 5, 1999

US-PAT-NO: 5856162
DOCUMENT-IDENTIFIER: US 5856162 A

TITLE: Receptor-type phosphotyrosine phosphatase-.kappa.

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schlessinger; Joseph	New York	NY		
Sap; Jan M.	New York	NY		
Ullrich; Axel	Munchen			DE
Vogel; Wolfgang	Germering			DE
Fuchs; Miriam	Starnberg			DE

US-CL-CURRENT: 435/196; 435/69.1, 435/69.7, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 63. Document ID: US 5854415 A

L2: Entry 63 of 100 File: USPT Dec 29, 1998

US-PAT-NO: 5854415
DOCUMENT-IDENTIFIER: US 5854415 A

TITLE: Methods for the diagnosis of glaucoma

DATE-ISSUED: December 29, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nguyen; Thai D.	Mill Valley	CA		
Polansky; Jon R.	Mill Valley	CA		
Huang; Weidong	San Francisco	CA		

US-CL-CURRENT: 536/23.5; 536/24.3, 536/24.31, 536/24.33

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 64. Document ID: US 5851984 A

L2: Entry 64 of 100 File: USPT Dec 22, 1998

US-PAT-NO: 5851984
DOCUMENT-IDENTIFIER: US 5851984 A

TITLE: Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Matthews; William	Woodside	CA		
Austin; Timothy W.	Morgan Hill	CA		

US-CL-CURRENT: 514/2; 424/85.1, 435/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 65. Document ID: US 5849879 A

L2: Entry 65 of 100 File: USPT Dec 15, 1998

US-PAT-NO: 5849879
DOCUMENT-IDENTIFIER: US 5849879 A

TITLE: Methods for the diagnosis of glaucoma

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nguyen; Thai D.	Mill Valley	CA		
Polansky; Jon R.	Mill Valley	CA		
Huang; Weidong	Irvine	CA		

US-CL-CURRENT: 530/387.9; 424/139.1, 424/141.1, 424/152.1, 424/9.34, 530/387.1, 530/391.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 66. Document ID: US 5849736 A

L2: Entry 66 of 100 File: USPT Dec 15, 1998

US-PAT-NO: 5849736
DOCUMENT-IDENTIFIER: US 5849736 A

TITLE: Isoxazoline and isoxazole fibrinogen receptor antagonists

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wityak; John	West Grove	PA		
Xue; Chu-Biao	Hockessin	DE		
Sielecki-Dzurdz; Thais Motria	Newark	DE		
Olson; Richard Eric	Wilmington	DE		
Degrado; William Frank	Moylan	PA		
Cain; Gary Avonn	Wilmington	DE		
Batt; Douglas Guy	Wilmington	DE		
Pinto; Donald	Newark	DE		
Hussain; Munir Alwan	Wilmington	DE		
Mousa; Shaker Ahmed	Lincoln University	PA		

US-CL-CURRENT: 514/227.8; 514/236.8, 514/269, 514/307, 514/310, 514/326, 514/340, 514/365, 514/378, 514/379, 514/380, 544/111, 544/137, 544/140, 544/297, 544/298, 544/322, 544/333, 544/60, 546/141, 546/143, 546/15, 546/209 , 546/275.4, 548/146, 548/240, 548/245, 548/248

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 67. Document ID: US 5846734 A

L2: Entry 67 of 100 File: USPT Dec 8, 1998

US-PAT-NO: 5846734
DOCUMENT-IDENTIFIER: US 5846734 A

TITLE: Mammalian adipogenic factors

DATE-ISSUED: December 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Serrero; Ginette	Lake Placid	NY		

US-CL-CURRENT: 435/7.1; 435/26, 435/29

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 68. Document ID: US 5830647 A

L2: Entry 68 of 100 File: USPT Nov 3, 1998

US-PAT-NO: 5830647
DOCUMENT-IDENTIFIER: US 5830647 A

TITLE: Hybridization and amplification of nucleic acids encoding mpl ligand

DATE-ISSUED: November 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Eaton; Dan L.	San Rafael	CA		
de Sauvage; Frederic J.	Foster City	CA		

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 435/91.5, 530/351, 530/399, 536/24.3, 536/24.31, 536/24.32, 536/24.33

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 69. Document ID: US 5817769 A

L2: Entry 69 of 100 File: USPT Oct 6, 1998

US-PAT-NO: 5817769
DOCUMENT-IDENTIFIER: US 5817769 A

TITLE: Antibodies to mammalian adipogenic factors

DATE-ISSUED: October 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Serrero; Ginette	Lake Placid	NY		

US-CL-CURRENT: 530/389.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 70. Document ID: US 5804601 A

L2: Entry 70 of 100 File: USPT Sep 8, 1998

US-PAT-NO: 5804601
DOCUMENT-IDENTIFIER: US 5804601 A

TITLE: Aromatic hydroxamic acid compounds, their production and use

DATE-ISSUED: September 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kato; Kaneyoshi	Kawanishi			JP
Miki; Shokyo	Ibaraki			JP
Naruo; Ken-ichi	Sanda			JP
Takahashi; Hideki	Ikeda			JP

US-CL-CURRENT: 514/563; 546/136, 546/147, 548/171, 548/217, 552/299, 552/310, 562/874

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 71. Document ID: US 5789169 A

L2: Entry 71 of 100 File: USPT Aug 4, 1998

US-PAT-NO: 5789169
DOCUMENT-IDENTIFIER: US 5789169 A

TITLE: Methods for the diagnosis of glaucoma

DATE-ISSUED: August 4, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nguyen; Thai D.	Mill Valley	CA		
Polansky; Jon R.	Mill Valley	CA		
Huang; Weidong	Irvine	CA		

US-CL-CURRENT: 435/6; 435/7.1, 435/91.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

72. Document ID: US 5770567 A

L2: Entry 72 of 100 File: USPT Jun 23, 1998

US-PAT-NO: 5770567
DOCUMENT-IDENTIFIER: US 5770567 A

TITLE: Sensory and motor neuron derived factor (SMDF)

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ho; Wei-Hsien	Palo Alto	CA		
Osheroff; Phyllis L.	Woodside	CA		

US-CL-CURRENT: 514/12; 514/2, 530/350, 530/395, 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

73. Document ID: US 5763213 A

L2: Entry 73 of 100 File: USPT Jun 9, 1998

US-PAT-NO: 5763213
DOCUMENT-IDENTIFIER: US 5763213 A

TITLE: Sensory and motor neuron derived factor (SMDF)

DATE-ISSUED: June 9, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ho; Wei-Hsien	Palo Alto	CA		
Osheroff; Phyllis L.	Woodside	CA		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 74. Document ID: US 5756456 A

L2: Entry 74 of 100 File: USPT May 26, 1998

US-PAT-NO: 5756456
DOCUMENT-IDENTIFIER: US 5756456 A

TITLE: Methods involving sensory and motor neuron derived factor (SMDF)

DATE-ISSUED: May 26, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ho; Wei-Hsien	Palo Alto	CA		
Osheroff; Phyllis L.	Woodside	CA		

US-CL-CURRENT: 514/12; 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 75. Document ID: US 5747522 A

L2: Entry 75 of 100 File: USPT May 5, 1998

US-PAT-NO: 5747522
DOCUMENT-IDENTIFIER: US 5747522 A

TITLE: Amino acid derivatives

DATE-ISSUED: May 5, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alig; Leo	Kaiseraugst			CH
Hadvary; Paul	Biel-Benken			CH
Hurzeler; Marianne	Daniken			CH
Muller; Marcel	Frenkendorf			CH
Steiner; Beat	Battwil			CH
Weller; Thomas	Basel			CH

US-CL-CURRENT: 514/423; 514/210.17, 514/330, 546/226, 548/530, 548/537, 548/539, 548/953

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 76. Document ID: US 5739101 A

L2: Entry 76 of 100 File: USPT Apr 14, 1998

US-PAT-NO: 5739101

DOCUMENT-IDENTIFIER: US 5739101 A

TITLE: Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

DATE-ISSUED: April 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roy; Soumitra	San Francisco	CA		
Vehar; Gordon A.	San Carlos	CA		

US-CL-CURRENT: 514/2; 514/12, 514/822, 530/380, 530/381, 530/829

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 77. Document ID: US 5705890 A

L2: Entry 77 of 100 File: USPT Jan 6, 1998

US-PAT-NO: 5705890
DOCUMENT-IDENTIFIER: US 5705890 A

TITLE: Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor

DATE-ISSUED: January 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blackburn; Brent K.	San Francisco	CA		
Robarge; Kirk	San Francisco	CA		
Somers; Todd C.	Foster City	CA		

US-CL-CURRENT: 514/220; 514/219, 540/487, 540/498

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 78. Document ID: US 5670515 A

L2: Entry 78 of 100 File: USPT Sep 23, 1997

US-PAT-NO: 5670515
DOCUMENT-IDENTIFIER: US 5670515 A

TITLE: Amino acid derivatives

DATE-ISSUED: September 23, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alig; Leo	Kaiseraugst			CH
Hadvary; Paul	Biel-Benken			CH
Hurzeler; Marianne	Daniken			CH
Muller; Marcel	Frenkendorf			CH
Steiner; Beat	Battwil			CH
Weller; Thomas	Basel			CH

US-CL-CURRENT: 514/304; 546/125, 546/129

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments

KWIC | Draw Desc | Image

---

79. Document ID: US 5667780 A

L2: Entry 79 of 100 File: USPT Sep 16, 1997

US-PAT-NO: 5667780
DOCUMENT-IDENTIFIER: US 5667780 A

TITLE: Antibodies to SMDF

DATE-ISSUED: September 16, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ho; Wei-Hsien	Palo Alto	CA		
Osheroff; Phyllis L.	Woodside	CA		

US-CL-CURRENT: 424/139.1; 530/387.3, 530/387.9, 530/388.23, 530/388.85, 530/389.2, 530/391.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments

KWIC | Draw Desc | Image

---

80. Document ID: US 5658928 A

L2: Entry 80 of 100 File: USPT Aug 19, 1997

US-PAT-NO: 5658928
DOCUMENT-IDENTIFIER: US 5658928 A

TITLE: Amino acid derivatives

DATE-ISSUED: August 19, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alig; Leo	Kaiseraugst			CH
Hadvary; Paul	Biel-Benken			CH
Hurzeler; Marianne	Daniken			CH
Muller; Marcel	Frenkendorf			CH
Steiner; Beat	Battwil			CH
Weller; Thomas	Basel			CH

US-CL-CURRENT: 514/316; 514/317, 514/318, 546/182, 546/186, 546/192, 546/193

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 81. Document ID: US 5648465 A

L2: Entry 81 of 100 File: USPT Jul 15, 1997

US-PAT-NO: 5648465
DOCUMENT-IDENTIFIER: US 5648465 A

TITLE: Cloning and expression of neurocan, a chondroitin sulfate proteoglycan

DATE-ISSUED: July 15, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Margolis; Richard U.	New York	NY		
Rauch; Uwe	New York	NY		
Margolis; Renee K.	New York	NY		

US-CL-CURRENT: 530/350; 435/69.1, 530/395

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 82. Document ID: US 5606043 A

L2: Entry 82 of 100 File: USPT Feb 25, 1997

US-PAT-NO: 5606043
DOCUMENT-IDENTIFIER: US 5606043 A

TITLE: Methods for the diagnosis of glaucoma

DATE-ISSUED: February 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nguyen; Thai D.	Mill Valley	CA		
Polansky; Jon R.	Mill Valley	CA		
Huang; Weidong	San Francisco	CA		

US-CL-CURRENT: 536/23.5; 435/320.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 83. Document ID: US 5589363 A

L2: Entry 83 of 100 File: USPT Dec 31, 1996

US-PAT-NO: 5589363
DOCUMENT-IDENTIFIER: US 5589363 A

TITLE: DNA encoding tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

DATE-ISSUED: December 31, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roy; Soumitra	San Francisco	CA		
Vehar; Gordon A.	San Carlos	CA		

US-CL-CURRENT: 435/69.6; 435/252.3, 435/325, 435/348, 435/358, 435/369, 435/419, 530/381, 536/23.4, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 84. Document ID: US 5545658 A

L2: Entry 84 of 100 File: USPT Aug 13, 1996

US-PAT-NO: 5545658
DOCUMENT-IDENTIFIER: US 5545658 A

TITLE: Amino acid derivatives

DATE-ISSUED: August 13, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alig; Leo	Kaiseraugst			CH
Hadvary; Paul	Biel-Benken			CH
H urzeler; Marianne	D aniken			CH
M uller; Marcel	Frenkendorf			CH
Steiner; Beat	B attwil			CH
Weller; Thomas	Basel			CH

US-CL-CURRENT: 514/423; 548/530, 548/537

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 85. Document ID: US 5493020 A

L2: Entry 85 of 100 File: USPT Feb 20, 1996

US-PAT-NO: 5493020
DOCUMENT-IDENTIFIER: US 5493020 A

TITLE: Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor

DATE-ISSUED: February 20, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blackburn; Brent K.	San Francisco	CA		
Robarge; Kirk	San Francisco	CA		
Somers; Todd C.	Montara	CA		

US-CL-CURRENT: 540/498

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 86. Document ID: US 5449757 A

L2: Entry 86 of 100 File: USPT Sep 12, 1995

US-PAT-NO: 5449757
DOCUMENT-IDENTIFIER: US 5449757 A

TITLE: Mammalian adipogenic factors

DATE-ISSUED: September 12, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Serrero; Ginette	Lake Placid	NY		

US-CL-CURRENT: 530/350; 424/520, 424/572, 530/359, 530/395, 530/399, 530/412, 530/416, 530/417, 530/813, 530/830, 530/846, 530/850, 530/853

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 87. Document ID: US 5378712 A

L2: Entry 87 of 100 File: USPT Jan 3, 1995

US-PAT-NO: 5378712
DOCUMENT-IDENTIFIER: US 5378712 A

TITLE: Amino acid derivatives

DATE-ISSUED: January 3, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alig; Leo	Kaiseraugst			CH
Hadvary; Paul	Biel-Benken			CH
Hurzeler; Marianne	Daniken			CH
Muller; Marcel	Frenkendorf			CH
Steiner; Beat	Battwil			CH
Weller; Thomas	Basel			CH

US-CL-CURRENT: 514/315; 514/316, 514/326, 514/327, 514/328, 546/188, 546/208, 546/220, 546/221, 546/242

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 88. Document ID: US 5346991 A

L2: Entry 88 of 100 File: USPT Sep 13, 1994

US-PAT-NO: 5346991
DOCUMENT-IDENTIFIER: US 5346991 A

TITLE: Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

DATE-ISSUED: September 13, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roy; Soumitra	San Francisco	CA		
Vehar; Gordon A.	San Carlos	CA		

US-CL-CURRENT: 530/350; 530/381, 530/829

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 89. Document ID: US 5288854 A

L2: Entry 89 of 100 File: USPT Feb 22, 1994

US-PAT-NO: 5288854
DOCUMENT-IDENTIFIER: US 5288854 A

TITLE: Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1

DATE-ISSUED: February 22, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Diamond; Michael S.	Cambridge	MA		
Staunton; Donald E.	Chestnut Hill	MA		
Springer; Timothy A.	Newton	MA		

US-CL-CURRENT: 530/395; 424/143.1, 424/278.1, 530/350, 530/388.22, 530/808, 530/827, 530/868

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 90. Document ID: US 5286654 A

L2: Entry 90 of 100 File: USPT Feb 15, 1994

US-PAT-NO: 5286654
DOCUMENT-IDENTIFIER: US 5286654 A

TITLE: Detection and purification of activin polypeptide

DATE-ISSUED: February 15, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cox; Edward T.	Foster City	CA		
Mather; Jennie P.	Millbrae	CA		
Sliwkowski; Mary B.	San Carlos	CA		
Woodruff; Teresa K.	Millbrae	CA		

US-CL-CURRENT: 436/501; 436/536, 530/388.22, 530/395, 530/413

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 91. Document ID: US 5216126 A

L2: Entry 91 of 100 File: USPT Jun 1, 1993

US-PAT-NO: 5216126
DOCUMENT-IDENTIFIER: US 5216126 A

TITLE: Receptor polypeptides and their production and uses

DATE-ISSUED: June 1, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cox; Edward T.	Foster City	CA		
Mather; Jennie P.	Millbrae	CA		
Sliwkowski; Mary B.	San Carlos	CA		
Woodruff; Teresa K.	Millbrae	CA		

US-CL-CURRENT: 530/350; 530/388.22, 530/389.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 92. Document ID: US 5177092 A

L2: Entry 92 of 100 File: USPT Jan 5, 1993

US-PAT-NO: 5177092
DOCUMENT-IDENTIFIER: US 5177092 A

TITLE: Medicinal use of certain tetrazolium salts

DATE-ISSUED: January 5, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Remy; David C.	North Wales	PA		
Baldwin; John J.	Gwyneed Valley	PA		
Claremon; David A.	Maple Glen	PA		
King; Stella W.	Lansdale	PA		

US-CL-CURRENT: 514/381; 548/251

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 93. Document ID: US 5152988 A

L2: Entry 93 of 100 File: USPT Oct 6, 1992

US-PAT-NO: 5152988

DOCUMENT-IDENTIFIER: US 5152988 A

TITLE: Imidazole compounds in compositions and methods in thrombolytic therapy

DATE-ISSUED: October 6, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Claremon; David A.	Audbon	PA		
Remy; David C.	North Wales	PA		
Baldwin; John J.	Gwynedd Valley	PA		

US-CL-CURRENT: 424/94.64; 514/14, 514/161, 514/2, 514/212.07, 514/212.08, 514/228.2, 514/254.05, 514/257

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 94. Document ID: US 5098707 A

L2: Entry 94 of 100 File: USPT Mar 24, 1992

US-PAT-NO: 5098707
DOCUMENT-IDENTIFIER: US 5098707 A

TITLE: Imidazole compounds and their use as transglutaminase inhibitors

DATE-ISSUED: March 24, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baldwin; John J.	Gwyneed Valley	PA		
Remy; David C.	North Wales	PA		
Claremon; David A.	Audubon	PA		

US-CL-CURRENT: 424/94.64; 514/161, 514/2, 514/256, 514/398, 514/56, 514/822

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 95. Document ID: US 5047416 A

L2: Entry 95 of 100 File: USPT Sep 10, 1991

US-PAT-NO: 5047416
DOCUMENT-IDENTIFIER: US 5047416 A

TITLE: Triazole compounds and their use as transglutaminase inhibitors

DATE-ISSUED: September 10, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Remy; David C.	North Wales	PA		
Baldwin; John J.	Gwyneed Valley	PA		
Claremon; David A.	Audubon	PA		
King; Stella W.	Lansdale	PA		

US-CL-CURRENT: 514/384; 546/119, 548/251, 548/255, 548/264.4, 548/370.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

96. Document ID: US 5030644 A

L2: Entry 96 of 100 File: USPT Jul 9, 1991

US-PAT-NO: 5030644
DOCUMENT-IDENTIFIER: US 5030644 A

TITLE: Imidazole compounds and their use as transglutaminase inhibitors

DATE-ISSUED: July 9, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baldwin; John J.	Gwyneed Valley	PA		
Remy; David C.	North Wales	PA		
Claremon; David A.	Audubon	PA		

US-CL-CURRENT: 514/393; 514/255.05, 514/256, 514/278, 514/338, 514/341, 514/395, 514/398, 544/333, 544/406, 546/15, 546/273.1, 546/273.7, 546/274.4, 548/302.7, 548/307.1, 548/321.5, 548/324.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

97. Document ID: US 5021440 A

L2: Entry 97 of 100 File: USPT Jun 4, 1991

US-PAT-NO: 5021440
DOCUMENT-IDENTIFIER: US 5021440 A

TITLE: Imidazole compounds and their use as transglutaminase inhibitors

DATE-ISSUED: June 4, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Remy; David C.	North Wales	PA		
Baldwin; John J.	Gwyneed Valley	PA		
Claremon; David A.	Audubon	PA		
King; Stella W.	Lansdale	PA		

US-CL-CURRENT: 514/381; 514/393, 514/397, 548/251, 548/302.7, 548/312.7, 548/324.1, 548/325.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

98. Document ID: US 5019572 A

L2: Entry 98 of 100 File: USPT May 28, 1991

US-PAT-NO: 5019572
DOCUMENT-IDENTIFIER: US 5019572 A

TITLE: Imidazole compounds and their use as transglutaminase inhibitors

DATE-ISSUED: May 28, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Claremon; David A.	Audbon	PA		
Baldwin; John J.	Gwynedd Valley	PA		
Remy; David C.	North Wales	PA		

US-CL-CURRENT: 514/212.07; 514/212.08, 514/228.2, 514/254.05, 514/326, 514/398, 540/451, 544/359, 544/61, 546/210, 548/302.7, 548/314.7, 548/315.1, 548/315.7, 548/324.1, 548/325.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 99. Document ID: US 4968713 A

L2: Entry 99 of 100 File: USPT Nov 6, 1990

US-PAT-NO: 4968713
DOCUMENT-IDENTIFIER: US 4968713 A

TITLE: Certain imidazole compounds as transglutaminase inhibitors

DATE-ISSUED: November 6, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baldwin; John J.	Gwyneed Valley	PA		
Remy; David C.	North Wales	PA		
Claremon; David A.	Audubon	PA		

US-CL-CURRENT: 514/398; 548/324.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 100. Document ID: US 20020037908 A1

L2: Entry 100 of 100 File: DWPI Mar 28, 2002

DERWENT-ACC-NO: 2002-589123
DERWENT-WEEK: 200263
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Composition capable of solubilizing conformationally altered protein useful for treating e.g. Alzheimer's disease and cerebral amyloid angiopathy, comprises picolinic acid derivative and cation

INVENTOR: AMIN, A N; DOUGLAS, M G

PRIORITY-DATA: 2001US-0904987 (July 12, 2001), 1995US-0581351 (December 29, 1995), 1996US-026992P (September 20, 1996), 1996US-024221P (October 22, 1996),

1997US-0843157 (April 11, 1997), 1998US-0127620 (August 1, 1998), 2000US-0657554 (September 8, 2000), 2000US-0657989 (September 8, 2000), 2000US-0677500 (October 2, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020037908 A1	March 28, 2002		024	A61K031/455

INT-CL (IPC): A61 K 31/455; C07 K 14/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWMC | Draw. Desc | Image

Generate Collection | Print

Term	Documents
SOLUBIL$	0
SOLUBIL.DWPI,TDBD,EPAB,USPT,PGPB.	69
SOLUBILASE.DWPI,TDBD,EPAB,USPT,PGPB.	2
SOLUBILATION.DWPI,TDBD,EPAB,USPT,PGPB.	4
SOLUBILAZED.DWPI,TDBD,EPAB,USPT,PGPB.	5
SOLUBILE.DWPI,TDBD,EPAB,USPT,PGPB.	77
SOLUBILED.DWPI,TDBD,EPAB,USPT,PGPB.	1
SOLUBILESED.DWPI,TDBD,EPAB,USPT,PGPB.	1
SOLUBILETY.DWPI,TDBD,EPAB,USPT,PGPB.	1
SOLUBILEZER.DWPI,TDBD,EPAB,USPT,PGPB.	1
(L1 AND (SOLUBIL$)).USPT,PGPB,EPAB,DWPI,TDBD.	100

There are more results than shown above. Click here to view the entire set.

Display Format: - | Change Format

Previous Page Next Page

1: Antimicrob Agents Chemother 1993 Nov;37(11):2422-6 Related Articles, Links

Protective effect of picolinic acid on mice intracerebrally infected with lethal doses of Candida albicans.

Blasi E, Mazzolla R, Pitzurra L, Barluzzi R, Bistoni F.

Department of Experimental Medicine, University of Perugia, Italy.

We have studied the effects of picolinic acid (PLA), a product of tryptophan degradation, on mouse susceptibility to intracerebral infection with Candida albicans. We show that intraperitoneal administration of PLA significantly enhances the median survival time of mice inoculated with the lethal challenge. Furthermore, intracerebral administration of this agent induces a protective state against the local lethal infection, the phenomenon depending upon the administration schedule and doses of PLA employed. According to survival data, yeast growth in the brain as well as yeast colonization of the kidneys are drastically reduced in PLA-treated mice compared with those for untreated controls. Northern (RNA) blot analysis of brain tissues demonstrates that mRNA levels specific for tumor necrosis factor and interleukin 1 are augmented and induced, respectively, after inoculation of PLA. These results indicate that PLA has a protective effect likely involving elicitation of a cytokine response in vivo against fungal infections.

PMID: 7506894 [PubMed - indexed for MEDLINE]

```
FILE 'HOME' ENTERED AT 15:05:01 ON 30 JAN 2003

=> index chemistry bioscience medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

INDEX 'AGRICOLA, ALUMINIUM, ANABSTR, APOLLIT, AQUIRE, BABS, BIOCOMMERCE,
       BIOTECHNO, CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN,
       COMPENDEX, CONFSCI, COPPERLIT, CORROSION, ENCOMPLIT, ENCOMPLIT2, FEDRIP,
       GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ...'
ENTERED AT 15:05:20 ON 30 JAN 2003

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s ((picolin? or picolinic (w) acid) or (fusaric (w) acid) (s) ((protein same
aggregation or (protein same conformation?))
UNMATCHED LEFT PARENTHESIS 'S) ((PROTEIN'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s ((picolin? or picolinic (w) acid) or (fusaric (w) acid)) (s) ((protein same
aggregation or (protein same conformation?))
UNMATCHED LEFT PARENTHESIS 'S) ((PROTEIN'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s ((picolin? or picolinic (w) acid) or (fusaric (w) acid) (s) ((protein (s)
aggregation) or (protein (s) conformation?) )
UNMATCHED LEFT PARENTHESIS '((PICOLIN?'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s ((picolin? or picolinic (w) acid) or (fusaric (w) acid)) (s) ((protein (s)
aggregation) or (protein (s) conformation?) )
          1   FILE BABS
   8 FILES SEARCHED...
          2   FILE CAPLUS
  19 FILES SEARCHED...
          0*  FILE FEDRIP
          1   FILE INSPEC
  29 FILES SEARCHED...
  38 FILES SEARCHED...
          1   FILE SCISEARCH
  50 FILES SEARCHED...
  55 FILES SEARCHED...
          7   FILE DGENE
  60 FILES SEARCHED...
  69 FILES SEARCHED...
          1   FILE IFIPAT
  78 FILES SEARCHED...
          1   FILE TOXCENTER
          3   FILE USPATFULL
  88 FILES SEARCHED...
          1   FILE VETU
          2   FILE WPIDS
          2   FILE WPINDEX
  91 FILES SEARCHED...

  11 FILES HAVE ONE OR MORE ANSWERS,   92 FILES SEARCHED IN STNINDEX
```

```
L1   QUE ((PICOLIN? OR PICOLINIC (W) ACID) OR (FUSARIC (W) ACID)) (S) ((PROTEIN
          (S) AGGREGATION) OR (PROTEIN (S) CONFORMATION?) )

=> file hits
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      11.00      11.21

FILE 'DGENE' ENTERED AT 15:17:30 ON 30 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 15:17:30 ON 30 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 15:17:30 ON 30 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:17:30 ON 30 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'BABS' ENTERED AT 15:17:30 ON 30 JAN 2003
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'INSPEC' ENTERED AT 15:17:30 ON 30 JAN 2003
Compiled and produced by the IEE in association with FIZ KARLSRUHE
COPYRIGHT 2003 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'SCISEARCH' ENTERED AT 15:17:30 ON 30 JAN 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'IFIPAT' ENTERED AT 15:17:30 ON 30 JAN 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'TOXCENTER' ENTERED AT 15:17:30 ON 30 JAN 2003
COPYRIGHT (C) 2003 ACS

FILE 'VETU' ENTERED AT 15:17:30 ON 30 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> sl1
SL1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1
L2            7 FILE DGENE
L3            3 FILE USPATFULL
L4            2 FILE CAPLUS
L5            2 FILE WPIDS
L6            1 FILE BABS
L7            1 FILE INSPEC
L8            1 FILE SCISEARCH
L9            1 FILE IFIPAT
L10           1 FILE TOXCENTER
L11           1 FILE VETU

TOTAL FOR ALL FILES
L12          20 L1
```

```
=> dup rem l12
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L12
L13          16 DUP REM L12 (4 DUPLICATES REMOVED)

=> d l13 1-16 ibib abs

L13  ANSWER 1 OF 16  USPATFULL                          DUPLICATE 1
ACCESSION NUMBER:        2002:67255  USPATFULL
TITLE:                   Methods and compositions for controlling protein
                         assembly or aggregation
INVENTOR(S):             Douglas, Michael G., St. Louis, MO, UNITED STATES
                         Amin, Avinash N., St. Louis, MO, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2002037908      A1   20020328
APPLICATION INFO.:       US 2001-904987     A1   20010712  (9)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 2000-677500, filed
                         on 2 Oct 2000, PENDING Continuation-in-part of Ser. No.
                         US 2000-657554, filed on 8 Sep 2000, PENDING
                         Continuation-in-part of Ser. No. US 2000-657989, filed
                         on 8 Sep 2000, PENDING Continuation-in-part of Ser. No.
                         US 1998-127620, filed on 1 Aug 1998, GRANTED, Pat. No.
                         US 6127393 Continuation-in-part of Ser. No. US
                         1997-843157, filed on 11 Apr 1997, ABANDONED
                         Continuation-in-part of Ser. No. US 1995-581351, filed
                         on 29 Dec 1995, GRANTED, Pat. No. US 5767135

                              NUMBER         DATE
                         ---------------- --------
PRIORITY INFORMATION:    US 1996-24221P     19961022 (60)
                         US 1996-26992P     19960920 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    THOMPSON COBURN, LLP, ONE FIRSTAR PLAZA, SUITE 3500, ST
                         LOUIS, MO, 63101
NUMBER OF CLAIMS:        48
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      11 Drawing Page(s)
LINE COUNT:              1292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       Compositions and methods for controlling prepathological and
         pathological protein assembly or aggregation using
         picolinic acid, analogs, or derivatives thereof are
         described. The compositions of the invention, capable of solubilizing a
         conformationally altered protein, comprise a
         carboxylic acid anion of picolinic acid, its
         analogs, or derivatives thereof and a cation. According to the methods
         of the invention, conformationally altered protein
         assembly or aggregation in an animal is prevented or reversed
         by introducing the compositions of the invention to the
         conformationally altered protein. The compositions can
         be administered systemically by injection, oral administration,
         inhalation, transdermal, or other routes of administration. The
         compositions and methods can be used to treat diseases manifested by
         conformationally altered protein assembly or
         aggregation including, but not limited to Alzheimer's disease,
         spongiform encephalopathy, cerebral amyloid angiopathy, Parkinson's
         disease, frontal temporal dementia, Pick's disease, amyotrophic lateral
         sclerosis, Huntington's disease and Creutzfelds-Jakob disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

L13 ANSWER 2 OF 16 WPIDS (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: 2002-599674 [64] WPIDS
DOC. NO. NON-CPI: N2002-475448
DOC. NO. CPI: C2002-169495
TITLE: Treating or diagnosing cell proliferation, particularly a cancer characterized by aberrant expression of a MUC1 receptor (e.g. breast or prostate cancer) comprises administering agents that modulate a MUC1 growth factor receptor.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BAMDAD, C C; BAMDAD, R S
PATENT ASSIGNEE(S): (MINE-N) MINERVA BIOTECHNOLOGIES CORP
COUNTRY COUNT: 98
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002056022	A2	20020718	(200264)*	EN	129

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002056022	A2	WO 2001-US44782	20011127

PRIORITY APPLN. INFO: US 2001-298272P 20010614; US 2000-253361P 20001127; US 2000-255370P 20001213; US 2000-256027P 20001215; US 2000-258157P 20001222; US 2001-259615P 20010103; US 2001-260186P 20010105; US 2001-266169P 20010202; US 2001-266929P 20010206; US 2001-278093P 20010323; US 2001-289444P 20010507; US 2001-294887P 20010531

AN 2002-599674 [64] WPIDS

AB WO 200256022 A UPAB: 20021007

NOVELTY - Treating a subject to reduce the risk of or progression of cancer by administering an agent for:

(a) inhibiting interaction of an activating ligand with a portion of a cell surface receptor that interacts with the activating ligand to promote cell proliferation; or

(b) preventative clustering of portions of cell surface receptors that interact with an activating ligand.

DETAILED DESCRIPTION - Treating a subject to reduce the risk of or progression of cancer by administering to a subject who is known to be at risk for cancer or is diagnosed with cancer, an agent for:

(a) inhibiting interaction of an activating ligand with a portion of a cell surface receptor that interacts with the activating ligand to promote cell proliferation; or

(b) preventative clustering of portions of cell surface receptors that interact with an activating ligand.

INDEPENDENT CLAIMS are also included for the following:

(1) methods for screening drugs;

(2) kits for drug screening, or for diagnosis or treatment of cell proliferation;

(3) compositions comprising:

(a) a portion of a shed cell surface receptor interchain binding region; and

(b) a signaling entity immobilized relative to or adapted to be

immobilized relative to the portion;

(4) a peptide species comprising a fragment of a sequence that corresponds to that portion of a cell surface receptor that interacts with an activating ligand such as a growth factor to promote cell proliferation, the portion being detached from any cell, and an affinity tag;

(5) methods for determining disruption of the interaction by the candidate drug;

(6) a method comprising determining an amount of cleavage of a cell surface receptor interchain binding region from a cell surface, and evaluating indication of cancer or potential for cancer, based upon the determining step;

(7) a method of determining a cleavage site of a cell surface; and

(8) a method of diagnosing a physiological state indicative of cancer or potential for cancer by determining a specific cleavage state of MUC 1 distinguishable from a different cleavage state of MUC1.

ACTIVITY - Cytostatic. T47D cells were grown to approximately 30 % confluency. Etomoxir was added and cell proliferation was observed to be arrested. Then a synthetic peptide, S2, was added to the cell growth media. Addition of S2 caused increased cell proliferation, due to consumption of Etomoxir by S2.

Pro-Ser-Met-Gly-Phe-Arg (S2)

MECHANISM OF ACTION - MUC1 Growth Factor Receptor modulator.

USE - The method is useful for treating or diagnosing cell proliferation, particularly cancer of the breast, prostate, lung, ovary, colorectal or brain. In particular, the cancer is characterized by aberrant expression of MUC1 receptor (all claimed).

Dwg.0/20

L13 ANSWER 3 OF 16 USPATFULL

ACCESSION NUMBER:	2001:150382 USPATFULL
TITLE:	Antigenic epitopes with Lym-1 reactivity and uses thereof
INVENTOR(S):	Rose, Larry M., Carmichael, CA, United States Meares, Claude F., Davis, CA, United States O'Donnell, Robert T., Sacramento, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001019828	A1	20010906
APPLICATION INFO.:	US 2001-832510	A1	20010410 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-181896, filed on 28 Oct 1998, GRANTED, Pat. No. US 6217871		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1473		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel peptide epitopes recognized by the non-Hodgkin's B cell lymphoma reactive Lym-1 antibody. These novel peptide epitopes are capable of generating antibodies directed against Lym-1 peptide epitope expressing B-NHL cells. This invention is also directed to the treatment of B-NHL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 16 USPATFULL

ACCESSION NUMBER:	2001:55449 USPATFULL
TITLE:	Antigenic epitopes with LYM-1 reactivity and uses thereof
INVENTOR(S):	Rose, Larry M., Carmichael, CA, United States

PATENT ASSIGNEE(S):	Meares, Claude F., Davis, CA, United States O'Donnell, Robert T., Sacramento, CA, United States The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6217871	B1	20010417	
APPLICATION INFO.:	US 1998-181896		19981028	(9)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Huff, Sheela
LEGAL REPRESENTATIVE:	Townsend & Townsend & Crew LLP
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT:	1381

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel peptide epitopes recognized by the non-Hodgkin's B cell lymphoma reactive Lym-1 antibody. These novel peptide epitopes are capable of generating antibodies directed against Lym-1 peptide epitope expressing B-NHL cells. This invention is also directed to the treatment of B-NHL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 16 SCISEARCH COPYRIGHT 2003 ISI (R)

ACCESSION NUMBER:	95:818131 SCISEARCH
THE GENUINE ARTICLE:	TF982
TITLE:	4,4'-BIS(2-PICOLINIMINO)-2,2'-BIBENZIMIDAZOLES - A NEW CLASS OF DINUCLEATING LIGANDS WHICH ALLOW FOR A TUNING OF THE METAL-METAL DISTANCE - STRUCTURES AND PROPERTIES OF A DICOPPER(II) COMPLEX AND OF 2 OXYGENATION PRODUCTS OF A DICOPPER(I) COMPLEX - A TENTATIVE COORDINATION CHEMICAL MODELING OF HEMOCYANIN
AUTHOR:	MULLER E (Reprint); BERNARDINELLI G; REEDIJK J
CORPORATE SOURCE:	LEIDEN UNIV, LEIDEN INST CHEM, GORLAEUS LABS, POB 9502, 2300 RA LEIDEN, NETHERLANDS (Reprint); UNIV GENEVA, CRISTALLOG LAB, CH-1211 GENEVA, SWITZERLAND
COUNTRY OF AUTHOR:	NETHERLANDS; SWITZERLAND
SOURCE:	INORGANIC CHEMISTRY, (22 NOV 1995) Vol. 34, No. 24, pp. 5979-5988. ISSN: 0020-1669.
DOCUMENT TYPE:	Article; Journal
FILE SEGMENT:	PHYS
LANGUAGE:	ENGLISH
REFERENCE COUNT:	86

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The title compounds (L), derived from 1,1'-disubstituted 4,4'-diamino-2,2'-bibenzimidazoles and 2-pyridinecarboxaldehyde, were developed as models for type 3 sites of the copper **proteins** hemocyanin and tyrosinase. These hollow, ditopic ligands can hold two metal ions face to face at distances of 3.15 Angstrom or larger. The metal-metal distance can be restricted (tuned) to a given value via a corresponding polymethylene bridge in the ligand's backbone. The complex [Cu-2(II)(L)(dmf)(3)(H2O)(2)](F3CSO3)(4) of the unrestricted ligand 1,1',5,5',6,6'-hexamethyl-4,4'-bis(2-**picolinimino**)-2, 2'-bibenzimidazole (L) (space group: P-1, a = 14.811(21) Angstrom, b = 15.358(26) Angstrom, c = 16.209(9) Angstrom, alpha = 95.57(9)degrees, beta = 107.56(9)degrees, gamma = 110.35(13)degrees, Z = 2) presents an open **conformation** with discrete (4 + 2) copper coordination environments, where two dimethylformamide (dmf) molecules occupy the fourth positions of the equatorial CuN3O squares ([Cu-N] = 2.02 Angstrom, [Cu-O] = 1.95 Angstrom). Two water molecules, a dmf and one of the triflate anions, are coordinated to the four axial positions (Cu-O of

2.28-2.74 Angstrom). The two halves of the ligand are rotated out of the cis-coplanar **conformation** by 115.7 degrees, resulting in a relatively long Cu ... Cu distance of 6.16 Angstrom. In acetonitrile, the complex shows two irreversible Cu(II)/Cu(I) redox potentials at 0.60 and 0.30 V (NHE). Two oxygenation products of the dicopper(I) complex of the restricted ligand 1,1'-trimethylene-5,5',6,6'-tetramethyl-4,4'- (L3), which best approaches the geometry of a type 3 site, were isolated in the crystalline state. The first one, [Cu-4(II)(H-2(L3)O-2(2-))(2)](ClO4)(4) (orthorhombic: Ccca, a = 16.171(3) Angstrom, b = 19.760(4) Angstrom, c = 22.168(5) Angstrom, Z = 4), is a tetranuclear copper (II) cluster, best described as a symmetric Cu4O4 eight membered ring (Cu ... Cu distances of 3.05, 3.50, and 6.30 Angstrom), attached to two L3 molecules, with the four oxy anions covalently linked to the azomethine carbons (forming the L3 derivative H-2(L3)O-2(2-)). The second oxygenation product, [Cu-2(I)(L3')(2)](ClO4)(2) (monoclinic: C2/c, a = 23.500-(3) Angstrom, b = 12.569(5) Angstrom, c = 19.926(8) Angstrom, beta = 106.71(2)degrees, Z = 4), is a dinuclear copper(I) complex of L3', a degradation product of L3, carrying a free amino group on one side. The copper(II) ions are in a bis(diimine) type, distorted tetrahedral environment (dihedral angle 79.1 degrees), with a Cu ... Cu distance of 4.59 Angstrom. About 25% of the ligand L3' appears to be oxidized at the free amino group to the corresponding quinonimine, as deduced from the X-ray structure determination.

L13 ANSWER 6 OF 16 VETU COPYRIGHT 2003 THOMSON DERWENT
ACCESSION NUMBER: 1997-61291 VETU
TITLE: Potential of exogenous metabolic modifiers for the pig industry.
AUTHOR: Dunshea F R; Walton P E
CORPORATE SOURCE: Victorian-Inst.Anim.Sci.
LOCATION: Werribee; Adelaide, Austr.
SOURCE: Manipulating Pig Prod. (5 Meet., 42-51, 1995) 7 Fig. 2 Tab. Ref.
AVAIL. OF DOC.: Agriculture Victoria, Victorian Institute of Animal Science, Werribee, Victoria 3030, Australia.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1997-61291 VETU
AB The role of metabolic modifiers, i.e. porcine somatotropin (pST), beta-agonists (ractopamine, salbutamol, cimaterol, clenbuterol, RO-16-8714, BRL-47672, L-644969), betaine, chromium picolinate, somatomedin C (IGF-I), in the grower/finisher pig and factors affecting their efficacy are reviewed. The possibility of manipulating the growth of the neonatal piglet, whose performance is far below potential, is discussed. (conference paper).
ABEX pST improves ADG and feed conversion efficiency (FCE), increasing lean deposition and reducing fat deposition in boars, gilts and barrows. Feed intake is reduced; efficiency of utilization of dietary **protein** and maintenance energy requirement are increased. Providing additional energy to pST treated pigs is beneficial, and for the full benefit feed intake needs to be maximized. Beta-agonists, particularly ractopamine, increase ADG, FCE and carcass lean without affecting feed intake; **protein** deposition is increased; effects on fat deposition are equivocal; there is no effect on nutrient digestibility, but dietary requirement for **protein** is increased. Efficiency of use of dietary **protein** is not affected. Response to ractopamine is limited by dietary energy intake. Betaine has no effect on ADG or feed intake but decreases backfat by repartitioning and changing body **conformation**. Betaine may interact with dietary methionine. Chromium **picolinate** has no effect on ADG or FCE but increases carcass lean, changes body **conformation** and repartitions nutrients. IGF-I improves lean tissue growth in **protein** restricted finisher pigs but negative feedback mechanisms limit its usefulness in those fed adequate dietary

protein. In very young piglets, unresponsive to pST, negative feedback to IGF-I is absent and IGF-I increases ADG and growth of small intestine, liver and spleen. As gut development and growth is essential for efficient nutrient absorption and protection against bacterial invasion this may be the mode of action of IGF-I.

L13 ANSWER 7 OF 16 INSPEC COPYRIGHT 2003 IEE
ACCESSION NUMBER: 1986:2572602 INSPEC
DOCUMENT NUMBER: A86011919
TITLE: Calibration of ring-current models for the heme ring.
AUTHOR: Cross, K.J.; Wright, P.E. (Dept. of Molecular Biol., Res. Inst. Scripps Clinic, La Jolla, CA, USA)
SOURCE: Journal of Magnetic Resonance (Sept. 1985) vol.64, no.2, p.220-31. 42 refs.
Price: CCCC 0022-2364/85$3.00
CODEN: JOMRA4 ISSN: 0022-2364
DOCUMENT TYPE: Journal
TREATMENT CODE: Experimental
COUNTRY: United States
LANGUAGE: English
DN A86011919
AB Three ring-current models for the heme ring system have been calibrated using data from cytochrome c, cytochrome c551, cytochrome b5, and pyridine and **picoline** complexes of zinc porphyrin. Excellent agreement between observed and calculated shifts was obtained, even for protons in close proximity to the heme ring. Best agreement was obtained with the eight-loop Johnson-Bovey and five-loop Haigh-Mallion models. Data was fitted less well when a Johnson-Bovey five-loop model was used. The new calibrations provide a basis for **conformational** studies of diamagnetic heme **proteins**.

L13 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1970:443242 CAPLUS
DOCUMENT NUMBER: 73:43242
TITLE: Antigenic properties of a homogeneous tobacco mosaic virus-hapten conjugate
AUTHOR(S): Slobin, Lawrence I.
CORPORATE SOURCE: Div. of Biol. Sci., Cornell Univ., Ithaca, NY, USA
SOURCE: Nature (London, United Kingdom) (1970), 225(5234), 698-701
CODEN: NATUAS; ISSN: 0028-0836
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The immune responses of mice and horses to **proteins** treated with Me **picolinimidate** suggested that anti-hapten antibodies are induced only if the hapten modifies the **conformation** of the **protein** carrier. Animals immunized with picolinimidated tobacco-mosaic virus (P-TMV) did not form antibodies with specificity toward the picolinimidyl group, although they produced large amts. of viral specific antibodies. The failure of P-TMV to elicit anti-hapten antibody may have been due to a lack of significant modification of the tertiary structure of the protein subunits or the quaternary structure of the intact virion by the amidination reaction.

L13 ANSWER 9 OF 16 DGENE (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: ABB78013 protein DGENE
TITLE: Composition capable of solubilizing **conformationally** altered **protein** useful for treating e.g. Alzheimer's disease and cerebral amyloid angiopathy, comprises **picolinic acid** derivative and cation -
INVENTOR: Douglas M G; Amin A N
PATENT ASSIGNEE: (DOUG-I) DOUGLAS M G.
(AMIN-I) AMIN A N.
PATENT INFO: US 2002037908 A1 20020328

APPLICATION INFO: US 2001-904987 20010712
PRIORITY INFO: US 1996-26992P 19960920
US 1996-24221P 19961022
US 1995-581351 19951229
US 1997-843157 19970411
US 1998-127620 19980801
US 2000-657554 20000908
US 2000-657989 20000908
US 2000-677500 20001002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-589123 [63]
AN ABB78013 protein DGENE
AB The specification describes a composition which is capable of solubilising a **conformationally** altered **protein**. The composition comprises a carboxylic acid anion of **picolinic acid**, its analogues or derivatives, and a cation, but does not include **picolinates** of zinc, chromium, molybdenum, iron, manganese, copper, boron or vanadium. The composition is useful for treating Alzheimer's disease, spongiform encephalopathy, cerebral amyloid angiopathy, Parkinson's disease, frontal temporal dementia, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease and Creutzfeld-Jakob disease. The present sequence represents a human huntingtin **protein**. The **protein** represents a **conformationally** altered **protein** which is solubilised by the composition of the invention.

L13 ANSWER 10 OF 16 DGENE (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: ABB78012 protein DGENE
TITLE: Composition capable of solubilizing **conformationally** altered **protein** useful for treating e.g. Alzheimer's disease and cerebral amyloid angiopathy, comprises **picolinic acid** derivative and cation -
INVENTOR: Douglas M G; Amin A N
PATENT ASSIGNEE: (DOUG-I) DOUGLAS M G.
(AMIN-I) AMIN A N.
PATENT INFO: US 2002037908 A1 20020328 24p
APPLICATION INFO: US 2001-904987 20010712
PRIORITY INFO: US 1996-26992P 19960920
US 1996-24221P 19961022
US 1995-581351 19951229
US 1997-843157 19970411
US 1998-127620 19980801
US 2000-657554 20000908
US 2000-657989 20000908
US 2000-677500 20001002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-589123 [63]
AN ABB78012 protein DGENE
AB The specification describes a composition which is capable of solubilising a **conformationally** altered **protein**. The composition comprises a carboxylic acid anion of **picolinic acid**, its analogues or derivatives, and a cation, but does not include **picolinates** of zinc, chromium, molybdenum, iron, manganese, copper, boron or vanadium. The composition is useful for treating Alzheimer's disease, spongiform encephalopathy, cerebral amyloid angiopathy, Parkinson's disease, frontal temporal dementia, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease and Creutzfeld-Jakob disease. The present sequence represents a human superoxide dismutase (SOD). The **protein** represents a **conformationally** altered **protein** which is solubilised by the composition of the invention.

L13 ANSWER 11 OF 16 DGENE (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: ABB78011 protein DGENE
TITLE: Composition capable of solubilizing **conformationally** altered **protein** useful for treating e.g. Alzheimer's disease and cerebral amyloid angiopathy, comprises **picolinic acid** derivative and cation -
INVENTOR: Douglas M G; Amin A N
PATENT ASSIGNEE: (DOUG-I) DOUGLAS M G.
(AMIN-I) AMIN A N.
PATENT INFO: US 2002037908 A1 20020328 24p
APPLICATION INFO: US 2001-904987 20010712
PRIORITY INFO: US 1996-26992P 19960920
US 1996-24221P 19961022
US 1995-581351 19951229
US 1997-843157 19970411
US 1998-127620 19980801
US 2000-657554 20000908
US 2000-657989 20000908
US 2000-677500 20001002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-589123 [63]
AN ABB78011 protein DGENE
AB The specification describes a composition which is capable of solubilising a **conformationally** altered **protein**. The composition comprises a carboxylic acid anion of **picolinic acid**, its analogues or derivatives, and a cation, but does not include **picolinates** of zinc, chromium, molybdenum, iron, manganese, copper, boron or vanadium. The composition is useful for treating Alzheimer's disease, spongiform encephalopathy, cerebral amyloid angiopathy, Parkinson's disease, frontal temporal dementia, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease and Creutzfeld-Jakob disease. The present sequence represents a human tau **protein**. The **protein** represents a **conformationally** altered **protein** which is solubilised by the composition of the invention.

L13 ANSWER 12 OF 16 DGENE (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: ABB78010 protein DGENE
TITLE: Composition capable of solubilizing **conformationally** altered **protein** useful for treating e.g. Alzheimer's disease and cerebral amyloid angiopathy, comprises **picolinic acid** derivative and cation -
INVENTOR: Douglas M G; Amin A N
PATENT ASSIGNEE: (DOUG-I) DOUGLAS M G.
(AMIN-I) AMIN A N.
PATENT INFO: US 2002037908 A1 20020328 24p
APPLICATION INFO: US 2001-904987 20010712
PRIORITY INFO: US 1996-26992P 19960920
US 1996-24221P 19961022
US 1995-581351 19951229
US 1997-843157 19970411
US 1998-127620 19980801
US 2000-657554 20000908
US 2000-657989 20000908
US 2000-677500 20001002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-589123 [63]
AN ABB78010 protein DGENE
AB The specification describes a composition which is capable of solubilising a **conformationally** altered **protein**. The composition comprises a carboxylic acid anion of **picolinic**

acid, its analogues or derivatives, and a cation, but does not include **picolinates** of zinc, chromium, molybdenum, iron, manganese, copper, boron or vanadium. The composition is useful for treating Alzheimer's disease, spongiform encephalopathy, cerebral amyloid angiopathy, Parkinson's disease, frontal temporal dementia, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease and Creutzfeld-Jakob disease. The present sequence represents a human alpha-synuclein **protein**. The **protein** represents a **conformationally** altered **protein** which is solubilised by the composition of the invention.

L13 ANSWER 13 OF 16 DGENE (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: ABB78009 protein DGENE
TITLE: Composition capable of solubilizing **conformationally** altered **protein** useful for treating e.g. Alzheimer's disease and cerebral amyloid angiopathy, comprises **picolinic acid** derivative and cation -
INVENTOR: Douglas M G; Amin A N
PATENT ASSIGNEE: (DOUG-I) DOUGLAS M G.
(AMIN-I) AMIN A N.
PATENT INFO: US 2002037908 A1 20020328 24p
APPLICATION INFO: US 2001-904987 20010712
PRIORITY INFO: US 1996-26992P 19960920
US 1996-24221P 19961022
US 1995-581351 19951229
US 1997-843157 19970411
US 1998-127620 19980801
US 2000-657554 20000908
US 2000-657989 20000908
US 2000-677500 20001002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-589123 [63]
AN ABB78009 protein DGENE
AB The specification describes a composition which is capable of solubilising a **conformationally** altered **protein**. The composition comprises a carboxylic acid anion of **picolinic acid**, its analogues or derivatives, and a cation, but does not include **picolinates** of zinc, chromium, molybdenum, iron, manganese, copper, boron or vanadium. The composition is useful for treating Alzheimer's disease, spongiform encephalopathy, cerebral amyloid angiopathy, Parkinson's disease, frontal temporal dementia, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease and Creutzfeld-Jakob disease. The present sequence represents a human prion **protein**. The **protein** represents a **conformationally** altered **protein** which is solubilised by the composition of the invention.

L13 ANSWER 14 OF 16 DGENE (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: ABB78008 protein DGENE
TITLE: Composition capable of solubilizing **conformationally** altered **protein** useful for treating e.g. Alzheimer's disease and cerebral amyloid angiopathy, comprises **picolinic acid** derivative and cation -
INVENTOR: Douglas M G; Amin A N
PATENT ASSIGNEE: (DOUG-I) DOUGLAS M G.
(AMIN-I) AMIN A N.
PATENT INFO: US 2002037908 A1 20020328 24p
APPLICATION INFO: US 2001-904987 20010712
PRIORITY INFO: US 1996-26992P 19960920
US 1996-24221P 19961022
US 1995-581351 19951229
US 1997-843157 19970411

US 1998-127620 19980801
US 2000-657554 20000908
US 2000-657989 20000908
US 2000-677500 20001002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-589123 [63]
AN ABB78008 protein DGENE
AB The specification describes a composition which is capable of solubilising a **conformationally** altered **protein**. The composition comprises a carboxylic acid anion of **picolinic acid**, its analogues or derivatives, and a cation, but does not include **picolinates** of zinc, chromium, molybdenum, iron, manganese, copper, boron or vanadium. The composition is useful for treating Alzheimer's disease, spongiform encephalopathy, cerebral amyloid angiopathy, Parkinson's disease, frontal temporal dementia, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease and Creutzfeld-Jakob disease. The present sequence represents a beta-amyloid precursor **protein** (APP). The **protein** represents a **conformationally** altered **protein** which is solubilised by the composition of the invention.

L13 ANSWER 15 OF 16 DGENE (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: ABB78007 peptide DGENE
TITLE: Composition capable of solubilizing **conformationally** altered **protein** useful for treating e.g. Alzheimer's disease and cerebral amyloid angiopathy, comprises **picolinic acid** derivative and cation -
INVENTOR: Douglas M G; Amin A N
PATENT ASSIGNEE: (DOUG-I) DOUGLAS M G.
(AMIN-I) AMIN A N.
PATENT INFO: US 2002037908 A1 20020328 24p
APPLICATION INFO: US 2001-904987 20010712
PRIORITY INFO: US 1996-26992P 19960920
US 1996-24221P 19961022
US 1995-581351 19951229
US 1997-843157 19970411
US 1998-127620 19980801
US 2000-657554 20000908
US 2000-657989 20000908
US 2000-677500 20001002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-589123 [63]
AN ABB78007 peptide DGENE
AB The specification describes a composition which is capable of solubilising a **conformationally** altered **protein**. The composition comprises a carboxylic acid anion of **picolinic acid**, its analogues or derivatives, and a cation, but does not include **picolinates** of zinc, chromium, molybdenum, iron, manganese, copper, boron or vanadium. The composition is useful for treating Alzheimer's disease, spongiform encephalopathy, cerebral amyloid angiopathy, Parkinson's disease, frontal temporal dementia, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease and Creutzfeld-Jakob disease. The present sequence represents the beta-amyloid peptide of beta-amyloid precursor **protein** (APP). The peptide represents a **conformationally** altered **protein** which is solubilised by the composition of the invention.

L13 ANSWER 16 OF 16 BABS COPYRIGHT 2003 BEILSTEIN CDS MDLI
ACCESSION NUMBER: 5988664 BABS
TITLE: Calibration of Ring-Current Models for the Heme Ring
AUTHOR(S): Cross, Keith J.; Wright, Peter E.
SOURCE: J.Magn.Reson. (1985), 64(2), 220-231

CODEN: JOMRA4
DOCUMENT TYPE: Journal
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 5988664 BABS
AB Three ring-current models for the heme ring system have been calibrated using data from cytochrome c, cytochrome c&551%, cytochrome b&5%, and pyridine and **picoline** complexes of zinc porphyrin.Excellent agreement between observed and calculated shifts was obtained, even for protons in close proximity to the heme ring.Best agreement was obtained with the eight-loop Johnson-Bovey and five-loop Haigh-Mallion models.Data was fitted less well when a Johnson-Bovey five-loop model was used.The new calibrations provide a basis for **conformational** studies of diamagnetic heme **proteins**.

=> s (picolin) and ((protein? or polypeptide?) (s) AGGREGATION)
) IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s picolin? and ((protein? or polypeptide?) (s) AGGREGATION)
L14 0 FILE DGENE
L15 159 FILE USPATFULL
L16 1 FILE CAPLUS
L17 1 FILE WPIDS
L18 0 FILE BABS
L19 0 FILE INSPEC
L20 0 FILE SCISEARCH
L21 1 FILE IFIPAT
L22 1 FILE TOXCENTER
L23 0 FILE VETU

TOTAL FOR ALL FILES
L24 163 PICOLIN? AND ((PROTEIN? OR POLYPEPTIDE?) (S) AGGREGATION)

=> dup rem l24
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L24
L25 159 DUP REM L24 (4 DUPLICATES REMOVED)

=> d l25 1-159 ibib abs

L25 ANSWER 1 OF 159 USPATFULL
ACCESSION NUMBER: 2003:31084 USPATFULL
TITLE: Structure, production and use of heregulin 2 ligands
INVENTOR(S): Vandlen, Richard L., Hillsborough, CA, UNITED STATES
Holmes, William E., Pacifica, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003023035	A1	20030130
APPLICATION INFO.:	US 2001-22609	A1	20011217 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-173480, filed on 14 Oct 1998, GRANTED, Pat. No. US 6399746 Continuation of Ser. No. US 1995-440401, filed on 12 May 1995, GRANTED, Pat. No. US 5856110 Continuation of Ser. No. US 1994-330161, filed on 25 Oct 1994, GRANTED, Pat. No. US 5834229 Continuation of Ser. No. US 1993-35430, filed on 22 Mar 1993, ABANDONED Continuation of Ser. No. US 1991-705256, filed on 24 May 1991, ABANDONED
DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 3512
AB Novel 2 polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

L25 ANSWER 2 OF 159 USPATFULL
ACCESSION NUMBER: 2003:30337 USPATFULL
TITLE: Uses of GDNF and GDNF receptor
INVENTOR(S): Klein, Robert D., South San Francisco, CA, UNITED STATES
Moore, Mark W., San Francisco, CA, UNITED STATES
Rosenthal, Arnon, Burlwgane, CA, UNITED STATES
Ryan, Anne M., Millbrae, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022284	A1	20030130
APPLICATION INFO.:	US 2001-33350	A1	20011102 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-860370, filed on 6 Jun 1997, PENDING A 371 of International Ser. No. WO 1997-US4363, filed on 13 Mar 1997, UNKNOWN Continuation-in-part of Ser. No. US 1996-615902, filed on 14 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-618236, filed on 14 Mar 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 4937
AB GDNFR.alpha., GDNFR.alpha. extracellular domain (ECD), GDNFR.alpha. variants, chimeric GDNFR.alpha. (e.g., GDNFR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR.alpha.-ligands, for example GDNF, by providing GDNFR.alpha. to the cell. Also provided are methods for using GDNFR.alpha., GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.

L25 ANSWER 3 OF 159 USPATFULL
ACCESSION NUMBER: 2003:24331 USPATFULL
TITLE: Protein C or activated protein C-like molecules
INVENTOR(S): Andersen, Kim Vilbour, Broenshoej, DENMARK
Pedersen, Anders Hjelholt, Lyngby, DENMARK
Freskgaard, Per Ola, Vellinge, SWEDEN
PATENT ASSIGNEE(S): Maxygen ApS, Hoersholm, DENMARK (3)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018175	A1	20030123
APPLICATION INFO.:	US 2001-997623	A1	20011129 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-978917, filed on 17 Oct 2001, PENDING

PRIORITY INFORMATION:	NUMBER	DATE
	DK 2000-1560	20001018
	DK 2000-200100970	20000621
	US 2001-300154P	20010621 (60)
	US 2000-242268P	20001018 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MAXYGEN, INC., 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 3670

AB The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and .alpha..sub.1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

L25 ANSWER 4 OF 159 USPATFULL
ACCESSION NUMBER: 2003:4070 USPATFULL
TITLE: Leptin/ob receptor having a WSX motif
INVENTOR(S): Bennett, Brian, Pacifica, CA, UNITED STATES
Matthews, William, Woodside, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004109	A1	20030102
APPLICATION INFO.:	US 2002-214802	A1	20020806 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-780562, filed on 8 Jan 1997, PENDING

PRIORITY INFORMATION:	NUMBER	DATE
	US 1996-64855P	19960108 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE, MARTENS, OLSON & BEAR, LLP, Sixteenth Floor, 620 Newport Center Drive, Newport Beach, CA, 92660
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 3770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The WSX receptor, WSX receptor extracellular domain (ECD), WSX receptor variants, chimeric WSX receptor (e.g., WSX receptor immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing anibodies) are disclosed. Various uses for thse molecules are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 5 OF 159 USPATFULL
ACCESSION NUMBER: 2003:6968 USPATFULL

TITLE: GDNF receptor
INVENTOR(S): Klein, Robert D., South San Francisco, CA, United States
Moore, Mark W., San Francisco, CA, United States
Rosenthal, Arnon, Burlingham, CA, United States
Ryan, Anne M., Millbrae, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6504007	B1	20030107	
	WO 9733912		19970918	
APPLICATION INFO.:	US 1997-860370		19970606	(8)
	WO 1997-US4363		19970313	
			19970606	PCT 371 date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-618236, filed on 14 Mar 1996, now abandoned Continuation-in-part of Ser. No. US 1996-615902, filed on 14 Mar 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary L.
ASSISTANT EXAMINER: Hayes, Robert C.
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear, LLP
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 4881
AB GDNFR.alpha., GDNFR.alpha. extracellular domain (ECD), GDNFR.alpha. variants, chimeric GDNFRae (e.g., GDNFR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR.alpha.-ligands, for example GDNF, by providing GDNFR.alpha. to the cell. Also provided are methods for using GDNFR.alpha., GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.

L25 ANSWER 6 OF 159 USPATFULL DUPLICATE 1
ACCESSION NUMBER: 2002:67255 USPATFULL
TITLE: Methods and compositions for controlling **protein** assembly or **aggregation**
INVENTOR(S): Douglas, Michael G., St. Louis, MO, UNITED STATES
Amin, Avinash N., St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002037908	A1	20020328	
APPLICATION INFO.:	US 2001-904987	A1	20010712	(9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-677500, filed on 2 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-657554, filed on 8 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-657989, filed on 8 Sep 2000, PENDING Continuation-in-part of Ser. No. US 1998-127620, filed on 1 Aug 1998, GRANTED, Pat. No. US 6127393 Continuation-in-part of Ser. No. US 1997-843157, filed on 11 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1995-581351, filed on 29 Dec 1995, GRANTED, Pat. No. US 5767135

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1996-24221P	19961022	(60)

US 1996-26992P 19960920 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMPSON COBURN, LLP, ONE FIRSTAR PLAZA, SUITE 3500, ST LOUIS, MO, 63101
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 1292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for controlling prepathological and pathological **protein** assembly or **aggregation** using **picolinic** acid, analogs, or derivatives thereof are described. The compositions of the invention, capable of solubilizing a conformationally altered **protein**, comprise a carboxylic acid anion of **picolinic** acid, its analogs, or derivatives thereof and a cation. According to the methods of the invention, conformationally altered **protein** assembly or **aggregation** in an animal is prevented or reversed by introducing the compositions of the invention to the conformationally altered **protein**. The compositions can be administered systemically by injection, oral administration, inhalation, transdermal, or other routes of administration. The compositions and methods can be used to treat diseases manifested by conformationally altered **protein** assembly or **aggregation** including, but not limited to Alzheimer's disease, spongiform encephalopathy, cerebral amyloid angiopathy, Parkinson's disease, frontal temporal dementia, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease and Creutzfelds-Jakob disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 7 OF 159 USPATFULL
ACCESSION NUMBER: 2002:338201 USPATFULL
TITLE: WSX RECEPTOR AGONIST ANTIBODIES
INVENTOR(S): CARTER, PAUL J., SAN FRANCISCO, CA, UNITED STATES
CHIANG, NANCY Y., SAN FRANCISCO, CA, UNITED STATES
KIM, KYUNG JIN, LOS ALTOS, CA, UNITED STATES
MATTHEWS, WILLIAM, WOODSIDE, CA, UNITED STATES
RODRIGUES, MARIA L., SOUTH SAN FRANCISCO, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193571	A1	20021219
APPLICATION INFO.:	US 1997-779457	A1	19970107 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-667197, filed on 20 Jun 1996, PENDING Continuation-in-part of Ser. No. US 1996-585005, filed on 8 Jan 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GINGER R. DREGER, KNOBBE, MARTENS, OLSON & BEAR, LLP, 620 NEWPORT CNETER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 61 Drawing Page(s)
LINE COUNT: 6038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Agonist antibodies which bind to and activate the WSX receptor are described along with various uses for these antibodies. Preferred antibodies are those which display an IC50 in the KIRA ELISA bioassay of about 0.5 .mu.g/ml or less.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 8 OF 159 USPATFULL
ACCESSION NUMBER: 2002:336829 USPATFULL
TITLE: Interferon gamma polypeptide variants
INVENTOR(S): Jensen, Anne Dam, Copenhagen, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002192183	A1	20021219
APPLICATION INFO.:	US 2002-116273	A1	20020404 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-282254P	20010406 (60)
	US 2001-289398P	20010507 (60)
	US 2002-356321P	20020211 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DONALD J. POCHOPIEN, ESQ., McANDREWS, HELD & MALLOY, LTD., 34TH FLOOR, 500 WEST MADISON STREET, CHICAGO, IL, 60661
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 4224
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis.

These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly better utilized.

Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variants when administered subcutaneously.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 9 OF 159 USPATFULL
ACCESSION NUMBER: 2002:314387 USPATFULL
TITLE: Treatment of hearing impairments
INVENTOR(S): Gao, Wei-Qiang, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002176859	A1	20021128
APPLICATION INFO.:	US 2002-153145	A1	20020521 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-823717, filed on 30 Mar 2001, GRANTED, Pat. No. US 6429191 Continuation of Ser. No. US 1997-778357, filed on 2 Jan 1997, GRANTED, Pat. No. US 6225282

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-44407P	19960105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 34

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 3309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing impairments involving neuronal damage, loss, or degeneration, preferably of spinal ganglion neurons, by administration of a therapeutically effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect, wherein the improvement includes administering a therapeutically effective amount of a trkB or trkC agonist to treat the ototoxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 10 OF 159 USPATFULL
ACCESSION NUMBER: 2002:301741 USPATFULL
TITLE: New multimeric interferon beta polypeptides
INVENTOR(S): Bornaes, Claus, Hellerup, DENMARK
Andersen, Kim Vilbour, Broenshoej, DENMARK
Rasmussen, Poul Baad, Soeborg, DENMARK
Pedersen, Anders Hjelholt, Lyngby, DENMARK

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002169290	A1	20021114	
APPLICATION INFO.:	US 2001-4201	A1	20011101	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245645P	20001102 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MAXYGEN, INC., 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 4119
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a single chain multimeric interferon .beta. polypeptide comprising at least two monomers linked via a peptide bond or a peptide linker, wherein at least one of said monomers is an interferon .beta. monomer comprising an amino acid sequence that differs from that of wildtype human interferon .beta. in at least one introduced glycosylation site, methods of preparing such polypeptides or conjugates, and the use of such polypeptides in therapy, in particular for the treatment of multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 11 OF 159 USPATFULL
ACCESSION NUMBER: 2002:301579 USPATFULL
TITLE: Treatment of balance impairments
INVENTOR(S): Gao, Wei-Qiang, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002169124	A1	20021114	
APPLICATION INFO.:	US 2002-96762	A1	20020312	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-664295, filed on 18 Sep 2000, GRANTED, Pat. No. US 6429196 Continuation of Ser. No. US 1995-581662, filed on 29 Dec 1995, GRANTED, Pat. No. US 6121235
DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 91614
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 2899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided for prophylactic or therapeutic treatment of balance impairments involving neuronal damage, loss, or degeneration, preferably of vestibular ganglion neurons, in an animal by administration of an effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 12 OF 159 USPATFULL
ACCESSION NUMBER: 2002:300820 USPATFULL
TITLE: Integrin/adhesion antagonists
INVENTOR(S): Feige, Ulrich, Newbury Park, CA, UNITED STATES
Kohno, Tadahiko, Thousand Oaks, CA, UNITED STATES
Lacey, David Lee, Newbury Park, CA, UNITED STATES
Boone, Thomas Charles, Newbury Park, CA, UNITED STATES
PATENT ASSIGNEE(S): Amgen Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002168363	A1	20021114	
APPLICATION INFO.:	US 2001-840277	A1	20010423	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201394P	20000503 (60)
	US 2000-198919P	20000421 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1929
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns fusion of half-life extending vehicles, preferably Fc domains, with peptide sequences that act as antagonists of integrins, selectins, cell adhesion molecules, or their respective receptors. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The peptide may be an existing peptide or a peptide selected by phage display, E. coli display, ribosome display, RNA-peptide screening, chemical-peptide screening, or other methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 13 OF 159 USPATFULL
ACCESSION NUMBER: 2002:287250 USPATFULL
TITLE: Microencapsulation of drugs by solvent exchange
INVENTOR(S): Yeo, Yoon, Lafayette, IN, UNITED STATES
Chen, Alvin Un-Teh, West Lafayette, IN, UNITED STATES
Basaran, Osman A., West Lafayette, IN, UNITED STATES
Park, Kinam, West Lafayette, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160109	A1	20021031

APPLICATION INFO.: US 2001-17338 A1 20011213 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-254920P	20001213 (60)
	US 2001-294263P	20010531 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MEDICUS ASSOCIATES, 6549 Mission Gorge Rd. # 370, San Diego, CA, 92120
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solvent exchange method is employed to provide microencapsulated compositions, such as microcapsules of pharmaceutical preparations. The method is based on an exchange of water and a hydrophilic organic solvent, whereby a decline in solvent quality for the organic solvent causes a polymer dissolved therein to be deposited onto an aqueous core. Optimal results are rationalized in terms of a balance of water solubility and surface tension for the organic solvent. In a preferred embodiment, microcapsules of selected drugs are formed by contacting microdroplets of an aqueous solution containing the drug with the organic solvent containing a polymer dissolved therein. A preferred method employs biodegradable poly(lactic acid-co-glycolic acid) (PLGA) dissolved in acetic acid, ethyl acetate, methyl acetate, or ethyl formate, to form a PLGA membrane around an aqueous drug core. The method is particularly attractive for encapsulating protein-based drugs without substantial denaturation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 14 OF 159 USPATFULL
ACCESSION NUMBER: 2002:266442 USPATFULL
TITLE: ANTIBODIES TO RECEPTOR PROTEIN KINASES
INVENTOR(S): GODOWSKI, PAUL J., BURLINGAME, CA, UNITED STATES
MARK, MELANIE R., BURLINGAME, CA, UNITED STATES
SCADDEN, DAVID T., WESTON, MA, UNITED STATES
BAKER, KEVIN P., MILLBRAE, CA, UNITED STATES
BARON, WILL F., BRISBANE, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147325	A1	20021010
APPLICATION INFO.:	US 1998-223490	A1	19981230 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-170558, filed on 20 Dec 1993, PATENTED Continuation of Ser. No. US 1993-157563, filed on 23 Nov 1993, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PIPER MARBURY RUDNICK & WOLFE LLP, STEVEN B KELBER, 1200 NINETEENTH STREET, NW, WASHINGTON, DC, 20036-2412
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 4386
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic

assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 15 OF 159 USPATFULL
ACCESSION NUMBER: 2002:265556 USPATFULL
TITLE: Treatment or prophylaxis of diseases caused by pilus-forming bacteria
INVENTOR(S): Hultgren, Scott, Ballwin, MO, UNITED STATES
Kuehn, Meta, Berkeley, CA, UNITED STATES
Xu, Zheng, Blue Bell, PA, UNITED STATES
Ogg, Derek, Stockholm, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, UNITED STATES
Kihlberg, Jan, Dalby, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002146428	A1	20021010
APPLICATION INFO.:	US 2001-799608	A1	20010307 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, PENDING Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 5621
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 16 OF 159 USPATFULL
ACCESSION NUMBER: 2002:259392 USPATFULL
TITLE: Single-chain polypeptides
INVENTOR(S): Nissen, Torben Lauesgaard, Frederiksberg C, DENMARK
Jensen, Anne Dam, Copenhagen, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142964	A1	20021003
APPLICATION INFO.:	US 2001-3496	A1	20011101 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245727P	20001102 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Joanne Petithory, Maxygen, Inc., 515 Galveston Drive, Redwood City, CA, 94063
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 3866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to single-chain multimeric polypeptides comprising at least two units of a monomeric polypeptide linked via a peptide bond or a peptide linker, wherein the monomeric polypeptide is of a type that is biologically active in monomeric form, and to polypeptide conjugates having at least one non-polypeptide moiety covalently bound to an attachment group of the polypeptide. The polypeptide is preferably a G-CSF dimer bound to a polymer molecule, preferably to one or more polyethylene glycol molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 17 OF 159 USPATFULL
ACCESSION NUMBER: 2002:258874 USPATFULL
TITLE: AL-2 neurotrophic factor
INVENTOR(S): Caras, Ingrid W., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142444	A1	20021003
APPLICATION INFO.:	US 2001-21121	A1	20011206 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-635130, filed on 19 Apr 1996, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 3875
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides nucleic acids encoding AL-2 protein, as well as AL-2 protein produced by recombinant DNA methods. Such AL-2 protein and nucleic acid are useful in preparing antibodies and antagonists and in diagnosing and treating various neuronal disorders and disorders or conditions associated with angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 18 OF 159 USPATFULL
ACCESSION NUMBER: 2002:251242 USPATFULL
TITLE: Cardiac hypertrophy factor and uses therefor
INVENTOR(S): Baker, Joffre, El Granada, CA, UNITED STATES
Chien, Kenneth, La Jolla, CA, UNITED STATES
King, Kathleen, Pacifica, CA, UNITED STATES
Pennica, Diane, Burlingame, CA, UNITED STATES
Wood, William, San Mateo, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137189	A1	20020926
APPLICATION INFO.:	US 2001-896856	A1	20010629 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-33114, filed on 2 Mar 1998, ABANDONED Continuation of Ser. No. US 1996-733850, filed on 18 Oct 1996, ABANDONED Continuation of Ser. No. US 1995-443129, filed on 17 May 1995, PATENTED Division of Ser. No. US 1994-286304,

filed on 5 Aug 1994, PATENTED Continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994, PATENTED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 4190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 19 OF 159 USPATFULL
ACCESSION NUMBER: 2002:171897 USPATFULL
TITLE: Calcitonin-related molecules
INVENTOR(S): Liu, Chuan-Fa, Longmont, CO, UNITED STATES
Marshall, William S., Boulder, CO, UNITED STATES
Reynolds, Angela, Evergreen, CO, UNITED STATES
PATENT ASSIGNEE(S): Amgen Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002090646	A1	20020711	
APPLICATION INFO.:	US 2001-847712	A1	20010502	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201511P	20000503 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: U.S. Patent Operations/ TJG, Dept. 4300, M/S 27-4-A, AMGEN INC., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 1677
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns therapeutic agents that modulate the activity of CT receptor. In accordance with the present invention, modulators of CT receptor comprise:

a. a CT receptor modulating domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and

b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred;

wherein the vehicle is covalently attached to the CT receptor modulating domain. The vehicle and the CT receptor modulating domain may be linked through the N- or C-terminus of the CT receptor modulating domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred CT receptor modulating domains comprise the amino acid sequences described in Table 1. Other CT receptor modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned

herein.

Further in accordance with the present invention is a process for making CT receptor modulators, which comprises:

a. selecting at least one peptide that binds to the CT receptor; and

b. covalently linking said peptide to a vehicle.

The preferred vehicle is an Fc domain. Step (a) is preferably carried out by selection from the peptide sequences in Table 1 hereinafter or from phage display, RNA-peptide screening, or the other techniques mentioned herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 20 OF 159 USPATFULL

ACCESSION NUMBER:	2002:157787 USPATFULL		
TITLE:	NOVEL RECEPTOR-TYPE PHOSPHOTYROSINE PHOSPHATASE-KAPPA		
INVENTOR(S):	Schlessinger, Joseph, New York, NY, UNITED STATES Sap, Jan M., New York, NY, UNITED STATES Ullrich, Axel, Munchen 40, GERMANY, FEDERAL REPUBLIC OF Vogel, Wolfgang, Germering, GERMANY, FEDERAL REPUBLIC OF Fuchs, Miriam, Starnberg, GERMANY, FEDERAL REPUBLIC OF		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002082397	A1	20020627
APPLICATION INFO.:	US 2001-887669	A1	20011001 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-234883, filed on 21 Jan 1999, ABANDONED Division of Ser. No. US 1993-87244, filed on 1 Jul 1993, PATENTED Continuation-in-part of Ser. No. US 1993-49384, filed on 21 Apr 1993, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY & LARDNER, WASHINGTON HARBOUR, 3000 K STREET NW, SUITE 500, WASHINGTON, DC, 20007-5109		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	33 Drawing Page(s)		
LINE COUNT:	2752		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel receptor-type protein tyrosine phosphatase-.kappa. (RPTP.kappa.) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. The RPTP.kappa. protein or glycoprotein may be produced by recombinant means. Antibodies to the protein, methods for measuring the quantity of the protein, methods for screening compounds, such as drugs, which can bind to the protein and inhibit or stimulate their enzymatic activity, are provided. Further, methods for inhibiting homophilic binding of Type II RPTP, especially RPTP.kappa. molecules are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 21 OF 159 USPATFULL

ACCESSION NUMBER:	2002:156704 USPATFULL		
TITLE:	Hair cell disorders		
INVENTOR(S):	Gao, Wei-Qiang, Foster City, CA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002081299	A1	20020627
APPLICATION INFO.:	US 2001-849868	A1	20010504 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-107522P	19981107 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 5225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Ligands which bind to the HER2 and/or HER3 receptors are useful as inner-ear-supporting cell growth factors to enhance proliferation-mediated generation of new hair cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 22 OF 159 USPATFULL
ACCESSION NUMBER: 2002:105676 USPATFULL
TITLE: Anti-IgE antibodies
INVENTOR(S): Lowman, Henry B., El Granada, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
Jardieu, Paula M., San Mateo, CA, UNITED STATES
Lowe, John, Daly City, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002054878	A1	20020509
APPLICATION INFO.:	US 2001-920171	A1	20010801 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-296005, filed on 21 Apr 1999, GRANTED, Pat. No. US 6290957 Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, GRANTED, Pat. No. US 5994511
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 5846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 23 OF 159 USPATFULL
ACCESSION NUMBER: 2002:99611 USPATFULL
TITLE: Diaminopropionic acid derivatives
INVENTOR(S): Fotouhi, Nader, Chatham, NJ, UNITED STATES
Gillespie, Paul, Westfield, NJ, UNITED STATES
Guthrie, Robert W., Saddle Brook, NJ, UNITED STATES
Pietranico-Cole, Sherrie L., Nutley, NJ, UNITED STATES

Yun, Weiya, Warren, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052512	A1	20020502
APPLICATION INFO.:	US 2001-879700	A1	20010612 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-407534, filed on 29 Sep 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-104120P	19981013 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
NUMBER OF CLAIMS: 81
EXEMPLARY CLAIM: 1
LINE COUNT: 7962
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula 1a ##STR1##

which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 24 OF 159 USPATFULL
ACCESSION NUMBER: 2002:99076 USPATFULL
TITLE: NEURTURIN RECEPTOR
INVENTOR(S): KLEIN, ROBERT D., PALO ALTO, CA, UNITED STATES
ROSENTHAL, ARNON, BURLINGAME, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002051972	A1	20020502
APPLICATION INFO.:	US 1999-388316	A1	19990901 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-24665, filed on 17 Feb 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-63258P	19971024 (60)
	US 1997-49818P	19970609 (60)
	US 1997-38839P	19970218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 4968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB NTNR.alpha., NTNR.alpha. extracellular domain (ECD), NTNR.alpha. variants, chimeric NTNR.alpha. (e.g., NTNR.alpha. immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR.alpha.-ligands, for example NTN, by providing NTNR.alpha. to the cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 25 OF 159 USPATFULL

ACCESSION NUMBER: 2002:92229 USPATFULL
TITLE: Model for alzheimer's disease and other neurodegenerative diseases
INVENTOR(S): Lynch, Gary, Irvine, CA, UNITED STATES
Bi, Xiaoning, Irvine, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002048746	A1	20020425
APPLICATION INFO.:	US 2001-917789	A1	20010731 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-283352P	20010413 (60)
	US 2000-222060P	20000731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 94
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Page(s)
LINE COUNT: 4252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a model for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can alter such development and/or pathologies. The model of the invention is especially useful as an Alzheimer's disease model. The model of the invention provides brain cells and a method for increasing neurodegenerative disease characteristics in such cells, especially, induction of neurofibrillary tangles and/or phosphorylated tau and/or tau fragments and/or the production and/or release of cytokines and/or microglia reactions and/or activations and/or inflammation and/or conversion of p35 to p25 and/or the levels and activities of protein kinases by selectively increasing the concentration of cathepsin D to an effective level, and/or by lowering the concentration of cholesterol in such cells. The model also provides a method of reversing such effects, by inhibiting cysteine protease and mitogen activated kinase activity, and especially, by inhibiting calpain, and/or MAP kinase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 26 OF 159 USPATFULL
ACCESSION NUMBER: 2002:85159 USPATFULL
TITLE: Treatment or prophylaxis of diseases caused by pilus-forming bacteria
INVENTOR(S): Hultgren, Scott, Ballwin, MO, UNITED STATES
Kuehn, Meta, Berkeley, CA, UNITED STATES
Xu, Zheng, Blue Bell, PA, UNITED STATES
Ogg, Derek, Stockholm, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, UNITED STATES
Kihlberg, Jan, Dalby, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045199	A1	20020418
APPLICATION INFO.:	US 2001-799540	A1	20010307 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, PENDING Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED
DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 5601
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 27 OF 159 USPATFULL
ACCESSION NUMBER: 2002:78433 USPATFULL
TITLE: Use of heregulin as a growth factor
INVENTOR(S): Sliwkowski, Mark X., San Carlos, CA, UNITED STATES
Kern, Jeffrey A., Iowa City, IA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002042087	A1	20020411
APPLICATION INFO.:	US 2001-792025	A1	20010223 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-20598, filed on 4 Feb 1998, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Supervisor, Patent Prosecution Services, PIPER MARBURY RUDNICK & WOLFE LLP, 1200 Nineteenth Street, N.W., Washington, DC, 20036-2412
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Page(s)
LINE COUNT: 4749
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Ligands which bind to the HER2, HER3 and/or HER4 receptors are useful as normal epithelial cell growth factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 28 OF 159 USPATFULL
ACCESSION NUMBER: 2002:72855 USPATFULL
TITLE: Treatment of hearing impairments
INVENTOR(S): Gao, Wei-Qiang, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002039995	A1	20020404
	US 6429191	B2	20020806
APPLICATION INFO.:	US 2001-823717	A1	20010330 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-778357, filed on 2 Jan 1997, GRANTED, Pat. No. US 6225282

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-44407P	19960105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 3389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing impairments involving neuronal damage, loss, or degeneration, preferably of spinal ganglion neurons, by administration of a therapeutically effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect, wherein the improvement includes administering a therapeutically effective amount of a trkB or trkC agonist to treat the ototoxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 29 OF 159 USPATFULL
ACCESSION NUMBER: 2002:12577 USPATFULL
TITLE: Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
INVENTOR(S): Henderson, Samuel T., Broomfield, CO, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002006959	A1	20020117	
APPLICATION INFO.:	US 2001-845741	A1	20010501	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-200980P	20000501 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 30 OF 159 USPATFULL
ACCESSION NUMBER: 2002:8483 USPATFULL
TITLE: G-CSF conjugates
INVENTOR(S): Nissen, Torben Lauesgaard, Frederiksberg, DENMARK
Andersen, Kim Vilbour, Copenhagen, DENMARK
Hansen, Christian Karsten, Vedbaek, DENMARK
Mikkelsen, Jan Moller, Gentofte, DENMARK
Schambye, Hans Thalsgard, Frederiksberg, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004483	A1	20020110

APPLICATION INFO.: US 2001-760008 A1 20010110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-24	20000110
	DK 2000-341	20000302
	DK 2000-943	20000616
	US 2000-176376P	20000114 (60)
	US 2000-189506P	20000315 (60)
	US 2000-215644P	20000630 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAW OFFICES OF JONATHAN ALAN QUINE, P O BOX 458, ALAMEDA, CA, 94501
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 3705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g., be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g., be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate has one or more improved properties such as increased biological half-life and reduced side effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 31 OF 159 USPATFULL
ACCESSION NUMBER: 2002:297432 USPATFULL
TITLE: Non-stochastic generation of genetic vaccines
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, United States
PATENT ASSIGNEE(S): Diversa Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6479258	B1	20021112
APPLICATION INFO.:	US 2000-495052		20000131 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-276860, filed on 26 Mar 1999 Continuation-in-part of Ser. No. US 1999-246178, filed on 4 Feb 1999, now patented, Pat. No. US 6171820 Continuation-in-part of Ser. No. US 1998-185373, filed on 3 Nov 1998 Continuation-in-part of Ser. No. US 1996-760489, filed on 5 Dec 1996, now patented, Pat. No. US 5830696

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-8311P	19951207 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Park, Hankyel T.
LEGAL REPRESENTATIVE: Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.
NUMBER OF CLAIMS: 86
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 61 Drawing Page(s)
LINE COUNT: 19213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods of obtaining vaccines by use of non-stochastic methods of directed evolution (DirectEvolution.TM.). These methods include non-stochastic polynucleotide site-satuaration mutagenesis (Gene Site Saturation Mutagenesis.TM.) and non-stochastic polynucleotide reassembly (GeneReassembly.TM.). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 32 OF 159 USPATFULL

ACCESSION NUMBER:	2002:246543 USPATFULL
TITLE:	Receptor polypeptides and their production and uses
INVENTOR(S):	Cox, Edward T., Foster City, CA, United States Mather, Jennie P., Millbrae, CA, United States Sliwkowski, Mary B., San Carlos, CA, United States Woodruff, Teresa K., Millbrae, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6455262	B1	20020924
APPLICATION INFO.:	US 1993-125065		19930921 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-12711, filed on 3 Feb 1993, now patented, Pat. No. US 5286654 Division of Ser. No. US 1991-716826, filed on 19 Jun 1991, now patented, Pat. No. US 5216126

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Kemmerer, Elizabeth
ASSISTANT EXAMINER:	DeBerry, Regina M.
LEGAL REPRESENTATIVE:	Hasak, Janet E.
NUMBER OF CLAIMS:	1
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT:	3010

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 33 OF 159 USPATFULL

ACCESSION NUMBER:	2002:238993 USPATFULL
TITLE:	VEGF-related protein
INVENTOR(S):	Lee, James, San Bruno, CA, United States Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451764	B1	20020917
APPLICATION INFO.:	US 1996-706054		19960830 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-3491P	19950908 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Saoud, Christine J.
LEGAL REPRESENTATIVE: Cui, Steven X.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 3090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 34 OF 159 USPATFULL
ACCESSION NUMBER: 2002:194876 USPATFULL
TITLE: Treatment of balance impairments
INVENTOR(S): Gao, Wei-Qiang, Foster City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6429196	B1	20020806
APPLICATION INFO.:	US 2000-664295		20000918 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-581662, filed on 29 Dec 1995, now patented, Pat. No. US 6121235
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Seidel, Marianne C.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear, LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2960
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for prophylactic or therapeutic treatment of balance impairments involving neuronal damage, loss, or degeneration, preferably of vestibular ganglion neurons, in an animal by administration of an effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 35 OF 159 USPATFULL
ACCESSION NUMBER: 2002:194869 USPATFULL
TITLE: Ligand antagonists for treatment of breast cancer
INVENTOR(S): Fuh, Germaine, San Francisco, CA, United States
Wells, James A., Burlingame, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6429186	B1	20020806

APPLICATION INFO.: US 1994-308879 19940919 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-20327, filed on 19 Feb 1993, now abandoned Continuation-in-part of Ser. No. US 1992-864120, filed on 6 Apr 1992, now abandoned Continuation-in-part of Ser. No. US 1991-698753, filed on 10 May 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Gates & Cooper LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have discovered that growth hormones form ternary complexes with their receptors in which site 1 on the hormone first binds to one molecule of receptor and then hormone site 2 then binds to another molecule of receptor, thereby producing a 1:2 complex. We believe this phenomenon is shared by other ligands having similar conformational structure. Assays based on this phenomenon are useful for identifying ligand agonists and antagonists. Sites 1 and 2 are structurally identified to facilitate generation of amino acid sequence variants of ternary complex-forming ligands. Novel variants of growth hormone, prolactin placental lactogen and other related ligands are provided. As a result of our studies with the ternary complex we have determined that selected antibodies to the receptor for these ligands are capable of acting as ligand agonists or antagonists. Novel growth hormones and novel uses for anti-growth hormone receptor antibodies are described. Methods for inhibiting the growth of breast cancer cells are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 36 OF 159 USPATFULL
ACCESSION NUMBER: 2002:174960 USPATFULL
TITLE: Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
INVENTOR(S): Hultgren, Scott, Ballwin, MO, United States
Kuehn, Meta, Berkeley, CA, United States
Xu, Zheng, Blue Bell, PA, United States
Ogg, Derek, Uppsala, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, United States
Kihlberg, Jan, Dalby, SWEDEN
PATENT ASSIGNEE(S): Washington University, St. Louis, MO, United States (U.S. corporation)
Siga Pharmaceuticals, Inc., Corvallis, OR, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6420127	B1	20020716	
	WO 9514028		19950526	
APPLICATION INFO.:	US 1996-640877		19961010	(8)
	WO 1994-US13455		19941118	
			19961010	PCT 371 date

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Swartz, Rodney P
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 25 Drawing Page(s)

LINE COUNT: 5398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 37 OF 159 USPATFULL
ACCESSION NUMBER: 2002:160571 USPATFULL
TITLE: NL4 tie ligand homologue nucleic acid
INVENTOR(S): Godowski, Paul, Burlingame, CA, United States
Gurney, Austin, Belmont, CA, United States
Hillan, Kenneth J., San Francisco, CA, United States
Botstein, David, Belmont, CA, United States
Goddard, Audrey, San Francisco, CA, United States
Roy, Margaret, San Francisco, CA, United States
Ferrara, Napoleone, San Francisco, CA, United States
Tumas, Daniel, Orinda, CA, United States
Schwall, Ralph, Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6413770	B1	20020702
APPLICATION INFO.:	US 1998-136801		19980819 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-960507, filed on 29 Oct 1997, now patented, Pat. No. US 6057435
Continuation-in-part of Ser. No. US 1997-933821, filed on 19 Sep 1997, now patented, Pat. No. US 5972338
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear LLP
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 3
NUMBER OF DRAWINGS: 31 Drawing Figure(s); 31 Drawing Page(s)
LINE COUNT: 4825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5, NL8, and NL4, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 38 OF 159 USPATFULL
ACCESSION NUMBER: 2002:130074 USPATFULL
TITLE: Structure, production and use of heregulin 2 ligands
INVENTOR(S): Vandlen, Richard L., Millsborough, CA, United States
Holmes, William E., Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6399746 B1 20020604
APPLICATION INFO.: US 1998-173480 19981014 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-440401, filed on 12 May 1995, now patented, Pat. No. US 5856110, issued on 5 Jan 1999 Continuation of Ser. No. US 1994-330161, filed on 25 Oct 1994, now patented, Pat. No. US 5834229, issued on 10 Nov 1998 Continuation of Ser. No. US 1993-35430, filed on 22 Mar 1993, now abandoned Continuation of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Arthur, Lisa B.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3485
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 39 OF 159 USPATFULL
ACCESSION NUMBER: 2002:129514 USPATFULL
TITLE: Methods of enhancing bioactivity of chemokines
INVENTOR(S): Pelus, Louis Martin, Richboro, PA, United States
Bhatnagar, Pradip Kumar, Exton, PA, United States
King, Andrew Garrison, Blue Bell, PA, United States
Balcarek, Joanna Maria, Bala Cynwyd, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6399053	B1	20020604
APPLICATION INFO.:	US 1999-467160		19991220 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 557142, now patented, Pat. No. US 6080398 Continuation of Ser. No. US 1993-73800, filed on 8 Jun 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Stucker, Jeffrey
ASSISTANT EXAMINER: Seharaseyon, Jegatheesan
LEGAL REPRESENTATIVE: Hall, Linda E., King, William T., Venetianer, Stephen A.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1487
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for the treatment of bacterial, fungal, and viral infections by administering a truncated Gro.beta..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 40 OF 159 USPATFULL

ACCESSION NUMBER: 2002:81238 USPATFULL
TITLE: Neurturin receptor
INVENTOR(S): Klein, Robert D., Palo Alto, CA, United States
Rosenthal, Arnon, Burlingame, CA, United States
PATENT ASSIGNEE(S): Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6372453	B1	20020416
APPLICATION INFO.:	US 1997-802805		19970218 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Duffy, Patricia A.
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear, LLP
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 5038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB NTNR.alpha., NTNR.alpha. extracellular domain (ECD), NTNR.alpha. variants, chimeric NTNR.alpha. (e.g., NTNR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR.alpha.-ligands, for example NTN. by providing NTNR.alpha. to the cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 41 OF 159 USPATFULL
ACCESSION NUMBER: 2002:19172 USPATFULL
TITLE: Neurturin receptor
INVENTOR(S): Klein, Robert D., Palo Alto, CA, United States
Rosenthal, Arnon, Burlingame, CA, United States
Hynes, Mary A., San Mateo, CA, United States
PATENT ASSIGNEE(S): Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6342348	B1	20020129
APPLICATION INFO.:	US 2000-487685		20000119 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-957063, filed on 24 Oct 1997, now patented, Pat. No. US 6025157 Division of Ser. No. US 1997-802805, filed on 18 Feb 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-38839P	19970218 (60)
	US 1997-49818P	19970609 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Clark, Deborah J. R.
ASSISTANT EXAMINER: Chen, Shin-Lin
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear, LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 5026
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB NTNR.alpha., NTNR.alpha. extracellular domain (ECD), NTNR.alpha. variants, chimeric NTNR.alpha. (e.g., NTNR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are

described, including methods to modulate cell activity and survival by response to NTNR.alpha.-ligands, for example NTN, by providing NTNR.alpha. to the cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 42 OF 159 USPATFULL

ACCESSION NUMBER:	2001:160973 USPATFULL		
TITLE:	Use of heregulin as a growth factor		
INVENTOR(S):	Sliwkowski, Mark X., San Carlos, CA, United States Kern, Jeffrey A., Iowa City, IA, United States		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001023241	A1	20010920
APPLICATION INFO.:	US 2001-773517	A1	20010202 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-243198, filed on 2 Feb 1999, ABANDONED		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-73866P	19980204 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Supervisor, Patent Prosecution Services, PIPER MARBURY RUDNICK & WOLFE LLP, 1200 Nineteenth Street, N.W., Washington, DC, 20036-2412		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	3786		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Ligands which bind to the HER2, HER3 and/or HER4 receptors are useful as normal epithelial cell growth factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 43 OF 159 USPATFULL

ACCESSION NUMBER:	2001:114507 USPATFULL		
TITLE:	CATIONIC LIPID FORMULATION DELIVERING NUCLEIC ACID TO PERITONEAL TUMORS		
INVENTOR(S):	SMITH, JANET G., REDWOOD CITY, CA, United States NIVEN, RALPH W., REDWOOD CITY, CA, United States ZHANG, YILIN, SAN MATEO, CA, United States		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001008772	A1	20010719
	US 6271209	B2	20010807
APPLICATION INFO.:	US 1999-283543	A1	19990401 (9)
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-80450P	19980403 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	49		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1547		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of transfecting cells in vivo, including tumor cells in the peritoneal cavity are provided. Related lipid:nucleic acid formulations adapted to transfecting cells in the peritoneal cavity are provided.

Assays, including high-throughput assays for screening lipid:nucleic acids are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 44 OF 159 USPATFULL

ACCESSION NUMBER:	2001:231375 USPATFULL
TITLE:	Diaminopropionic acid derivatives
INVENTOR(S):	Fotouhi, Nader, Chatham, NJ, United States Gillespie, Paul, Westfield, NJ, United States Guthrie, Robert William, Saddle Brook, NJ, United States Pietranico-Cole, Sherrie Lynn, Nutley, NJ, United States Yun, Weiya, Warren, NJ, United States
PATENT ASSIGNEE(S):	Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6331640	B1	20011218
APPLICATION INFO.:	US 1999-407534		19990929 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-104120P	19981013 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Stockton, Laura L.
LEGAL REPRESENTATIVE:	Johnston, George W., Epstein, William H., Dubberley, F. Aaron
NUMBER OF CLAIMS:	32
EXEMPLARY CLAIM:	1
LINE COUNT:	7049

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula 1a ##STR1##

which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 45 OF 159 USPATFULL

ACCESSION NUMBER:	2001:231038 USPATFULL
TITLE:	Structurally determined cyclic metallo-constructs and applications
INVENTOR(S):	Sharma, Shubh D., Plainsboro, NJ, United States
PATENT ASSIGNEE(S):	Palatin Technologies, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6331285	B1	20011218
APPLICATION INFO.:	US 1999-464358		19991215 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-660697, filed on 5 Jun 1996, now patented, Pat. No. US 6027711		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Jones, Dameron L.
LEGAL REPRESENTATIVE:	Slusher, Stephen A.Peacock, Myers & Adams
NUMBER OF CLAIMS:	16
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT:	4839

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 46 OF 159 USPATFULL
ACCESSION NUMBER: 2001:163018 USPATFULL
TITLE: TRAF inhibitors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech Inc., South San Francisco, CA, United States (U.S. corporation)
Tularik, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294348	B1	20010925
APPLICATION INFO.:	US 1998-20683		19980209 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-700749, filed on 14 Aug 1996, now patented, Pat. No. US 5789550

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-2382P	19950817 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Scheiner, Laurie
LEGAL REPRESENTATIVE: Dreger, Ginger, Marschang, Diane L.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 47 OF 159 USPATFULL
ACCESSION NUMBER: 2001:157795 USPATFULL
TITLE: Anti-IgE antibodies and method of improving

polypeptides

INVENTOR(S): Lowman, Henry B., 400 San Juan Ave., El Granada, CA, United States 94018
Presta, Leonard G., 1900 Gough St. #206, San Francisco, CA, United States 94109
Jardieu, Paula M., 33 Hayward Ave. #110, San Mateo, CA, United States 94401-4319
Lowe, John, 396 Michelle La., Daly City, CA, United States 94080

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6290957	B1	20010918	
APPLICATION INFO.:	US 1999-296005		19990421	(9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, now patented, Pat. No. US 5994511
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Saunders, David
LEGAL REPRESENTATIVE: Svoboda, Craig G.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for adjusting the affuinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 48 OF 159 USPATFULL
ACCESSION NUMBER: 2001:126028 USPATFULL
TITLE: Use of idebenone and analogues against .beta. amyloid induced cytotoxicity

INVENTOR(S): Miyamoto, Masaomi, Hyogo, Japan
Hirai, Keisuke, Osaka, Japan
Goto, Giichi, Osaka, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6271266	B1	20010807	
	WO 9802149		19980122	
APPLICATION INFO.:	US 1998-180463		19981109	(9)
	WO 1997-JP2391		19970710	
			19981109	PCT 371 date
			19981109	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-182095	19960711

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dwayne C.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack, L.L.P.

NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula: ##STR1##

wherein R.sup.1 represents a lower alkyl; R.sup.2 represents H, an optionally substituted alkyl or an optionally substituted alkenyl; R.sup.3 and R.sup.4 each represents an optionally substituted lower alkyl or a lower alkoxy, or R.sup.3 and R.sup.4 form, taken together, an optionally substituted butadienylene; and X.sup.1 and X.sup.2 each represents an optionally esterified or etherified hydroxy, or a salt thereof is useful for protecting cells from the cytotoxicity of .beta.-amyloid protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 49 OF 159 USPATFULL
ACCESSION NUMBER: 2001:125760 USPATFULL
TITLE: O-fucosyltransferase
INVENTOR(S): Wang, Yang, Milbrae, CA, United States
Spellman, Michael W., Belmont, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6270987	B1	20010807
APPLICATION INFO.:	US 1999-333729		19990615 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-978741, filed on 26 Nov 1997, now patented, Pat. No. US 6100076, issued on 8 Aug 2000 Continuation-in-part of Ser. No. US 1997-792498, filed on 31 Jan 1997, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Rao, Manjunath N.
LEGAL REPRESENTATIVE: Barnes, Elizabeth M.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 3080
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes the identification, purification, recombinant production and characterization of novel O-fucosyltransferase enzymes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 50 OF 159 USPATFULL
ACCESSION NUMBER: 2001:93633 USPATFULL
TITLE: Trabecular meshwork induced glucocorticoid response (TIGR) fusion protein
INVENTOR(S): Nguyen, Thai D., 17 Central Dr., Mill Valley, CA, United States 94941
Polansky, Jon R., 15 Stanton Way, Mill Valley, CA, United States 94941
Huang, Weidong, 42 Behr Ave., San Francisco, CA, United States 94131

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6248867	B1	20010619
APPLICATION INFO.:	US 1995-546568		19951020 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-336235, filed on 3 Nov 1994, now patented, Pat. No. US 5606043
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Pak, Michael
LEGAL REPRESENTATIVE: Howrey, Simon, Arnold & White, LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 51 OF 159 USPATFULL
ACCESSION NUMBER: 2001:63659 USPATFULL
TITLE: Treatment of hearing impairments
INVENTOR(S): Gao, Wei-Qiang, Foster City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6225282	B1	20010501
APPLICATION INFO.:	US 1997-778357		19970102 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-44407P	19960105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear, LLP
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 3619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing impairments involving neuronal damage, loss, or degeneration, preferably of spinal ganglion neurons, by administration of a therapeutically effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect, wherein the improvement includes administering a therapeutically effective amount of a trkB or trkC agonist to treat the ototoxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 52 OF 159 USPATFULL
ACCESSION NUMBER: 2001:52024 USPATFULL
TITLE: Angiogenesis inhibitor
INVENTOR(S): Fukiage, Chiho, Katano, Japan
Azuma, Mitsuyoshi, Nishinomiya, Japan
Inoue, Jun, Kobe, Japan
Nakamura, Masayuki, Himeji, Japan
Yoshida, Yuka, Nishiwaki, Japan
PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6214800	B1	20010410
APPLICATION INFO.:	US 1999-282501		19990409 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-243822, filed on 3 Feb 1999 Division of Ser. No. US 1996-740069, filed on 24 Oct 1996, now patented, Pat. No. US 6057290

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-277485	19951025
	JP 1996-248046	19960919

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davenport, Avis M.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack, L.L.P.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2480
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I) ##STR1##

and compounds of the formula (VI) ##STR2##

can be used. The angiogenesis inhibitor of the present invention suppresses new formation of blood vessels in the living tissues, so that it can be used as a superior therapeutic or prophylactic agent of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; and angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, senile discoid macular degeneration and the like, as well as for prevention of metastasis of tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 53 OF 159 USPATFULL
ACCESSION NUMBER: 2001:33271 USPATFULL
TITLE: Pyrimidine derivative
INVENTOR(S): Yamada, Satoshi, Otsu, Japan
Kinoshita, Naosumi, Kusatsu, Japan
Yasumura, Koichi, Otsu, Japan
Edamatsu, Kouji, Otsu, Japan
Nagahama, Takao, Otsu, Japan
Ishikawa, Shintaro, Otsu, Japan
Yamauchi, Takeshi, Kyoto, Japan
Kishi, Kazumasa, Kurita-gun, Japan
Sugiyama, Kazuhisa, Otsu, Japan
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6197774	B1	20010306	
	WO 9841526		19980924	
APPLICATION INFO.:	US 1999-380742		19990913	(9)
	WO 1998-JP1042		19980312	
			19990913	PCT 371 date
			19990913	PCT 102(e) date

	NUMBER	DATE

PRIORITY INFORMATION: JP 1997-61550 19970314
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Liu, Hong
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 2219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a novel pyrimidine derivative represented by the general formula (1): ##STR1##

(wherein R, R.sup.4 and R.sup.8 are the same as defined in the specification) or pharmaceutically acceptable salt thereof, which possesses an excellent activity for inhibiting the formation of NO (nitrogen oxide) in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 54 OF 159 USPATFULL
ACCESSION NUMBER: 2001:4887 USPATFULL
TITLE: Anti-IgE antibodies and method of improving polypeptides
INVENTOR(S): Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6172213	B1	20010109	
APPLICATION INFO.:	US 1998-109207		19980630	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51554P	19970702 (60)

DOCUMENT TYPE: Patent
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Ewoldt, Gerald R.
LEGAL REPRESENTATIVE: Svoboda, Craig G.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 55 OF 159 USPATFULL
ACCESSION NUMBER: 2000:167510 USPATFULL

TITLE: Uses of Wnt polypeptides
INVENTOR(S): Matthews, William, Woodside, CA, United States
Austin, Timothy W., Morgan Hill, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6159462		20001212
APPLICATION INFO.:	US 1997-911860		19970815 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24068P	19960816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Svoboda, Craig G., Carpenter, David A.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 3907
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation, differentiation or maintenance of a hematopoietic stem/progenitor cell using a Wnt polypeptide, and optionally another cytokine, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 56 OF 159 USPATFULL
ACCESSION NUMBER: 2000:160985 USPATFULL
TITLE: Stable non-hygroscopic crystalline form of N-[N-[N-4-(piperidin-4-yl)butanoyl)-N-ethylglycyl] aspartyl]-L-.beta.-cyclohexyl alanine amide
INVENTOR(S): Chrzan, Zofia J., Sellersville, PA, United States
Mencel, James J., Lansdale, PA, United States
Toledo-Velasquez, David, Lansdale, PA, United States
Windisch, Vincent, Green Lane, PA, United States
Woodward, Rick G., Harleysville, PA, United States
Salazar, deceased, Diane C., late of Wayne, PA, United States by Richard C. Salazar, executor
Vemuri, Narasimha M., Phoenixville, PA, United States
Gardetto, Anthony J., Oley, PA, United States
Powers, Matthew R., Barto, PA, United States
Kubiak, Gregory G., Wilmington, DE, United States
Liu, Robert C., Walnut Creek, CA, United States
Vanasse, Benoit J., Collegeville, PA, United States
Sherbine, James P., Voorhees, NJ, United States
Rodriguez, Walter, Douglasville, PA, United States
Sledeski, Adam W., Collegeville, PA, United States
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153588		20001128
APPLICATION INFO.:	US 1999-251030		19990218 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-US14756, filed on 21 Aug 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-2281	19980225

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Celsa, Bennett
LEGAL REPRESENTATIVE: Newman, Irving
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 2030
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-[N-[N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl]-(L)-aspartyl]-(L)-.beta.-cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula ##STR1## wherein: A, B, Z, E.sup.1, E.sup.2, G, R, m, n, and p are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 57 OF 159 USPATFULL
ACCESSION NUMBER: 2000:160793 USPATFULL
TITLE: Treatment or prophylaxis of diseases caused by pilus-forming bacteria
INVENTOR(S): Hultgren, Scott, Ballwin, MO, United States
Kuehn, Meta, Berkeley, CA, United States
Xu, Zheng, Blue Bell, PA, United States
Ogg, Derek, Uppsala, Sweden
Harris, Mark, Uppsala, Sweden
Lepisto , Matti, Lund, Sweden
Kihlberg, Jan, Dalby, Sweden
Jones, Charles Hal, St. Louis, MO, United States
PATENT ASSIGNEE(S): SIGA Pharmaceuticals, Inc., New York, NY, United States (U.S. corporation)
Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153396		20001128
APPLICATION INFO.:	US 1995-465275		19950605 (8)

RELATED APPLN. INFO.: Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 which is a continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Swartz, Rodney P.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 24 Drawing Page(s)
LINE COUNT: 5410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 58 OF 159 USPATFULL
ACCESSION NUMBER: 2000:157214 USPATFULL
TITLE: Methods for the diagnosis of glaucoma
INVENTOR(S): Nguyen, Thai D., Mill Valley, CA, United States
Polansky, Jon R., Mill Valley, CA, United States
Huang, Weidong, San Francisco, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6150161		20001121
APPLICATION INFO.:	US 1998-220459		19981224 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-882238, filed on 25 Jun 1997, now patented, Pat. No. US 5854415 which is a division of Ser. No. US 1996-649432, filed on 17 May 1996, now patented, Pat. No. US 5789169 which is a continuation-in-part of Ser. No. US 1995-546568, filed on 20 Oct 1995 which is a continuation-in-part of Ser. No. US 1994-336235, filed on 3 Nov 1994, now patented, Pat. No. US 5606043
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Horlick, Kenneth R.
LEGAL REPRESENTATIVE: Howrey Simon Arnold & White, LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 59 OF 159 USPATFULL
ACCESSION NUMBER: 2000:125012 USPATFULL
TITLE: Treatment of balance impairments
INVENTOR(S): Gao, Wei-Qiang, Foster City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121235		20000919
APPLICATION INFO.:	US 1995-581662		19951229 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, Dwayne C.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear LLP
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 3419
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided for prophylactic or therapeutic treatment of balance impairments involving neuronal damage, loss, or degeneration, preferably of vestibular ganglion neurons, in an animal by administration of an effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 60 OF 159 USPATFULL
ACCESSION NUMBER: 2000:121293 USPATFULL
TITLE: Assay for cardiac hypertrophy
INVENTOR(S): King, Kathleen, Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117650		20000912
APPLICATION INFO.:	US 1997-898911		19970723 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-452555, filed on 25 May 1995, now abandoned which is a continuation of Ser. No. US 1994-286304, filed on 5 Aug 1994, now patented, Pat. No. US 5571893 which is a continuation of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gitomer, Ralph
LEGAL REPRESENTATIVE: Conley, Deirdre L.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An assay to test for hypertrophic activity in myocytes is described where wells are precoated with D-MEM/F-12 and fetal calf serum, plated with myocytes, cultured, and any change in size of the cells is determined. The growth medium may contain insulin, transferrin and aprotinin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 61 OF 159 USPATFULL
ACCESSION NUMBER: 2000:117709 USPATFULL
TITLE: Isoxazoline and isoxazole fibrogen receptor antagonists
INVENTOR(S): Wityak, John, West Grove, PA, United States
Xue, Chu-Biao, Hockessin, DE, United States
Sielecki-Dzurdz, Thais Motria, Newark, DE, United States
Olson, Richard Eric, Wilmington, DE, United States
Degrado, William Frank, Moylan, PA, United States
Cain, Gary Avonn, Wilmington, DE, United States
Batt, Douglas Guy, Wilmington, DE, United States
Pinto, Donald, Newark, DE, United States
Hussain, Munir Alwan, Wilmington, DE, United States
Mousa, Shaker Ahmed, Lincoln University, PA, United States
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6114328		20000905
APPLICATION INFO.:	US 1997-978295		19971125 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-455436, filed on 31 May 1995, now patented, Pat. No. US 5849736 which is a continuation-in-part of Ser. No. US 1994-337929, filed on 10 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-232961, filed on 22 Apr 1994 which is a continuation-in-part of Ser. No. US 1993-157598, filed on 24 Nov 1993

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Covington, Raymond
LEGAL REPRESENTATIVE: Reinert, Norbert F.
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 12644
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 62 OF 159 USPATFULL
ACCESSION NUMBER: 2000:102109 USPATFULL
TITLE: O-fucosyltransferase
INVENTOR(S): Wang, Yang, Milbrae, CA, United States
Spellman, Michael W., Belmont, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6100076		20000808
APPLICATION INFO.:	US 1997-978741		19971126 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-792498, filed on 31 Jan 1997, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Sisson, Bradley L.
ASSISTANT EXAMINER: Longton, Enrique D.
LEGAL REPRESENTATIVE: Svoboda, Craig G.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 3438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes the identification, purification, recombinant production and characterization of novel O-fucosyltransferase enzymes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 63 OF 159 USPATFULL
ACCESSION NUMBER: 2000:98212 USPATFULL
TITLE: Nucleic acids encoding protein tryosine kinases
INVENTOR(S): Godowski, Paul J., 460 Point San Bruno Blvd., South San Fran, CA, United States 94080
Mark, Melanie R., 460 Point San Bruno Blvd., South San Fran, CA, United States 94080
Scadden, David T., 460 Point San Bruno Blvd., South San Fran, CA, United States 94080

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6096527		20000801
APPLICATION INFO.:	US 1995-445461		19950522 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-170558, filed on 20

Dec 1993 which is a continuation of Ser. No. US 1993-157663, filed on 23 Nov 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Teng, Sally P.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 4638
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 64 OF 159 USPATFULL
ACCESSION NUMBER: 2000:87974 USPATFULL
TITLE: Protein tyrosine kinases
INVENTOR(S): Scadden, David T., Weston, MA, United States
Baker, Kevin P., Millbrae, CA, United States
Baron, Will F., Brisbane, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6087144		20000711
APPLICATION INFO.:	US 1995-447314		19950522 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-170558, filed on 20 Dec 1993 which is a continuation of Ser. No. US 1993-157563, filed on 23 Nov 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Teng, Sally
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 4606
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 65 OF 159 USPATFULL
ACCESSION NUMBER: 2000:80406 USPATFULL
TITLE: Truncated gro and KC chemokines having enhanced bioactivity
INVENTOR(S): Pelus, Louis Martin, Richboro, PA, United States
Bhatnagar, Pradip Kumar, Exton, PA, United States
King, Andrew Garrison, Blue Bell, PA, United States
Balcarek, Joanna Maria, Bala Cynwyd, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA,

United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6080398		20000627	
	WO 9429341		19941222	
APPLICATION INFO.:	US 1996-557142		19960305	(8)
	WO 1994-US6264		19940603	
			19960305	PCT 371 date
			19960305	PCT 102(e) date

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-73800, filed on 8 Jun 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fitzgerald, David L.
LEGAL REPRESENTATIVE: Hall, Linda E., Venetianer, Stephen A., Kinzig, Charles M.
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1,53
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 2185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides method of increasing the biological activity of KC, gro-.alpha., gro-.beta., and gro-.gamma. proteins, truncated and modified proteins characterized by having biological activity at least 1 log better than the full-length protein, and pharmaceutical compositions containing same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 66 OF 159 USPATFULL
ACCESSION NUMBER: 2000:61401 USPATFULL
TITLE: TRAF Inhibitors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)
Tularik, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6063585		20000516	
APPLICATION INFO.:	US 1998-20685		19980209	(9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-700749, filed on 14 Aug 1996, now patented, Pat. No. US 5789550

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-2382P	19950817 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
LEGAL REPRESENTATIVE: Dreger, Ginger, Marschang, Diane L.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2009
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 67 OF 159 USPATFULL
ACCESSION NUMBER: 2000:57597 USPATFULL
TITLE: TRAF inhibitors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)
Tularik, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6060303		20000509	
APPLICATION INFO.:	US 1998-20467		19980209	(9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-700749, filed on 14 Aug 1996, now patented, Pat. No. US 5789550

	NUMBER	DATE
PRIORITY INFORMATION:	US 1985-2382P	19850817 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
LEGAL REPRESENTATIVE: Dreger, Ginger, Marschang, Diane L.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 68 OF 159 USPATFULL
ACCESSION NUMBER: 2000:54107 USPATFULL
TITLE: Substituted amidinobenzene derivatives and medicinal compositions thereof
INVENTOR(S): Matsumoto, Yuzo, Toride, Japan
Akamatsu, Seijiro, Tsukuba, Japan
Ichihara, Masato, Tsukuba, Japan
Kawasaki, Tomihisa, Tsukuba, Japan
Kaku, Seiji, Tsukuba, Japan
Yanagisawa, Isao, Tokyo, Japan
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd, Tokyo, Japan (non-U.S. corporation)
Merck Patent Gesellschaft Mit Beschrankter Haftung, Darmstadt, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6057324		20000502	
	WO 9745413		19970412	
APPLICATION INFO.:	US 1998-194202		19981020	(9)
	WO 1997-JP1804		19970528	
			19981120	PCT 371 date
			19981120	PCT 102(e) date

	NUMBER	DATE

PRIORITY INFORMATION:	JP 1996-137273	19960530
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Patel, Sudhaker B.	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	1481	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A substituted-amidinobenzene derivative of the following general formula (I) or a salt thereof, and a pharmaceutical composition comprising said derivative or a salt thereof and a pharmaceutically acceptable carrier. ##STR1## (the symbols in the above formula have the following meanings: R.sup.1 : a group which can be converted into an amidino group in vivo;

R.sup.2 and R.sup.3 : the same or different and each represents a carboxyl group or a group which can be converted into a carboxyl group in vivo;

X.sup.1 and X.sup.2 : the same or different and each represents a lower alkylene group;

m: 0, 1 or 2;

n: 0 or 1, provided that n=1 when m=0.

They have GPIIb/IIIa receptor antagonizing activity and are useful as medicines for ameliorating ischemic cardiac disorders, adminicula in cardiosurgery operations or in vascular surgery operations, medicines for ameliorating cerebrovascular disorders, And medicines for ameliorating peripheral artery disorders. In addition, they are useful as a prodrug excellent in peroral absorbability and sustainment of the effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 69 OF 159 USPATFULL

ACCESSION NUMBER:	2000:54073 USPATFULL
TITLE:	Angiogenesis inhibitor
INVENTOR(S):	Fukiage, Chiho, Katano, Japan Azuma, Mitsuyoshi, Nishinomiya, Japan Inoue, Jun, Kobe, Japan Nakamura, Masayuki, Himeji, Japan Yoshida, Yuka, Nishiwaki, Japan
PATENT ASSIGNEE(S):	Senju Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6057290		20000502	
APPLICATION INFO.:	US 1996-740069		19961024	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-277485	19951025
	JP 1996-248046	19960919

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Davenport, Avis M.
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack, L.L.P.
NUMBER OF CLAIMS:	26
EXEMPLARY CLAIM:	1

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2599
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I) ##STR1## and compounds of the formula (VI) ##STR2## can be used. The angiogenesis inhibitor of the present invention suppresses new formation of blood vessels in the living tissues, so that it can be used as a superior therapeutic or prophylactic agent of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; and angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, senile discoid macular degeneration and the like, as well as for prevention of metastasis of tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 70 OF 159 USPATFULL
ACCESSION NUMBER: 2000:31527 USPATFULL
TITLE: Humanized anti-CD11a antibodies
INVENTOR(S): Jardieu, Paula M., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6037454		20000314	
APPLICATION INFO.:	US 1997-974899		19971120	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31971P	19961127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Lee, Wendy M., Schwartz, Timothy R.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 3180
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Humanized anti-CD11a antibodies and various uses therefor are disclosed. The humanized anti-CD11a antibody may bind specifically to human CD11a I-domain, have an IC50(nM) value of no more than about 1 nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1, and/or an IC50 (nM) value of no more than about 1 nM in the mixed lymphocyte response assay.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 71 OF 159 USPATFULL
ACCESSION NUMBER: 2000:21206 USPATFULL
TITLE: Structurally determined metallo-constructs and applications
INVENTOR(S): Sharma, Shubh D., Albuquerque, NM, United States
PATENT ASSIGNEE(S): RhoMed Incorporated, Edison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6027711		20000222	
APPLICATION INFO.:	US 1996-660697		19960605	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-476652, filed on 7 Jun 1995, now patented, Pat. No. US 5891418, issued on 6 Apr 1999
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose G.
ASSISTANT EXAMINER: Jones, Dameron
LEGAL REPRESENTATIVE: Slusher, Stephen A., Todaro, John C., Peacock, Deborah A.
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 4915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 72 OF 159 USPATFULL
ACCESSION NUMBER: 2000:18243 USPATFULL
TITLE: Neurturin receptor
INVENTOR(S): Klein, Robert D., Palo Alto, CA, United States
Rosenthal, Arnon, Burlingame, CA, United States
Hynes, Mary A., San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6025157		20000215	
APPLICATION INFO.:	US 1997-957063		19971024	(8)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-38839P	19970218	(60)
	US 1997-49818P	19970609	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Campell, Bruce R.
ASSISTANT EXAMINER: Chen, Shin-Lin
LEGAL REPRESENTATIVE: Knobbe, Martens Olson & Bear, LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 5116

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB NTNR.alpha., NTNR.alpha. extracellular domain (ECD), NTNR.alpha. variants, chimeric NTNR.alpha. (e.g., NTNR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR.alpha.-ligands, for example NTN, by providing NTNR.alpha. to the cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 73 OF 159 USPATFULL

ACCESSION NUMBER: 2000:10010 USPATFULL

TITLE: Human transaldolase: an autoantigen with a function in metabolism

INVENTOR(S): Perl, Andras, Jamesville, NY, United States

PATENT ASSIGNEE(S): The Research Foundation of State University of New York, Albany, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6018021		20000125
APPLICATION INFO.:	US 1994-326119		19941019 (8)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Feisee, Lila

ASSISTANT EXAMINER: Davis, Minh-Tam

LEGAL REPRESENTATIVE: Morrison & Foerster

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Figure(s); 22 Drawing Page(s)

LINE COUNT: 2981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Transaldolase is an enzyme which acts as an autoantigen in immune-related neurodegenerative diseases, particularly multiple sclerosis. Human transaldolase, the DNA coding therefore, peptides derived therefrom, and DNA control elements associated therewith and anti-transaldolase antibodies are disclosed. These compositions are useful in methods such as immunoassays for detecting subjects making anti-transaldolase antibodies and diagnosing the neurodegenerative disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 74 OF 159 USPATFULL

ACCESSION NUMBER: 1999:166594 USPATFULL

TITLE: TRAF inhibitors

INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
Tularik, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004553		19991221
APPLICATION INFO.:	US 1998-20684		19980209 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-700749, filed on 14 Aug 1996, now patented, Pat. No. US 5789550

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-2382P	19950817 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
LEGAL REPRESENTATIVE: Dreger, Ginger, Marschang, Diane L.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1914
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 75 OF 159 USPATFULL
ACCESSION NUMBER: 1999:163678 USPATFULL
TITLE: Treatment or prophylaxis of diseases caused by pilus-forming bacteria
INVENTOR(S): Hultgren, Scott, 1637 Country Hill La., Ballwin, MO, United States
Kuehn, Meta, 7351 Claremont Ave., #2, Berkeley, CA, United States 94705
Xu, Zheng, 887 Village Cir., Blue Bell, PA, United States 19422
Ogg, Derek, Artillerigatan 16B, S-752 37, Uppsala, Sweden
Harris, Mark, Norbykallvagen 2, S-756 45 Uppsala, Sweden
Lepisto , Matti, Flygelvaagen 257, S-224 73 Lund, Sweden
Kihlberg, Jan, Havrevagen 16, S-240 10 Dalby, Sweden
Jones, Charles Hal, 1104 Moorlands Dr., St. Louis, MO, United States 63110

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6001823		19991214
APPLICATION INFO.:	US 1995-462436		19950605 (8)

RELATED APPLN. INFO.: Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 which is a continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Figure(s); 24 Drawing Page(s)
LINE COUNT: 5409
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 76 OF 159 USPATFULL

ACCESSION NUMBER:	1999:163476 USPATFULL
TITLE:	Protein tyrosine kinases
INVENTOR(S):	Godowski, Paul J., Burlingame, CA, United States Mark, Melanie R., Burlingame, CA, United States Scadden, David T., Weston, MA, United States
PATENT ASSIGNEE(S):	Genetech, Inc., South San Francisco, CA, United States (U.S. corporation) New England Deaconess (NED) Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6001621		19991214
APPLICATION INFO.:	US 1993-170558		19931220 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-157563, filed on 23 Nov 1993, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Teng, Sally P.
LEGAL REPRESENTATIVE:	Lee, Wendy M., Schwartz, Timothy R.
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT:	4591

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 77 OF 159 USPATFULL

ACCESSION NUMBER:	1999:155894 USPATFULL
TITLE:	Anti-IgE antibodies and methods of improving polypeptides
INVENTOR(S):	Lowman, Henry B., El Granada, CA, United States Presta, Leonard G., San Francisco, CA, United States Jardieu, Paula M., San Mateo, CA, United States Lowe, John, Daly City, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994511		19991130
APPLICATION INFO.:	US 1997-887352		19970702 (8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Saunders, David
LEGAL REPRESENTATIVE:	Svoboda, Craig G.
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT:	5816

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and

screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 78 OF 159 USPATFULL

ACCESSION NUMBER:	1999:151182 USPATFULL
TITLE:	Agents affecting thrombosis and hemostasis
INVENTOR(S):	Wolf, David L., Palo Alto, CA, United States Sinha, Uma, San Francisco, CA, United States
PATENT ASSIGNEE(S):	COR Therapeutics Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5990079		19991123
APPLICATION INFO.:	US 1998-16400		19980130 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-469301, filed on 6 Jun 1995, now patented, Pat. No. US 5837679 which is a division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Degen, Nancy
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius LLP
NUMBER OF CLAIMS:	16
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT:	1981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilia conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 79 OF 159 USPATFULL

ACCESSION NUMBER:	1999:137250 USPATFULL
TITLE:	Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
INVENTOR(S):	Ali, Fadia El-Fehail, Cherry Hill, NJ, United States Bondinell, William, Wayne, PA, United States Huffman, William Francis, Malvern, PA, United States Lago, M. Amparo, Audubon, PA, United States Keenan, Richard McCulloch, Malvern, PA, United States Kwon, Chet, King of Prussia, PA, United States Miller, William Henry, Schwenksville, PA, United States Nguyen, Thomas, King of Prussia, PA, United States Takata, Dennis T., Flourtown, PA, United States
PATENT ASSIGNEE(S):	SmithKline Beecham Corporation, Philadelphia, PA,

United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5977101		19991102	
	WO 9600730		19960111	
APPLICATION INFO.:	US 1996-505171		19961220	(8)
	WO 1995-US8306		19950629	
			19961220	PCT 371 date
			19961220	PCT 102(e) date

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gupta, Yogendra N.
LEGAL REPRESENTATIVE: McCarthy, Mary E., Venetianer, Stephen, Kinzig, Charles M.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 5856
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Vitronectin receptor antagonists having the formula: ##STR1## which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 80 OF 159 USPATFULL
ACCESSION NUMBER: 1999:128513 USPATFULL
TITLE: Agents affecting thrombosis and hemostasis
INVENTOR(S): Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5968897		19991019	
APPLICATION INFO.:	US 1998-16403		19980130	(9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-469301, filed on 6 Jun 1995, now patented, Pat. No. US 5837679 which is a division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy
LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius LLP
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1908
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 81 OF 159 USPATFULL
ACCESSION NUMBER: 1999:110296 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Hartman, George D., Lansdale, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Hunt, Cecilia A., Plymouth Meeting, PA, United States
Krause, Amy E., Blue Bell, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Askew, Benny C., Lansdale, PA, United States
Brashear, Karen M., Perkasie, PA, United States
Ihle, Nathan C., Mercer Island, WA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5952306		19990914	
APPLICATION INFO.:	US 1997-783635		19970114	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9965P	19960116 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Parr, Richard S., Winokur, Melvin
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 3283
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2## which are useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 82 OF 159 USPATFULL
ACCESSION NUMBER: 1999:92675 USPATFULL
TITLE: Piperazine derivatives and use as cysteine inhibitors
INVENTOR(S): Inoue, Jun, Kobe, Japan
Yoshida, Yuka, Nishiwaki, Japan
Cui, Ying-She, Minoo, Japan
Azuma, Mitsuyoshi, Nishinomiya, Japan
PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5935959		19990810	
	WO 9703060		19970130	
APPLICATION INFO.:	US 1998-983034		19980107	(8)
	WO 1996-JP1884		19960704	
			19980107	PCT 371 date
			19980107	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-176975	19950713

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bernhardt, Emily
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack, L.L.P
NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1
LINE COUNT: 1491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a compound of the following formula (I) inclusive of its salt ##STR1## [wherein R.sup.1 represents either carboxy which may be esterified or amidated carboxy which may be substituted; R.sup.2 represents hydrogen or lower alkyl and may be linked to R.sup.3 or R.sup.4 to form a ring; R.sup.3 and R.sup.4 may be the same or different and each represents hydrogen, lower alkyl which may be substituted, or a sulfide group which may be substituted, and R.sup.3 and R.sup.4 may conjoinedly form a ring; R.sup.5 represents a substituted phenyl group of formula (II) ##STR2## (wherein R.sup.6 represents halogen or alkoxy) or a substituted sulfonyl group of formula (III)

--SO.sub.2 --R.sup.7 (III)

(wherein R.sup.7 represents either aryl which may be substituted by lower alkyl or amino which may be substituted); n is to 0 or 1] and to a method for producing the same compound, which is useful for the treatment of cysteine protease-associated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 83 OF 159 USPATFULL
ACCESSION NUMBER: 1999:43660 USPATFULL
TITLE: Aromatic hydroxamix acid compounds, their production and use
INVENTOR(S): Kato, Kaneyoshi, Kawanishi, Japan
Sugiura, Yoshihiro, Nara, Japan
Naruo, Ken-ichi, Sanda, Japan
Takahashi, Hideki, Osaka, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5891916		19990406	
APPLICATION INFO.:	US 1996-662240		19960614	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-154414	19950621

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Qazi, Sabiha N.
LEGAL REPRESENTATIVE: Fitzpatrick, Cella, Harper & Scinto
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 2891
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound represented by the formula: ##STR1## wherein Ar.sup.1 and Ar.sup.2 independently represent an optionally substituted aromatic group; Q represents an optionally substituted divalent aliphatic hydrocarbon group optionally containing O or S; R.sup.1 represents H, acyl group, etc.; and X represents an electron-withdrawing group, an optionally substituted aromatic group, a group of the formula: ##STR2## wherein R.sup.2 and R.sup.3 independently represent H, acyl group or an optionally substituted hydrocarbon group, etc., etc.; or salts thereof are useful as an excellent anti-neurodegenerative agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 84 OF 159 USPATFULL

ACCESSION NUMBER: 1999:30594 USPATFULL
TITLE: Human transaldolase: an autoantigen with a function in metabolism
INVENTOR(S): Perl, Andras, Jamesville, NY, United States
PATENT ASSIGNEE(S): The Research Foundation of State University of New York, Albany, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5879909		19990309
APPLICATION INFO.:	US 1998-57762		19980409

RELATED APPLN. INFO.: Division of Ser. No. US 1994-326119, filed on 19 Oct 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Davis, Minh-Tam
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Transaldolase is an enzyme which acts as an autoantigen in immune-related neurodegenerative diseases, particularly multiple sclerosis. Human transaldolase, the DNA coding therefore, peptides derived therefrom, and DNA control elements associated therewith and anti-transaldolase antibodies are disclosed. These compositions are useful in methods such as immunoassays for detecting subjects making anti-transaldolase antibodies and diagnosing the neurodegenerative disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 85 OF 159 USPATFULL
ACCESSION NUMBER: 1999:15946 USPATFULL
TITLE: Fibrinogen receptor antagonist and pharmaceutical compositions comprising the same
INVENTOR(S): Hayashi, Yoshio, Kanagawa, Japan
Harada, Takeo, Kanagawa, Japan
Katada, Jun, Kanagawa, Japan
Tachiki, Akira, Kanagawa, Japan
Okazaki, Takeo, Kanagawa, Japan
Satoh, Yoshimi, Kanagawa, Japan
Miyazaki, Hiroshi, Kanagawa, Japan
Asari, Tohru, Kanagawa, Japan
PATENT ASSIGNEE(S): Nippon Steel Corporation, Chiyoda-ku, Japan (non-U.S. corporation)
Nippon Steel Chemical Co., Ltd., Chuo-Ku, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5866592		19990202	
APPLICATION INFO.:	US 1997-882356		19970625	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-328980	19941228
	JP 1995-252841	19950929
	JP 1995-341746	19951227
	JP 1996-167982	19960627

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huang, Evelyn

LEGAL REPRESENTATIVE: Kenyon & Kenyon
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 4974
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the following general formula (I) and pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 86 OF 159 USPATFULL
ACCESSION NUMBER: 1999:13028 USPATFULL
TITLE: HTK ligand
INVENTOR(S): Bennett, Brian D., Pacifica, CA, United States
Matthews, William, Woodside, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5864020		19990126
APPLICATION INFO.:	US 1995-436054		19950505 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-277722, filed on 20 Jul 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Bakalyar, Heather A.
LEGAL REPRESENTATIVE: Lee, Wendy, Kresnak, Mark T.Flehr Hohbach Test Albritton and HerbertLLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel hepatoma transmembrane kinase receptor ligand (Htk ligand) which binds to, and activates, the Htk receptor is disclosed. As examples, mouse and human Htk ligands have been identified in a variety of tissues using a soluble Htk-Fc fusion protein. The ligands have been cloned and sequenced. The invention also relates to nucleic acids encoding the ligand, methods for production and use of the ligand, and antibodies directed thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 87 OF 159 USPATFULL
ACCESSION NUMBER: 1999:12769 USPATFULL
TITLE: Nucleic acid encoding novel receptor-type phosphotyrosine phosphatase-.kappa.
INVENTOR(S): Schlessinger, Joseph, New York, NY, United States
Sap, Jan M., New York, NY, United States
Ullrich, Axel, Munchen, Germany, Federal Republic of
Vogel, Wolfgang, Germering, Germany, Federal Republic of
Fuchs, Miriam, Starnberg, Germany, Federal Republic of
PATENT ASSIGNEE(S): Max Planck Gessellschaft, Gottingen, Germany, Federal Republic of (non-U.S. corporation)
New York University Medical Center, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5863755		19990126
APPLICATION INFO.:	US 1993-87244		19930701 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-49384, filed on 21 Apr 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Teng, Sally
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 4
NUMBER OF DRAWINGS: 49 Drawing Figure(s); 37 Drawing Page(s)
LINE COUNT: 3616
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel receptor-type protein tyrosine phosphatase-.kappa. (RPTP.kappa.) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. The RPTP.kappa. protein or glycoprotein may be produced by recombinant means. Antibodies to the protein, methods for measuring the quantity of the protein, methods for screening compounds, such as drugs, which can bind to the protein and inhibit or stimulate their enzymatic activity, are provided. Further, methods for inhibiting homophilic binding of Type II RPTP, especially RPTP.kappa. molecules are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 88 OF 159 USPATFULL
ACCESSION NUMBER: 1999:7483 USPATFULL
TITLE: Trabecular meshwork induced glucocorticoid response (TIGR) nucleic acid molecules
INVENTOR(S): Nguyen, Thai D., Mill Valley, CA, United States
Polansky, Jon R., Mill Valley, CA, United States
Huang, Weidong, San Francisco, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5861497		19990119
APPLICATION INFO.:	US 1996-667790		19960621 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-336235, filed on 3 Nov 1994, now patented, Pat. No. US 5606043
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth
LEGAL REPRESENTATIVE: Howrey & Simon
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 89 OF 159 USPATFULL
ACCESSION NUMBER: 1999:4859 USPATFULL
TITLE: Antibodies specific for heregulin 2-.alpha.
INVENTOR(S): Vandlen, Richard L., Hillsborough, CA, United States
Holmes, William E., Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 5859206 19990112
APPLICATION INFO.: US 1995-419878 19950411 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 1994-330161, filed on 25 Oct 1994 which is a continuation of Ser. No. US 1993-35430, filed on 22 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 90 OF 159 USPATFULL
ACCESSION NUMBER: 1999:1500 USPATFULL
TITLE: Receptor-type phosphotyrosine phosphatase-.kappa.
INVENTOR(S): Schlessinger, Joseph, New York, NY, United States
Sap, Jan M., New York, NY, United States
Ullrich, Axel, Munchen, Germany, Federal Republic of
Vogel, Wolfgang, Germering, Germany, Federal Republic of
Fuchs, Miriam, Starnberg, Germany, Federal Republic of
PATENT ASSIGNEE(S): New York University Medical Center, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5856162		19990105
APPLICATION INFO.:	US 1995-449644		19950524 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-87244, filed on 1 Jul 1993 which is a continuation-in-part of Ser. No. US 1993-49384, filed on 21 Apr 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Teng, Sally P.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 2,4
NUMBER OF DRAWINGS: 49 Drawing Figure(s); 37 Drawing Page(s)
LINE COUNT: 3605
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel receptor-type protein tyrosine phosphatase-.kappa. (RPTP.kappa.) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. The RPTP.kappa. protein or glycoprotein may be produced by recombinant means. Antibodies to the protein, methods for measuring the quantity of the protein, methods for screening compounds, such as drugs, which can bind to the protein and inhibit or stimulate their enzymatic activity, are provided. Further, methods for inhibiting homophilic binding of Type II RPTP, especially

RPTP.kappa. molecules are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 91 OF 159 USPATFULL
ACCESSION NUMBER: 1999:1449 USPATFULL
TITLE: Method of using HRG2-.alpha. to stimulate P185.sup.HeR2
INVENTOR(S): Vandlen, Richard L., Hillsborough, CA, United States
Holmes, William E., Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5856110		19990105
APPLICATION INFO.:	US 1995-440401		19950512 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-330161, filed on 25 Oct 1994 which is a continuation of Ser. No. US 1993-35430, filed on 22 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Arthur, Lisa B.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3433
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel 2 polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 92 OF 159 USPATFULL
ACCESSION NUMBER: 1998:162672 USPATFULL
TITLE: Methods for the diagnosis of glaucoma
INVENTOR(S): Nguyen, Thai D., Mill Valley, CA, United States
Polansky, Jon R., Mill Valley, CA, United States
Huang, Weidong, San Francisco, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5854415		19981229
APPLICATION INFO.:	US 1997-882238		19970625 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-649432, filed on 17 May 1996, now patented, Pat. No. US 5789169 which is a continuation-in-part of Ser. No. US 1995-546568, filed on 20 Oct 1995 which is a continuation-in-part of Ser. No. US 1994-336235, filed on 3 Nov 1994, now patented, Pat. No. US 5606043
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Horlick, Kenneth R.
LEGAL REPRESENTATIVE: Howrey & Simon

NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1651
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabeclar meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 93 OF 159 USPATFULL
ACCESSION NUMBER: 1998:159975 USPATFULL
TITLE: Fibrinogen receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
Hartman, George D., Lansdale, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Young, Steven D., Lansdale, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Wai, John S., Harleysville, PA, United States
Egbertson, Melissa S., Ambler, PA, United States
Vassallo, Laura M., Haverton, PA, United States
Libby, Laura A., North Wales, PA, United States
Krause, Amy E., Blue Bell, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Ihle, Nathan C., Seattle, WA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5852045		19981222	
APPLICATION INFO.:	US 1996-729968		19961015	(8)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1995-5602P	19951019	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huang, Evelyn
LEGAL REPRESENTATIVE: Winokur, Melvin, Parr, Richard S.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 3457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fibrinogen receptor antagonists having the structure, for example, of ##STR1## for example ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 94 OF 159 USPATFULL
ACCESSION NUMBER: 1998:159916 USPATFULL
TITLE: Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
INVENTOR(S): Matthews, William, Woodside, CA, United States
Austin, Timothy W., Morgan Hill, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5851984		19981222	
APPLICATION INFO.:	US 1996-696566		19960816	(8)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Fitzgerald, David L.
ASSISTANT EXAMINER: Basham, Daryl A.
LEGAL REPRESENTATIVE: Svoboda, Craig G., Marschang, Diane L.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 3923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation or differentiation of a hematopoietic stem/progenitor cell using a Wnt polypeptide, and optionally another cytokine, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 95 OF 159 USPATFULL
ACCESSION NUMBER: 1998:157478 USPATFULL
TITLE: Methods for the diagnosis of glaucoma
INVENTOR(S): Nguyen, Thai D., Mill Valley, CA, United States
Polansky, Jon R., Mill Valley, CA, United States
Huang, Weidong, Irvine, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849879		19981215
APPLICATION INFO.:	US 1996-645900		19960514 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-546568, filed on 20 Oct 1995 which is a continuation-in-part of Ser. No. US 1994-336235, filed on 3 Nov 1994, now patented, Pat. No. US 5606043
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cunningham, Thomas M.
ASSISTANT EXAMINER: Lubet, Martha T.
LEGAL REPRESENTATIVE: Howrey & Simon
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1621
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 96 OF 159 USPATFULL
ACCESSION NUMBER: 1998:157338 USPATFULL
TITLE: Isoxazoline and isoxazole fibrinogen receptor antagonists
INVENTOR(S): Wityak, John, West Grove, PA, United States
Xue, Chu-Biao, Hockessin, DE, United States
Sielecki-Dzurdz, Thais Motria, Newark, DE, United States
Olson, Richard Eric, Wilmington, DE, United States
Degrado, William Frank, Moylan, PA, United States
Cain, Gary Avonn, Wilmington, DE, United States
Batt, Douglas Guy, Wilmington, DE, United States
Pinto, Donald, Newark, DE, United States
Hussain, Munir Alwan, Wilmington, DE, United States
Mousa, Shaker Ahmed, Lincoln University, PA, United

States
PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849736		19981215
APPLICATION INFO.:	US 1995-455436		19950531 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-337920, filed on 10 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-232961, filed on 22 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-157598, filed on 24 Nov 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Ferguson, Blair Q.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 11841
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 97 OF 159 USPATFULL
ACCESSION NUMBER: 1998:157300 USPATFULL
TITLE: Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIb/IIIa
INVENTOR(S): Wells, Gregory James, Wilmington, DE, United States
Wityak, John, West Grove, PA, United States
Parthasarathy, Anju, New Castle, DE, United States
DeGrado, William Frank, Moylan, PA, United States
Jackson, Sharon Anne, Chadds Ford, PA, United States
Mousa, Shaker Ahmed, Lincoln University, PA, United States
PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849693		19981215
APPLICATION INFO.:	US 1997-820424		19970312 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-338977, filed on 14 Nov 1994, now patented, Pat. No. US 5773411 which is a continuation of Ser. No. US 1992-978475, filed on 18 Nov 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
ASSISTANT EXAMINER: Wessendorf, T. D.
LEGAL REPRESENTATIVE: Larsen, Scott K.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 2495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel cyclic compounds linked by a

heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 98 OF 159 USPATFULL

ACCESSION NUMBER:	1998:154052 USPATFULL
TITLE:	Mammalian adipogenic factors
INVENTOR(S):	Serrero, Ginette, Lake Placid, NY, United States
PATENT ASSIGNEE(S):	W. Alton Jones Cell Science Center, Lake Placid, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5846734		19981208
APPLICATION INFO.:	US 1995-485795		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-215673, filed on 22 Mar 1994, now patented, Pat. No. US 5449757 which is a continuation of Ser. No. US 1992-824847, filed on 17 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-531393, filed on 1 Jun 1990, now abandoned		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Hutzell, Paula K.
ASSISTANT EXAMINER:	Wortman, Donna C.
LEGAL REPRESENTATIVE:	Browdy and Neimark
NUMBER OF CLAIMS:	2
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT:	1573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian adipogenic factors, including purified proteins or glycoproteins, capable of inducing the adipose differentiation of adipogenic cells are disclosed, as are antibodies to such proteins, DNA encoding the proteins and host cells expressing the proteins. A method for determining the susceptibility of a subject to obesity by measuring the levels of one or more adipogenic factors in a biological fluid or tissue extract is also disclosed, as is a method for evaluating an anti-obesity drug which comprises contacting the drug with cells capable of producing one or more adipogenic factors and measuring the amount of the factors produced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 99 OF 159 USPATFULL

ACCESSION NUMBER:	1998:147247 USPATFULL
TITLE:	Nucleic acids, vectors and host cells encoding heregulin
INVENTOR(S):	Vandlen, Richard L., Hillsborough, CA, United States Holmes, William E., Pacifica, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840525		19981124
APPLICATION INFO.:	US 1995-456241		19950531 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-126145, filed on 23 Sep 1993, now abandoned which is a continuation of Ser. No. US 1992-880917, filed on 11 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-847743, filed on 6 Mar 1992, now patented, Pat.		

No. US 5367060, issued on 22 Nov 1994 which is a continuation-in-part of Ser. No. US 1991-790801, filed on 8 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-765212, filed on 25 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Arthur, Lisa B.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1,5,6,7,11
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 4160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel polypeptide with binding affinity for the p185.sup.HER2 receptor, designated heregulin-.alpha., has been identified and purified from cultured human cells. DNA sequences encoding additional heregulin polypeptides, designated heregulin-.alpha., heregulin-.beta.1, heregulin-.beta.2, heregulin-.beta.2-like, and heregulin-.beta.3, have been isolated, sequenced and expressed. Provided herein are nucleic acid sequences encoding the amino acid sequences of heregulins useful in the production of heregulins by recombinant means. Further provided are the amino acid sequences of heregulins and purification methods therefor. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 100 OF 159 USPATFULL
ACCESSION NUMBER: 1998:144079 USPATFULL
TITLE: Agents affecting thrombosis and hemostasis
INVENTOR(S): Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837679		19981117
APPLICATION INFO.:	US 1995-469301		19950606 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US -808329 which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Degen, Nancy J.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2092
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 101 OF 159 USPATFULL
ACCESSION NUMBER: 1998:138672 USPATFULL
TITLE: Nucleic acids vectors and host cells encoding and expressing heregulin 2-.alpha.
INVENTOR(S): Vandlen, Richard L., Hillsborough, CA, United States
Holmes, William E., Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834229		19981110
APPLICATION INFO.:	US 1994-330161		19941025 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-35430, filed on 22 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Arthur, Lisa B.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1,9
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3467
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel 2 polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 102 OF 159 USPATFULL
ACCESSION NUMBER: 1998:134803 USPATFULL
TITLE: Hybridization and amplification of nucleic acids encoding mpl ligand
INVENTOR(S): Eaton, Dan L., San Rafael, CA, United States
de Sauvage, Frederic J., Foster City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830647		19981103
APPLICATION INFO.:	US 1995-429764		19950426 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-348658, filed on 2 Dec 1994 which is a continuation of Ser. No. US 1994-185607, filed on 21 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-176553, filed on 3 Jan 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
ASSISTANT EXAMINER: Fredman, Jeffrey
LEGAL REPRESENTATIVE: Winter, Daryl B.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 3338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 103 OF 159 USPATFULL
ACCESSION NUMBER: 1998:122517 USPATFULL
TITLE: Antibodies to mammalian adipogenic factors
INVENTOR(S): Serrero, Ginette, Lake Placid, NY, United States
PATENT ASSIGNEE(S): W. Alton Jones Cell Science Center, Lake Placid, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5817769		19981006
APPLICATION INFO.:	US 1995-476034		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-215673, filed on 22 Mar 1994, now patented, Pat. No. US 5449757 which is a continuation of Ser. No. US 1992-824847, filed on 17 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-531393, filed on 1 Jun 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Wortman, Donna C.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian adipogenic factors, including purified proteins or glycoproteins, capable of inducing the adipose differentiation of adipogenic cells are disclosed, as are antibodies to such proteins, DNA encoding the proteins and host cells expressing the proteins. A method for determining the susceptibility of a subject to obesity by measuring the levels of one or more adipogenic factors in a biological fluid or tissue extract is also disclosed, as is a method for evaluating an anti-obesity drug which comprises contacting the drug with cells capable of producing one or more adipogenic factors and measuring the amount of the factors produced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 104 OF 159 USPATFULL
ACCESSION NUMBER: 1998:108431 USPATFULL
TITLE: Aromatic hydroxamic acid compounds, their production and use
INVENTOR(S): Kato, Kaneyoshi, Kawanishi, Japan
Miki, Shokyo, Ibaraki, Japan
Naruo, Ken-ichi, Sanda, Japan
Takahashi, Hideki, Ikeda, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804601		19980908

APPLICATION INFO.: US 1996-629623 19960409 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-84342	19950410
	JP 1995-215932	19950824

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Fitzpatrick, Cella, Harper & Scinto
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 4448
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a compound of the formula: ##STR1## wherein Ar represents an optionally substituted aromatic group; Q represents a divalent aliphatic hydrocarbon group; R.sub.1 represents hydrogen, cyano, an optionally substituted hydrocarbon group, a group of the formula: ##STR2## wherein R.sup.3 and R.sub.4 independently represent hydrogen, acyl or an optionally substituted hydrocarbon group, or R.sup.3 and R.sup.4 jointly form a ring, or acyl; R.sup.2 represents acyl; ..... represents a single bond or a double bond; m represents 1 or 2 or a salt, a process of producing thereof and an anti-neurodegenerative composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 105 OF 159 USPATFULL
ACCESSION NUMBER: 1998:92166 USPATFULL
TITLE: TRAF inhibitors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
Tularik, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5789550		19980804	
APPLICATION INFO.:	US 1996-700749		19960814	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-2382P	19950817 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Eyler, Yvonne
LEGAL REPRESENTATIVE: Dreger, Ginger R.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 106 OF 159 USPATFULL
ACCESSION NUMBER: 1998:91800 USPATFULL

TITLE: Methods for the diagnosis of glaucoma
INVENTOR(S): Nguyen, Thai D., Mill Valley, CA, United States
Polansky, Jon R., Mill Valley, CA, United States
Huang, Weidong, Irvine, CA, United States
PATENT ASSIGNEE(S): Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789169		19980804
APPLICATION INFO.:	US 1996-649432		19960517 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-336235, filed on 3 Nov 1994, now patented, Pat. No. US 5606043 And Ser. No. US 1995-546568, filed on 20 Oct 1995 which is a continuation-in-part of Ser. No. US 1994-336235, filed on 3 Nov 1994, now patented, Pat. No. US 5606043
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Horlick, Kenneth R.
LEGAL REPRESENTATIVE: Howrey & Simon
NUMBER OF CLAIMS: 106
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 107 OF 159 USPATFULL
ACCESSION NUMBER: 1998:82767 USPATFULL
TITLE: Fibrinogen receptor antagonists
INVENTOR(S): Wai, John, Harleysville, PA, United States
Fisher, Thorsten E., Hatfield, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780480		19980714
APPLICATION INFO.:	US 1997-807843		19970226 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-12380P	19960228 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Ngo, Tamthom T.
LEGAL REPRESENTATIVE: Parr, Richard S., Winokur, Mel, Quagliato, Carol S.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fibrinogen receptor antagonists of the general formula:

X-A-Y-Z-B I

and which includes, for example, the compounds of formula ##STR1## are

useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, and preventing thrombus or embolus formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 108 OF 159 USPATFULL
ACCESSION NUMBER: 1998:75588 USPATFULL
TITLE: Benzamidine derivatives and pharmaceutical composition containing them
INVENTOR(S): Akamatsu, Seijiro, Ibaraki, Japan
Matsumoto, Yuzo, Ibaraki, Japan
Ichihara, Masato, Ibaraki, Japan
Kawasaki, Tomihisa, Ibaraki, Japan
Kaku, Seiji, Ibaraki, Japan
Yanagisawa, Isao, Tokyo, Japan
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5773442		19980630	
	WO 9624583		19960815	
APPLICATION INFO.:	US 1997-875702		19970804	(8)
	WO 1996-JP274		19960208	
			19970804	PCT 371 date
			19970804	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-22640	19950210
	JP 1995-81426	19950406

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Rao, Deepak R.
LEGAL REPRESENTATIVE: Burgess, Ryan & Wayne
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1341
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are benzamidine derivatives of the following general formula (I), salts thereof, hydrates thereof or solvates thereof, and pharmaceutical compositions comprising the derivatives, salts thereof, hydrates thereof or solvates thereof along with pharmaceutically-acceptable carriers. ##STR1## The derivatives and their compositions have GPIIb/IIIa receptor antagonistic activity and are useful for the treatment and prophylaxis of vascular system disorders as medicines for ameliorating ischemic cardiac disorders, adminicula in cardiosurgery operations or in vascular surgery operations, medicines for ameliorating cerebrovascular disorders, and medicines for ameliorating peripheral artery disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 109 OF 159 USPATFULL
ACCESSION NUMBER: 1998:75557 USPATFULL
TITLE: Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIB/IIIA
INVENTOR(S): Wells, Gregory James, Wilmington, DE, United States
Wityak, John, West Grove, PA, United States
Parthasarathy, Anju, New Castle, DE, United States
DeGrado, William Frank, Moylan, PA, United States
Jackson, Sharon Anne, Chadds Ford, PA, United States

	Mousa, Shaker Ahmed, Lincoln University, PA, United States
PATENT ASSIGNEE(S):	The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5773411		19980630
APPLICATION INFO.:	US 1994-338977		19941114 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-978475, filed on 18 Nov 1992, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Chan, Christina Y.
ASSISTANT EXAMINER:	Wessendorf, T. D.
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1,5
LINE COUNT:	2512

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel cyclic compounds linked by a heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation. A representative compound of the invention is cyclo-(D-Val-N(Me)Arg-Gly-Asp-[5-aminomethyl]-2-furoate).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 110 OF 159 USPATFULL

ACCESSION NUMBER:	1998:72592 USPATFULL
TITLE:	Sensory and motor neuron derived factor (SMDF)
INVENTOR(S):	Ho, Wei-Hsien, Palo Alto, CA, United States Osheroff, Phyllis L., Woodside, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5770567		19980623
APPLICATION INFO.:	US 1994-339517		19941114 (8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Hutzell, Paula K.
ASSISTANT EXAMINER:	Gucker, Stephen
LEGAL REPRESENTATIVE:	Lee, Wendy M.
NUMBER OF CLAIMS:	22
EXEMPLARY CLAIM:	2
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT:	3771

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic methods of preparing SMDF are disclosed. SMDF contains a .beta.-type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 111 OF 159 USPATFULL

ACCESSION NUMBER: 1998:65003 USPATFULL
TITLE: Sensory and motor neuron derived factor (SMDF)
INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osheroff, Phyllis L., Woodside, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5763213		19980609
APPLICATION INFO.:	US 1995-428298		19950425 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-339517, filed on 14 Nov 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Gucker, Stephen
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 3837
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic methods of preparing SMDF are disclosed. SMDF contains a .beta.-type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 112 OF 159 USPATFULL
ACCESSION NUMBER: 1998:57880 USPATFULL
TITLE: Methods involving sensory and motor neuron derived factor (SMDF)
INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osheroff, Phyllis L., Woodside, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5756456		19980526
APPLICATION INFO.:	US 1995-428927		19950425 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-339517, filed on 14 Nov 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Mutzell, Paula R.
ASSISTANT EXAMINER: Gucker, Stephen
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 3757
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for activating the HER2 receptor comprising contacting a cell which expresses this receptor with SMDF polypeptides is discussed. A method for enhancing differentiation and/or proliferation of a cell using SMDF polypeptides is also disclosed. These methods may be

performed in vitro or in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 113 OF 159 USPATFULL
ACCESSION NUMBER: 1998:48440 USPATFULL
TITLE: Amino acid derivatives
INVENTOR(S): Alig, Leo, Kaiseraugst, Switzerland
Hadvary, Paul, Biel-Benken, Switzerland
Hurzeler, Marianne, Daniken, Switzerland
Muller, Marcel, Frenkendorf, Switzerland
Steiner, Beat, Battwil, Switzerland
Weller, Thomas, Basel, Switzerland
PATENT ASSIGNEE(S): Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5747522		19980505
APPLICATION INFO.:	US 1995-452614		19950525 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-310016, filed on 21 Sep 1994, now patented, Pat. No. US 5658928 which is a division of Ser. No. US 1992-854135, filed on 19 Mar 1992, now patented, Pat. No. US 5378712

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1991-910	19910326
	CH 1992-176	19920122

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ivy, C. Warren
ASSISTANT EXAMINER: Huang, Evelyn
LEGAL REPRESENTATIVE: Johnston, George W., Epstein, William H., Parise, John P.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 1628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R"' and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive **proteins** to blood platelets and by blood platelet **aggregation** and cell-cell adhesion. They are manufactured by cleaving off protecting groups in corresponding protected compounds or by converting the cyano group into the amidino group in corresponding nitriles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 114 OF 159 USPATFULL
ACCESSION NUMBER: 1998:42387 USPATFULL
TITLE: Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
INVENTOR(S): Illig, Carl R., Phoenixville, PA, United States
Soll, Richard M., Lawrenceville, NJ, United States
Salvino, Joseph M., Schwenksville, PA, United States
Tomczuk, Bruce E., Collegeville, PA, United States
Lu, Tianbao, Exton, PA, United States
Subasinghe, Nalin L., West Chester, PA, United States
PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., Exton, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 5741819 19980421
APPLICATION INFO.: US 1995-488196 19950607 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Owens, Amelia
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox, P.L.L.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 1240
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds of structure: ##STR1## or pharmaceutically acceptable salts thereof; wherein

R.sup.1 is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; R.sup.2 is one of hydrogen, alkyl, cycloalkyl or aryl; R.sup.3 is one of hydrogen, hydroxy or alkoxy; R.sup.4 is one of --NH.sub.2, phenyl or pyridyl, wherein said phenyl and said pyridyl are optionally substituted with one or two of halogen, hydroxy, hydroxyalkyl, alkoxy, amino, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl and/or dialkylaminoalkyl; X is one of --CH.sub.2 -- or --C(O)--; and n is from zero to eleven; provided that when R.sup.4 is --NH.sub.2, then R.sup.3 is hydrogen and n is other than zero; and also provided that when R.sup.3 is hydroxy or alkoxy, then R.sup.4 is other than --NH.sub.2, and n is other than zero.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 115 OF 159 USPATFULL
ACCESSION NUMBER: 1998:42239 USPATFULL
TITLE: Tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741667		19980421
APPLICATION INFO.:	US 1995-446915		19950522 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-331394, filed on 28 Oct 1994, now patented, Pat. No. US 5670319 which is a continuation-in-part of Ser. No. US 1994-250858, filed on 27 May 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Dreger, Ginger R.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAFs. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2) and CD40, and are involved in the mediation of TNF and CD40 ligand biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 116 OF 159 USPATFULL
ACCESSION NUMBER: 1998:39493 USPATFULL

TITLE: Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
INVENTOR(S): Roy, Soumitra, San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5739101		19980414
APPLICATION INFO.:	US 1995-440814		19950515 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-246978, filed on 20 May 1994, now patented, Pat. No. US 5589363 which is a division of Ser. No. US 1991-714819, filed on 13 Jun 1991, now patented, Pat. No. US 5346991
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A tissue factor **protein** mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet **aggregation** in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 117 OF 159 USPATFULL
ACCESSION NUMBER: 1998:22344 USPATFULL
TITLE: Method of purifying cardiac hypertrophy factor
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5723585		19980303
APPLICATION INFO.:	US 1995-443130		19950517 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994, now patented, Pat. No. US 5571893 which is a continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Borin, Michael L.
LEGAL REPRESENTATIVE: Hasak, Janet E., Torchia, Timothy E., Conley, Deirdre L.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CHF, isolated DNA encoding CHF, recombinant or synthetic methods of preparing CHF, and a method of purifying CHF are disclosed.

These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 118 OF 159 USPATFULL
ACCESSION NUMBER: 1998:6783 USPATFULL
TITLE: Antibodies specific for Rse receptor protein tyrosine kinase
INVENTOR(S): Godowski, Paul J., Burlingame, CA, United States
Mark, Melanie R., Burlingame, CA, United States
Scadden, David T., Weston, MA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
New England Deaconess Hosp., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5709858		19980120	
APPLICATION INFO.:	US 1995-445640		19950522	(8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-170558, filed on 20 Dec 1993 which is a continuation of Ser. No. US 1993-157563, filed on 23 Nov 1993, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Chan, Christina Y.			
ASSISTANT EXAMINER:	Cech, Emma			
LEGAL REPRESENTATIVE:	Lee, Wendy M., Schwartz, Timothy R.			
NUMBER OF CLAIMS:	31			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 23 Drawing Page(s)			
LINE COUNT:	3805			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 119 OF 159 USPATFULL
ACCESSION NUMBER: 1998:2162 USPATFULL
TITLE: Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
INVENTOR(S): Blackburn, Brent K., San Francisco, CA, United States
Robarge, Kirk, San Francisco, CA, United States
Somers, Todd C., Foster City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5705890		19980106	
	WO 9504057		19950209	
APPLICATION INFO.:	US 1994-313069		19940926	(8)
	WO 1994-US7989		19940715	
			19940926	PCT 371 date
			19940926	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-99019, filed on 29 Jul 1993, now patented, Pat. No. US 5493020, issued on 20 Feb 1996
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bond, Robert T.
LEGAL REPRESENTATIVE: Winter, Daryl B.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 4804
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 120 OF 159 USPATFULL
ACCESSION NUMBER: 97:109888 USPATFULL
TITLE: Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
INVENTOR(S): DeGrado, William Frank, Moylan, PA, United States
Xue, Chu-Biao, Hockessin, DE, United States
PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5691329		19971125
APPLICATION INFO.:	US 1996-694043		19960808 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-343159, filed on 22 Nov 1994, now patented, Pat. No. US 5563158 which is a continuation-in-part of Ser. No. US 1993-174552, filed on 28 Dec 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 3887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 121 OF 159 USPATFULL
ACCESSION NUMBER: 97:96744 USPATFULL
TITLE: Gene encoding cardiac hypertrophy factor
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5679545		19971021
APPLICATION INFO.:	US 1995-443952		19950517 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994, now patented, Pat. No. US 5571893, issued on 5 Nov 1996 which is a continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615, issued on 9 Jul 1996

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Arthur, Lisa B.
LEGAL REPRESENTATIVE: Hasak, Janet E., Torchia, Timothy E., Conley, Deirdre L.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1,8,9,10
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. These CT-1 molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 122 OF 159 USPATFULL
ACCESSION NUMBER: 97:86623 USPATFULL
TITLE: Amino acid derivatives
INVENTOR(S): Alig, Leo, Kaiseraugst, Switzerland
Hadvary, Paul, Biel-Benken, Switzerland
Hurzeler, Marianne, Daniken, Switzerland
Muller, Marcel, Frenkendorf, Switzerland
Steiner, Beat, Battwil, Switzerland
Weller, Thomas, Basel, Switzerland
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5670515		19970923
APPLICATION INFO.:	US 1995-452616		19950525 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-310016, filed on 21 Sep 1994 which is a division of Ser. No. US 1992-854135, filed on 19 Mar 1992, now patented, Pat. No. US 5378712

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1991-910	19910326
	CH 1992-176	19920122

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Johnston, George W., Coletti, Ellen Ciambrone
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 1765
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R'" and Q have the definitions given in the specification, are for the treatment or prophylaxis of illnesses which

are caused by the binding of adhesive **proteins** to blood platelets, by blood platelet **aggregation** and cell-cell adhesion. They are manufactured by cleaving off protecting groups in corresponding protected compounds or by converting the cyano group into the amidino group in corresponding nitriles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 123 OF 159 USPATFULL
ACCESSION NUMBER: 97:83613 USPATFULL
TITLE: Antibodies to SMDF
INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osheroff, Phyllis L., Woodside, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5667780		19970916
APPLICATION INFO.:	US 1995-428926		19950425 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-339517, filed on 14 Nov 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 3743
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated SMDF, isolated DNA encoding SMDF, and antibodies to SMDF are disclosed. SMDF contains a .beta.-type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 124 OF 159 USPATFULL
ACCESSION NUMBER: 97:73635 USPATFULL
TITLE: Amino acid derivatives
INVENTOR(S): Alig, Leo, Kaiseraugst, Switzerland
Hadvary, Paul, Biel-Benken, Switzerland
Hurzeler, Marianne, Daniken, Switzerland
Muller, Marcel, Frenkendorf, Switzerland
Steiner, Beat, Battwil, Switzerland
Weller, Thomas, Basel, Switzerland
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658928		19970819
APPLICATION INFO.:	US 1994-310016		19940921 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-854135, filed on 19 Mar 1992, now patented, Pat. No. US 5378712

NUMBER	DATE

PRIORITY INFORMATION:	CH 1991-910	19910326
	CH 1992-176	19920122

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Johnston, George W., Coletti, Ellen Ciambrone
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 1800
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R'" and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive **proteins** to blood platelets and by blood platelet **aggregation** and cell-cell adhesion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 125 OF 159 USPATFULL
ACCESSION NUMBER: 97:61794 USPATFULL
TITLE: Cloning and expression of neurocan, a chondroitin sulfate proteoglycan
INVENTOR(S): Margolis, Richard U., New York, NY, United States
Rauch, Uwe, New York, NY, United States
Margolis, Renee K., New York, NY, United States
PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S. corporation)
The Research Foundation of State University of New York, Albany, NY, United States (U.S. corporation) a part interest

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5648465		19970715
APPLICATION INFO.:	US 1994-340428		19941114 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-922911, filed on 3 Aug 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fitzgerald, David L.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 2
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2928
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel eukaryotic neurocan polypeptides, derivatives and analogs thereof and nucleic acid encoding therefor, which are useful for providing soluble, biologically active heterologous proteins in hosts, as well as hosts transformed with this nucleic acid and methods for producing soluble heterologous proteins in hosts using such molecules, and therapeutic uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 126 OF 159 USPATFULL
ACCESSION NUMBER: 97:54319 USPATFULL
TITLE: Method for purifying heregulin
INVENTOR(S): Vandlen, Richard L., Hillsborough, CA, United States
Holmes, William E., Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5641869		19970624
APPLICATION INFO.:	US 1995-456201		19950531 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-126145, filed on 23 Sep 1993, now abandoned which is a continuation of Ser. No. US 1992-880917, filed on 11 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-847743, filed on 6 Mar 1992, now patented, Pat. No. US 5367060, issued on 22 Nov 1994 which is a continuation-in-part of Ser. No. US 1991-790801, filed on 8 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-765212, filed on 25 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Arthur, Lisa B.
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 3894
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel polypeptide with binding affinity for the p185.sup.HER2 receptor, designated heregulin-.alpha., has been identified and purified from cultured human cells. DNA sequences encoding additional heregulin polypeptides, designated heregulin-.alpha., heregulin-.beta.1, heregulin-.beta.2, heregulin-.beta.2-like, and heregulin-.beta.3, have been isolated, sequenced and expressed. Provided herein are nucleic acid sequences encoding the amino acid sequences of heregulins useful in the production of heregulins by recombinant means. Further provided are the amino acid sequences of heregulins and purification methods therefor. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 127 OF 159 USPATFULL
ACCESSION NUMBER: 97:38416 USPATFULL
TITLE: Hybridomas producing antibodies to cardiac hypertrophy factor
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., United States (U.S. corporation)
The Regents of the University of California, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627073		19970506
APPLICATION INFO.:	US 1995-443129		19950517 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Reeves, Julie E.
LEGAL REPRESENTATIVE: Torchia, Timothy E., Hasak, Janet E.
NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CHF (also referred to cardiac hypertrophy factor or cardiotrophin-1), isolated DNA encoding CHF, hybridomas and cell lines producing antibodies to CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 128 OF 159 USPATFULL
ACCESSION NUMBER: 97:36159 USPATFULL
TITLE: Method for using Htk ligand
INVENTOR(S): Bennett, Brian D., Pacifica, CA, United States
Matthews, William, Woodside, CA, United States
PATENT ASSIGNEE(S): Genentech Inc., So. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5624899		19970429
APPLICATION INFO.:	US 1995-436044		19950505 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-277722, filed on 20 Jul 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Adams, Donald E.
ASSISTANT EXAMINER: Gucker, Stephen
LEGAL REPRESENTATIVE: Dreger, Walter H.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel hepatoma transmembrane kinase receptor ligand (Htk ligand) which binds to, and activates, the Htk receptor is disclosed. As examples, mouse and human Htk ligands have been identified in a variety of tissues using a soluble Htk-Fc fusion protein. The ligands have been cloned and sequenced. The invention also relates to nucleic acids encoding the ligand, methods for production and use of the ligand, and antibodies directed thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 129 OF 159 USPATFULL
ACCESSION NUMBER: 97:36067 USPATFULL
TITLE: Antibodies to cardiac hypertrophy factor and uses thereof
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 5624806 19970429
APPLICATION INFO.: US 1995-442745 19950517 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994 which is a continuation of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Knode, Marian C.
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Hasak, Janet E., Torchia, Timothy E.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated CHF, isolated DNA encoding cardiac hypertrophy factor (CHF), and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 130 OF 159 USPATFULL
ACCESSION NUMBER: 97:22821 USPATFULL
TITLE: Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
INVENTOR(S): Tianbao, Lu, Exton, PA, United States
Soll, Richard M., Lawrenceville, NJ, United States
PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., Exton, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5612378		19970318
APPLICATION INFO.:	US 1995-470579		19950606 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jos e G.
ASSISTANT EXAMINER: Ledynh, Lily
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 730
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds of structure: ##STR1## wherein each R.sup.1 is independently one of alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;

each R.sup.2 and R.sup.3 is independently one of hydrogen, alkyl, aryl or arylalkyl;

Y is a bond, or is one of --(CH.sub.2).sub.p --, cycloalkyl, aryl or C.sub.2-10 heterocycle; and

m, n and p are each independently 1 to 10.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 131 OF 159 USPATFULL
ACCESSION NUMBER: 97:16194 USPATFULL
TITLE: Methods for the diagnosis of glaucoma
INVENTOR(S): Nguyen, Thai D., Mill Valley, CA, United States
Polansky, Jon R., Mill Valley, CA, United States
Huang, Weidong, San Francisco, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5606043		19970225
APPLICATION INFO.:	US 1994-336235		19941103 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Hobbs, Lisa J.
LEGAL REPRESENTATIVE: Howrey & Simon
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1378
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 132 OF 159 USPATFULL
ACCESSION NUMBER: 96:120775 USPATFULL
TITLE: DNA encoding tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
INVENTOR(S): Roy, Soumitra, San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5589363		19961231
APPLICATION INFO.:	US 1994-246978		19940520 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1991-714819, filed on 13 Jun 1991, now patented, Pat. No. US 5346991
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S., Winter, Daryl B.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2528
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB DNA enclosing a tissue factor **protein** mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet **aggregation** in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.blll.sub.a inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 133 OF 159 USPATFULL
ACCESSION NUMBER: 96:113902 USPATFULL
TITLE: Agents affecting thrombosis and hemostasis
INVENTOR(S): Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5583107		19961210
APPLICATION INFO.:	US 1994-268003		19940629 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Degen, Nancy J.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 134 OF 159 USPATFULL
ACCESSION NUMBER: 96:101657 USPATFULL
TITLE: Cardiac hypertrophy factor
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5571893		19961105
APPLICATION INFO.:	US 1994-286304		19940805 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Hayes, Robert C.
LEGAL REPRESENTATIVE: Torchia, Timothy E., Hasak, Janet E.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed, These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 135 OF 159 USPATFULL
ACCESSION NUMBER: 96:101443 USPATFULL
TITLE: Detection and amplification of candiotrophin-1(cardiac hypertrophy factor)
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5571675		19961105
APPLICATION INFO.:	US 1995-444083		19950517 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
ASSISTANT EXAMINER: Fredman, Jeffrey
LEGAL REPRESENTATIVE: Torchia, Timothy E., Hasak, Janet E.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4298
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 136 OF 159 USPATFULL
ACCESSION NUMBER: 96:92076 USPATFULL
TITLE: Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
INVENTOR(S): DeGrado, William F., Moylan, PA, United States
Xue, Chu-Biao, Hockessin, DE, United States
PATENT ASSIGNEE(S): The Dupont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5563158		19961008
APPLICATION INFO.:	US 1994-343159		19941122 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-174552, filed on 28 Dec 1993, now abandoned
DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 4191
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 137 OF 159 USPATFULL
ACCESSION NUMBER: 96:72906 USPATFULL
TITLE: Amino acid derivatives
INVENTOR(S): Alig, Leo, Kaiseraugst, Switzerland
Hadvary, Paul, Biel-Benken, Switzerland
H urzeler, Marianne, D aniken, Switzerland
M uller, Marcel, Frenkendorf, Switzerland
Steiner, Beat, B attwil, Switzerland
Weller, Thomas, Basel, Switzerland
PATENT ASSIGNEE(S): Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5545658		19960813
APPLICATION INFO.:	US 1995-452615		19950525 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-310016, filed on 21 Sep 1994 which is a division of Ser. No. US 1992-854135, filed on 19 Mar 1992, now patented, Pat. No. US 5378712

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1991-910	19910326
	CH 1992-176	19920122

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Johnston, George W., Coletti, Ellen Ciambrone
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1663
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R'" and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive **proteins** to blood platelets and by blood platelet **aggregation** and cell-cell adhesion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 138 OF 159 USPATFULL
ACCESSION NUMBER: 96:60798 USPATFULL
TITLE: Cardiac hypertrophy factor and uses therefor
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennice, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States

(U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5534615		19960709	
APPLICATION INFO.:	US 1994-233609		19940425	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Wax, Robert A.			
ASSISTANT EXAMINER:	Kim, Hyosuk			
LEGAL REPRESENTATIVE:	Hasak, Janet E., Torchia, Timothy E.			
NUMBER OF CLAIMS:	1			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)			
LINE COUNT:	3897			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 139 OF 159 USPATFULL

ACCESSION NUMBER:	96:29438 USPATFULL			
TITLE:	Selecting ligand agonists and antagonists			
INVENTOR(S):	Cunningham, Brian C., Piedmont, CA, United States DeVos, Abraham M., Oakland, CA, United States Mulkerrin, Michael G., Redwood City, CA, United States Ultsch, Mark, Mill Valley, CA, United States Wells, James A., Burlingame, CA, United States			
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5506107		19960409	
	WO 9221029		19921126	
APPLICATION INFO.:	US 1993-122548		19930929	(8)
	WO 1992-US3743		19920506	
			19930929	PCT 371 date
			19930929	PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-864120, filed on 6 Apr 1992, now abandoned which is a continuation of Ser. No. US 1991-698753, filed on 10 May 1991, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Saunders, David			
LEGAL REPRESENTATIVE:	Skjerven, Morrill, MacPherson, Franklin & Friel, Terlizzi, Laura, Haliday, Emily M.			
NUMBER OF CLAIMS:	18			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 18 Drawing Page(s)			
LINE COUNT:	2546			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have discovered that growth hormones form ternary complexes with their receptors in which site 1 on the hormone first binds to one molecule of receptor and then hormone site 2 then binds to another molecule of receptor, thereby producing a 1:2 complex. We believe this phenomenon is shared by other ligands having similar conformational

structure. Assays based on this phenomenon are useful for identifying ligand agonists and antagonists. Sites 1 and 2 are structurally identified to facilitate generation of amino acid sequence variants of ternary complex-forming ligands. Novel variants of growth hormone, prolactin placental lactogen and other related ligands are provided. As a result of our studies with the ternary complex we have determined that selected antibodies to the receptor for these ligands are capable of acting as ligand agonists or antagonists. Novel growth hormones and novel uses for anti-growth hormone receptor antibodies are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 140 OF 159 USPATFULL
ACCESSION NUMBER: 96:14918 USPATFULL
TITLE: Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
INVENTOR(S): Blackburn, Brent K., San Francisco, CA, United States
Robarge, Kirk, San Francisco, CA, United States
Somers, Todd C., Montara, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5493020		19960220	
APPLICATION INFO.:	US 1993-99019		19930729	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bond, Robert T.
LEGAL REPRESENTATIVE: Winter, Daryl B.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 3570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A trycylic benzodiazepine derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 141 OF 159 USPATFULL
ACCESSION NUMBER: 95:82351 USPATFULL
TITLE: Mammalian adipogenic factors
INVENTOR(S): Serrero, Ginette, Lake Placid, NY, United States
PATENT ASSIGNEE(S): W. Alton Jones Cell Science Center, Lake Placid, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5449757		19950912	
APPLICATION INFO.:	US 1994-215673		19940322	(8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-824847, filed on 17 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-531393, filed on 1 Jun 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Beisner, William H.
ASSISTANT EXAMINER: Sayala, C.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1633
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian adipogenic factors, including purified proteins or glycoproteins, capable of inducing the adipose differentiation of adipogenic cells are disclosed, as are antibodies to such proteins, DNA encoding the proteins and host cells expressing the proteins. A method for determining the susceptibility of a subject to obesity by measuring the levels of one or more adipogenic factors in a biological fluid or tissue extract is also disclosed, as is a method for evaluating an anti-obesity drug which comprises contacting the drug with cells capable of producing one or more adipogenic factors and measuring the amount of the factors produced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 142 OF 159 USPATFULL
ACCESSION NUMBER: 95:1615 USPATFULL
TITLE: Amino acid derivatives
INVENTOR(S): Alig, Leo, Kaiseraugst, Switzerland
Hadvary, Paul, Biel-Benken, Switzerland
Hurzeler, Marianne, Daniken, Switzerland
Muller, Marcel, Frenkendorf, Switzerland
Steiner, Beat, Battwil, Switzerland
Weller, Thomas, Basel, Switzerland
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc, Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5378712		19950103	
APPLICATION INFO.:	US 1992-854135		19920319	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1991-91091	19910326
	CH 1992-17692	19920122

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cintins, Marianne M.
ASSISTANT EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Gould, George M., Johnston, George W., Coletti, Ellen Ciambrone
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
LINE COUNT: 1789
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R"' and Q have the significance given in the description, can be used for the treatment or control of illnesses which are caused by the binding of adhesive **proteins** to blood platelets and by blood platelet **aggregation** and cell-cell adhesion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 143 OF 159 USPATFULL
ACCESSION NUMBER: 94:102323 USPATFULL
TITLE: Structure, production and use of heregulin
INVENTOR(S): Vandlen, Richard L., Hillsborough, CA, United States
Holmes, William E., Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5367060		19941122
APPLICATION INFO.:	US 1992-847743		19920306 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-790801, filed on 8 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-765212, filed on 25 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Carlson, K. Cochrane
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 3698
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel polypeptide with binding affinity for the p185.sup.HER2 receptor, designated heregulin-.alpha., has been identified and purified from cultured human cells. DNA sequences encoding additional heregulin polypeptides, designated heregulin-.alpha., heregulin-.beta.1, heregulin-.beta.2, heregulin-.beta.2-like, and heregulin-.beta.3, have been isolated, sequenced and expressed. Provided herein are nucleic acid sequences encoding the amino acid sequences of heregulins useful in the production of heregulins by recombinant means. Further provided are the amino acid sequences of heregulins and purification methods therefor. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 144 OF 159 USPATFULL
ACCESSION NUMBER: 94:80075 USPATFULL
TITLE: Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
INVENTOR(S): Roy, Soumitra, San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5346991		19940913
APPLICATION INFO.:	US 1991-714819		19910613 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Winter, Daryl B.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A tissue factor **protein** mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet **aggregation** in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 145 OF 159 USPATFULL
ACCESSION NUMBER: 94:15878 USPATFULL
TITLE: Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
INVENTOR(S): Diamond, Michael S., Cambridge, MA, United States
Staunton, Donald E., Chestnut Hill, MA, United States
Springer, Timothy A., Newton, MA, United States
PATENT ASSIGNEE(S): Center For Blood Research, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5288854		19940222	
APPLICATION INFO.:	US 1990-618286		19901128	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Cunningham, T.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 2374
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 146 OF 159 USPATFULL
ACCESSION NUMBER: 94:13452 USPATFULL
TITLE: Detection and purification of activin polypeptide
INVENTOR(S): Cox, Edward T., Foster City, CA, United States
Mather, Jennie P., Millbrae, CA, United States
Sliwkowski, Mary B., San Carlos, CA, United States
Woodruff, Teresa K., Millbrae, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5286654		19940215	
APPLICATION INFO.:	US 1993-12711		19930203	(8)

RELATED APPLN. INFO.: Division of Ser. No. US 1991-716826, filed on 19 Jun 1991, now patented, Pat. No. US 5216126
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Y. Christina
ASSISTANT EXAMINER: Adams, Arnold E.
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2945
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 147 OF 159 USPATFULL
ACCESSION NUMBER: 93:44360 USPATFULL
TITLE: Receptor polypeptides and their production and uses
INVENTOR(S): Cox, Edward T., Foster City, CA, United States
Mather, Jennie P., Millbrae, CA, United States
Sliwkowski, Mary B., San Carlos, CA, United States
Woodruff, Teresa K., Millbrae, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5216126		19930601
APPLICATION INFO.:	US 1991-716826		19910619 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Y. Christina
ASSISTANT EXAMINER: Adams, Donald E.
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2843
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 148 OF 159 USPATFULL
ACCESSION NUMBER: 93:1393 USPATFULL
TITLE: Medicinal use of certain tetrazolium salts
INVENTOR(S): Remy, David C., North Wales, PA, United States
Baldwin, John J., Gwyneed Valley, PA, United States
Claremon, David A., Maple Glen, PA, United States
King, Stella W., Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5177092		19930105
APPLICATION INFO.:	US 1991-716200		19910617 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1989-386645, filed on 31 Jul 1989, now patented, Pat. No. US 5047416, issued on 10 Sep 1991
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Robertson, Alice O., Speer, Raymond M.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Azole compounds including azoles and azolium salts, and their use as transglutaminase inhibitors are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 149 OF 159 USPATFULL
ACCESSION NUMBER: 92:82569 USPATFULL
TITLE: Imidazole compounds in compositions and methods in thrombolytic therapy
INVENTOR(S): Claremon, David A., Audbon, PA, United States
Remy, David C., North Wales, PA, United States
Baldwin, John J., Gwynedd Valley, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5152988		19921006
APPLICATION INFO.:	US 1991-657921		19910220 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1990-476863, filed on 7 Feb 1990, now patented, Pat. No. US 5019572
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Saucier, Sandra
LEGAL REPRESENTATIVE: Robertson, Alice O., Speer, Raymond M.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 982
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of imidazoles of the formula ##STR1## and imidazolium salts of the formula ##STR2## in thromobolytic therapy are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 150 OF 159 USPATFULL
ACCESSION NUMBER: 92:22991 USPATFULL
TITLE: Imidazole compounds and their use as transglutaminase inhibitors
INVENTOR(S): Baldwin, John J., Gwyneed Valley, PA, United States
Remy, David C., North Wales, PA, United States
Claremon, David A., Audubon, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5098707		19920324
APPLICATION INFO.:	US 1991-692430		19910429 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1989-386641, filed on 31 Jul 1989, now patented, Pat. No. US 5030644
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Waddell, Frederick E.
ASSISTANT EXAMINER: Hook, Gregory
LEGAL REPRESENTATIVE: Robertson, Alice O., Pfeiffer, Hesna J.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions useful for thrombolytic therapy comprising a plasminogen activator such as tPA or streptokinase together with an imidazolium salt having the formula ##STR1## in a pharmaceutically acceptable carrier and methods for inhibiting hard clot formation or supplementing fibrinolytic therapy are described. The imidazolium salt also may be used with a platelet aggregation inhibitor or anticoagulant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 151 OF 159 USPATFULL
ACCESSION NUMBER: 92:3782 USPATFULL
TITLE: Carboxylic acid derivatives
INVENTOR(S): Nomura, Hiroaki, Osaka, Japan
Akimoto, Hiroshi, Hyogo, Japan
Imamiya, Eiko, Osaka, Japan
Inoue, Keizo, Tokyo, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5081245		19920114	
APPLICATION INFO.:	US 1989-395524		19890818	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1988-206969	19880819
	JP 1989-80593	19890330

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ford, John M.
LEGAL REPRESENTATIVE: Wegner, Cantor, Mueller & Player
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 1770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound represented by the formula: ##STR1## wherein R represents a hydrogen atom or a lower alkyl group;

R.sup.1 represents a higher alkyl group which may be substituted;

R.sup.2 represents a hydrogen atom or a lower alkyl group, a lower alkanoyl group or a nitrogen-containing 5- to 7-membered heterocyclic group each of which may be substituted; X represents a divalent group represented by the formula:

--(OCH.sub.2 CH.sub.2).sub.p --

wherein p represents an integer of 1 to 5, a divalent group represented by the formula:

--O(CH.sub.2).sub.q --

wherein q represents an integer of 3 to 8, or a divalent group represented by the formula:

--(OCH.sub.2 CH.sub.2).sub.p --J--(CH.sub.2).sub.q --

wherein J represents an oxygen atom or a group represented by the formula: --S(O).sub.r -- (wherein r represents 0, 1 or 2), and p and q are the same as defined above; Y represents a divalent group containing tertiary or quaternary nitrogen atom(s); and Z represents an alkylene group which may be substituted and/or interrupted, or a group represented by the formula:

--Q--T-- or --T--W--

wherein Q and W represent an alkylene group which may be substituted, and T represents a phenhylene group, a naphthylene group, a cycloalkylene group; and a salt thereof exhibit excellent antitumor action including differentiation inducing action and are useful as pharmaceuticals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 152 OF 159 USPATFULL
ACCESSION NUMBER: 91:73368 USPATFULL
TITLE: Triazole compounds and their use as transglutaminase inhibitors
INVENTOR(S): Remy, David C., North Wales, PA, United States
Baldwin, John J., Gwyneed Valley, PA, United States
Claremon, David A., Audubon, PA, United States
King, Stella W., Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5047416		19910910
APPLICATION INFO.:	US 1989-386645		19890731 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lee, Mary C.
ASSISTANT EXAMINER: Whittenbaugh, Robert C.
LEGAL REPRESENTATIVE: Robertson, Alice O., Pfeiffer, Hesna J.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Azole compounds including azoles and azolium salts, and their use as transglutaminase inhibitors are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 153 OF 159 USPATFULL
ACCESSION NUMBER: 91:54782 USPATFULL
TITLE: Imidazole compounds and their use as transglutaminase inhibitors
INVENTOR(S): Baldwin, John J., Gwyneed Valley, PA, United States
Remy, David C., North Wales, PA, United States
Claremon, David A., Audubon, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5030644		19910709
APPLICATION INFO.:	US 1989-386641		19890731 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lee, Mary C.
ASSISTANT EXAMINER: Miltenberger, Lenora A.
LEGAL REPRESENTATIVE: Robertson, Alice O., Pfeiffer, Hesna J.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 154 OF 159 USPATFULL
ACCESSION NUMBER: 91:44750 USPATFULL
TITLE: Imidazole compounds and their use as transglutaminase inhibitors
INVENTOR(S): Remy, David C., North Wales, PA, United States
Baldwin, John J., Gwyneed Valley, PA, United States
Claremon, David A., Audubon, PA, United States

	King, Stella W., Lansdale, PA, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5021440		19910604	
APPLICATION INFO.:	US 1989-386646		19890731	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lee, Mary C.
ASSISTANT EXAMINER: Miltenberger, Lenora A.
LEGAL REPRESENTATIVE: Robertson, Alice O., Pfeiffer, Hesna J.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 155 OF 159 USPATFULL
ACCESSION NUMBER: 91:42712 USPATFULL
TITLE: Imidazole compounds and their use as transglutaminase inhibitors
INVENTOR(S): Claremon, David A., Audbon, PA, United States
Baldwin, John J., Gwynedd Valley, PA, United States
Remy, David C., North Wales, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5019572		19910528	
APPLICATION INFO.:	US 1990-476863		19900207	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Chang, Celia
LEGAL REPRESENTATIVE: Robertson, Alice O., Caruso, Charles M.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 938
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 156 OF 159 USPATFULL
ACCESSION NUMBER: 90:85650 USPATFULL
TITLE: Certain imidazole compounds as transglutaminase inhibitors
INVENTOR(S): Baldwin, John J., Gwyneed Valley, PA, United States
Remy, David C., North Wales, PA, United States
Claremon, David A., Audubon, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4968713		19901106	
APPLICATION INFO.:	US 1989-386642		19890731	(7)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Datlow, Philip I.
LEGAL REPRESENTATIVE: Robertson, Alice O., Caruso, Charles M.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 604
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for inhibiting transglutaminase activity, especially Factor XIIIa activity with certain imidazole compounds is described. The imidazole compounds are those selected from

(A) a imidazole having the formula ##STR1## or its acid addition salt, and ##STR2## wherein: R is hydrogen or lower alkyl;

R.sup.1 is lower alkyl;

R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl;

R.sup.4 is lower alkyl; and

X is the negative radical of a pharmaceutically acceptable salt.

Also described are compositions suitable for use in inhibiting transglutaminase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 157 OF 159 USPATFULL
ACCESSION NUMBER: 79:27080 USPATFULL
TITLE: Separation of blood coagulation factors with non-activating polyelectrolytes
INVENTOR(S): Fields, Joseph E., Ballwin, MO, United States
Slocombe, Robert J., St. Louis, MO, United States
PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4157431		19790605
APPLICATION INFO.:	US 1978-933698		19780815 (5)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1977-818918, filed on 25 Jul 1977, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Levin, Stanford M.
LEGAL REPRESENTATIVE: Meyer, Scott J., Williams, Jr., James W.
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1,9,16
LINE COUNT: 1198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Blood coagulation factors such as Factor VIII are separated from admixture with other blood proteins without producing activation of said coagulation factors by contacting with a water-insoluble, cross-linked polyelectrolyte copolymer of (a) C.sub.2-18 unsaturated monomer and (b) C.sub.4-12 unsaturated polycarboxylic acid or anhydride which is partially substituted at its free carboxyl or anhydride sites with amine-imides and in which substantially all the remaining free carboxyl or anhydride sites are blocked with alkoxyalkylamine to form alkoxyalkylimide units.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 158 OF 159 USPATFULL
ACCESSION NUMBER: 78:56193 USPATFULL

TITLE: Aggregated polyelectrolytes
INVENTOR(S): Fields, Joseph E., Balwin, MO, United States
Slocombe, Robert J., St. Louis, MO, United States
PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4118554		19781003	
APPLICATION INFO.:	US 1977-818919		19770725	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Levin, Stanford M.
LEGAL REPRESENTATIVE: Meyer, Scott J., Williams, Jr., James W.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1,6
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The filterability, drying characteristics and physical form of water-insoluble, cross-linked polyelectrolytes containing amine-imide functional groups is improved without substantially diminishing the protein adsorption capacity of said polyelectrolytes by heating the polymeric starting material in inert organic solvent at a temperature ranging from about 115.degree. C to about 160.degree. C but lower than the softening point of said polymer for at least about 15 minutes and until said polymer is substantially aggregated prior to crosslinking.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L25 ANSWER 159 OF 159 USPATFULL
ACCESSION NUMBER: 75:39155 USPATFULL
TITLE: 2,6-Disubstituted purine cyclic nucleotides
INVENTOR(S): Shuman, Dennis A., Mission Viejo, CA, United States
Meyer, Jr., Rich B., Laguna Beach, CA, United States
Robins, Roland K., Santa Ana, CA, United States
PATENT ASSIGNEE(S): ICN Pharmaceuticals, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 3897413		19750729	
APPLICATION INFO.:	US 1971-201157		19711122	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Brown, Johnnie R.
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of structure ##SPC1##

Wherein X is Cl, F or Br and Y is Cl or Br, are prepared by diazotization of 2-amino-6-halo-9-.beta.-D-ribofuranosylpurine 3',5'-cyclic phosphates in the presence of an appropriate concentrated halogen-containing acid. The 2' hydroxyl of the subject compounds may be C.sub.1 -C.sub.18 acylated. The compounds are useful, e.g., as intermediates in the production of biologically active analogs of adenosine 3',5'-cyclic phosphate (cyclic AMP) such as 2-chloroadenosine 3',5'-cyclic phosphate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>